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Implementation of protocols for prudent use of antimicrobials on dairies results in 
economic returns, sustainability of products, and addresses public health concerns such as 
resistance and residues. Two main areas of application are intramammary (IMM) treatment of 
clinical mastitis (CM) and dry-cow therapy, which account for 80% of antibiotic use on dairies.  
The objectives herein were to 1) evaluate if the antibiotic hetacillin fell within a margin of 
efficacy or “noninferiority” to the reference treatment, a critically important (to human medicine) 
third-generation cephalosporin, ceftiofur; 2) assess a protocol that selectively treats CM cases 
based on daily culture results; 3) determine if similar protocols can be effectively executed on 
moderate-sized dairies without daily access to a professional laboratory; 4) determine if the 
metagenomic profiles of CM cases highlight a missed opportunity for non-treated cases; and 5) 
evaluate a culture-independent selective dry-cow therapy (SDCT) protocol. Noninferiority of 
hetacillin was concluded for bacteriological and clinical cures, as well as for many secondary 
outcomes. Administration of hetacillin over ceftiofur decreased treatment pen time with no 
statistical differences in bacteriological, pathogen, or clinical cures; milk yield and linear score 
(LS) postevent; nor additional risk of culling or quarter-level mastitis after the event.  Use of a 
selective pathogen-based protocol decreased milk withholding time with no statistical differences 
in days to clinical cure, milk yield, and LS postevent; nor additional odds of culling in the 
months following.  When similar strategies were applied on 8 moderate-sized dairies using on-
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farm or 5 day/week diagnostics, irregularity of data recording was drastically improved and no 
negative changes were reported. Reductions in antimicrobial use ranged from 6.8% to 92.5% and 
economic savings amounted to $2,200 to $4,600/dairy/yr. 16S rRNA analysis validated that 
despite dysbacteriosis in the mammary gland, there was no pathogen profile that was associated 
with negative or positive health and production outcomes; missed opportunities were not 
apparent. Finally, application of a data-driven, SDCT protocol resulted in no statistical 
differences in new infection risk, milk production and LS, or additional odds of culling or 
mastitis over the periparturient period between selectively or blanket-treated  low-risk cows. 
Using SDCT or pathogen-based protocols for the treatment and prevention of CM can reduce 
antibiotic use by up to 2/3.  
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LITERATURE REVIEW: DEFINITION AND DIAGNOSIS OF CLINICAL MASTITIS 
IN DAIRY CATTLE AND CONSIDERATIONS FOR IMPLEMENTATION OF 
PROTOCOLS THAT PROMOTE PRUDENT USE OF ANTIMICROBIALS FOR 
TREATMENT AND PREVENTION 
  
A portion of this literature review was published* in the proceedings of the annual meeting of the 
National Mastitis Conference, 2017 
  
 
 
 
 
 
 
 
 
 
* Nydam, D., and A. Vasquez. 2017. Selective dry cow therapy: what are the possibilities for 
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National Mastitis Council, Madison, WI. 
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INTRODUCTION 
Mastitis is a major cause of economic loss in the dairy industry due to reduced milk 
yields, increased culling, discarded milk, and decreased fertility (Seegers et al., 2003; Halasa et 
al., 2007). It is also a cattle welfare concern (Byrd et al., 2017). These reasons make the disease a 
main focus on dairies for treatment and control measures. In the US, approximately 1.5 million 
mastitis cases are treated annually (USDA-APHIS, 2008). The following literature review will 
discuss the epidemiology, treatment, prevention, and economics of clinical mastitis (CM) during 
lactation and over the dry period. It will highlight recent studies that have shown successful 
implementation of protocols that promote the prudent use of antimicrobials. Finally, it will 
outline the need to develop easy and quick methods for determining which cows would benefit 
most from the administration of antibiotics. 
 
CLINICAL MASTITIS IN LACTATING DAIRY CATTLE 
Clinical mastitis is defined as inflammation or infection of the mammary gland and is 
detected as abnormal consistency or appearance of milk, swelling or redness of the affected 
quarter(s), and less often as systemic signs such as fever, depression, weakness, and inappetence. 
The disease is often recorded as mild, moderate, or severe corresponding to, and graduating 
from, the presence of minimal local signs such as abnormal milk, to signs of udder inflammation, 
to systemic illness. No one-to-one relationship between clinical severity and causative agent has 
been established (Klaas and Zadoks, 2017). While Watts (1988) identified 137 contributing 
organisms including yeasts and algae, CM is caused by a bacterial pathogen more than 90% of 
the time (Watts, 1988; Olde Riekerink et al., 2008). Traditionally, pathogens are classified as 
“environmental,” those that live in the cow’s environment, or “contagious,” those that are host- 
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adapted and transmitted primarily during milking. The most common environmental pathogens 
are Escherichia coli, Klebsiella spp., Enterobacter spp., Streptococcus uberis, Streptococcus 
dysgalactiae, and Coagulase-negative Staphylococcus spp. (CNS). The most common contagious 
CM pathogens are Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp. 
However, categorization should be based on the mechanistic understanding of pathogen survival 
and pathogenesis and should be applied at the strain level, as recent research has documented 
contagious or persistent characteristics of environmental pathogens, such as with Strep. uberis, 
Klebsiella, and E. coli, and environmental origins of contagious pathogens such as Strep. 
agalactiae (Bradley and Green, 2001; Zadoks et al., 2003; Munoz et al., 2007; Zadoks et al., 
2011; Klaas and Zadoks, 2017).  
Mastitis is a commonly encountered disease on North American dairy farms with 
lactational risks ranging from 20.4% to 51%, dependent upon region, method of data collection, 
and farms represented by the study or survey performed (Erskine et al., 1988; Olde Riekerink et 
al., 2008). The USDA-NAHMS survey (2014) indicated that of the 3,500 dairy producers 
surveyed, 99.7% reported having at least one case of CM during the previous year (USDA, 
2016a).  
 
CLINICAL DIAGNOSIS OF MASTITIS 
In addition to using clinical signs, there are several methods available for diagnosis of 
clinical or subclinical mastitis cases; fewer methods are available for etiologic diagnosis. 
Somatic cell count (SCC), or the total number of white blood cells and epithelial cells in milk, 
becomes elevated during acute or chronic inflammation and has been used as a proxy for the 
presence of an intramammary infection (IMI) (Schukken et al., 2003). Due to its documented 
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optimal sensitivity and specificity (73% and 86%, respectively), a cutoff for SCC of 200,000 
cells/mL has been used as a diagnostic indicator for the presence of an IMI (Dohoo and Leslie, 
1991). Evaluation of SCC can be performed in a diagnostic laboratory using high capacity, 
accurate cell counters such as the Fossomatic cell counter, or on farm (Miller et al., 1986). A 
semi-quantitative cow-side tool for measuring SCC is the California Mastitis Test (CMT) which 
uses a reagent to disrupt cells and form a congealed mass when SCC is elevated. Currently, 
quantitative on-farm SCC counters are also available. The sensitivities and specificities of these 
tools are varied, but also depend on factors such as stage of lactation, time of day, or when 
during the milking procedures the sample was retrieved (Luedecke et al., 1967; Sargeant et al., 
2001; Sarikaya and Bruckmaier, 2006). Due to its increasing presence in automatic milking 
systems, electrical conductivity measurement is another method of CM detection that is recently 
receiving attention. Conductivity measurements at tested cutoffs have specificities >85%, but 
have varying sensitivities (66%-85%) that are dependent upon pathogen prevalence in an 
individual herd (Nielen et al., 1992; Fosgate et al., 2013). It must also be noted that CM is not the 
only circumstance that causes the ionic content of milk to change, which is a drawback of this 
method. Measurement of N-acetyl-beta-D-glucosaminidase (NAG-ase) has been shown to be an 
accurate indicator of subclinical and CM but is also sensitive to the stage of lactation of the 
animal (Hovinen et al., 2016). Finally, lactate dehydrogenase (LDH) is an enzyme with increased 
activity during mastitis. Use of LDH measurements had high sensitivities and specificities for 
detection of CM when used in a model (Chagunda et al., 2006). Additionally, when combined 
with SCC in a field study, researchers were able to differentiate between gram-positive and 
gram-negative pathogens (Hernandez-Castellano et al., 2017). Practical application of LDH or 
NAG-ase in the dairy industry for detecting IMIs has not been implemented.  
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The current gold-standard for etiologic diagnosis of CM is aerobic culture, which can be 
performed by diagnostic laboratories, veterinary clinics, or by dairy personnel. Most often, non-
selective media and ancillary tests such as potassium hydroxide, catalase, and motility tests are 
used to characterize and identify CM pathogens. However, culture systems such as the selective 
Minnesota tri- and bi-plates (University of Minnesota, St. Paul, MN), 3M Petrifilm (3M, St. 
Paul, MN), and Accumast colorimetric media (FERA Animal Health, Ithaca, NY) have been 
developed for on-farm diagnostics and some have been tested for successful use with minimal 
training and guidance (McCarron et al., 2009; Royster et al., 2014; Ganda et al., 2016b). 
Currently, 57.0% of dairy operations culture milk; 47.2% of operations use commercial and 
private veterinary labs, and 7.9% use on-farm culture (USDA, 2016a). Culture methods in 
diagnostic laboratories are often supplemented using proteomic-based testing such as matrix-
assisted laser desorption ionization time-of-flight mass spectrometry analysis (MALDI-TOF) 
(Schabauer et al., 2014). Molecular methods such as polymerase chain reaction (PCR) and 
sequencing methods such as 16S rRNA or shotgun have been used to define the causative 
pathogen and to describe the milk microbiome in laboratory situations (Koskinen et al., 2009; 
Oultram et al., 2017). PCR technology as an on-farm method is currently under development.  
 
EPIDEMIOLOGY OF MASTITIS PATHOGENS 
The etiologic distribution of CM pathogens can be diverse, even within the dairy-dense 
regions of North America, and the current distribution is vastly different from the relative 
prevalence of pathogens 30 years ago. In the 1980s, the most commonly cultured bacterial 
isolates were the contagious pathogens Staph. aureus and Strep. agalactiae (Oliver and Mitchell, 
1984; González et al., 1988). The last 30 years’ efforts of controlling contagious CM pathogens, 
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including the advent and use of FDA-approved intramammary (IMM) antimicrobials as well as 
improvements in parlor procedures have been successful; the predominant pathogens are 
currently environmental or “opportunistic” and include E. coli, Streptococcus spp., Klebsiella 
spp., Enterobacter spp., CNS and yeast. The most recent large-scale study characterizing CM 
was performed by Oliveira et al. (2013) on 50 large dairy herds in Wisconsin. Approximately 1/3 
of CM cultures (35.6%) represented gram-negative pathogens such as E. coli (22.5%), Klebsiella 
spp. (6.9%), and Enterobacter spp. (3.6%). Another 1/3 of cultures were gram-positive 
pathogens (27.5%) such as environmental streptococci (12.8%), CNS (6.1%), Enterococcus spp. 
(2.0%), and S. aureus (2.8%). The final 1/3 of cultures were negative for pathogen growth 
(27.3%). Yeast, a non-bacterial pathogen, was present in 3.1% of samples. This compares with a 
Canadian study that included 115 dairy farms (n = 3,033 cultures) where they described 8.4% of 
cases diagnosed as E. coli, 4.3% Klebsiella spp., 12.3% environmental streptococci, 5.1% CNS, 
2.2% Enterococcus spp., and 10.3% Staph. aureus (Olde Riekerink et al., 2008). Almost half 
(43.9%) of the submissions in the Olde Riekerink study were culture-negative. Absent among the 
listed pathogens are Mycoplasma species. Mycoplasma spp. are a contagious group of pathogens 
which, due to unresponsiveness of cases to therapy, are uncommonly included or characterized 
in mastitis research trials. However, these can be important organisms on dairies; mycoplasma 
mastitis varies in its prevalence from 2% to 20%, dependent on herd size and geographic location 
(Fox, 2012). 
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FACTORS INFLUENCING TREATMENT DECISIONS 
Preventative Practices 
The consideration of factors such as improved management and housing conditions, use 
of teat disinfectants, routine maintenance of milking equipment, testing of all new animal 
introductions, and culling and segregation of contagious mastitis cases can aid in prevention and 
control of new CM cases (Dodd, 1983; Bramley and Dodd, 1984). Internal teat sealants during 
the dry period can also effectively reduce incidence of new IMI (Rabiee and Lean, 2013). 
Finally, several mastitis vaccines have shown success for the reduction of clinical signs or 
prevalence of mastitis pathogens. The E. coli J5 core vaccination can reduce the severity of CM 
and reduce yield losses if used as labeled (Bradley et al., 2015). This differs from the efficacy of 
an SRP-technology based Klebsiella vaccine, which showed statistically significant protection 
from Klebsiella mastitis in addition to decreases in SCC and increases in milk production for 
cows that were vaccinated (Gorden et al., 2017).  
 
Cow Level Factors 
Cure rates for mastitis pathogens and associated outcomes can be influenced by cow 
parity, SCC, duration of infection, energy balance, vaccination status, bacterial colony counts in 
milk, number of quarters infected, and quarter location (Suriyasathaporn et al., 2000; Burvenich 
et al., 2003; Barkema et al., 2006; Bradley et al., 2015). For example, Staph. aureus cure rates 
decrease with increasing age, increasing SCC, increasing duration of infection, increasing 
bacterial colony counts, increasing number of quarters and with hind quarter location (Barkema 
et al., 2006). The probability of cure in animals experiencing Strep. uberis mastitis was higher 
among 1st and 2nd parity animals compared with older cows, and in animals with a single 
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elevated SCC prior to diagnosis as compared with those with multiple high SCC (Samson et al., 
2016). Additionally, those animals with no elevation of SCC before diagnosis were more likely 
to cure. Because these many factors contribute to cure rates, many should be accounted for when 
making individual cow treatment decisions. 
 
ANTIBIOTIC USAGE ON DAIRIES 
Antibiotic treatment of CM in dairy cattle is an important component of mastitis control 
programs. In fact, CM has been recognized as the most frequent reason for antimicrobial use on 
dairy facilities, with the percentage of cows affected and treated reported as 18.2% and 16.4%, 
respectively (USDA, 2008). Pol and Ruegg (2007) used data from 20 conventional farms in 
Wisconsin to quantify overall exposure to antimicrobial drugs: 5.43 defined daily doses (DDD; 
the maximum dose that a 680 kg animal would receive if treated with the on-label dose) per year 
per cow was quantified for mastitis treatments. This compares to foot infections at 0.39 DDD, 
respiratory infections at 0.14 DDD, and 0.32 DDD for uterine infections. Of the 5.43 DDD 
attributed to mastitis treatments, 3.58 DDD was for IMM use and 1.85 DDD was given 
parenterally. Intramammary treatment was further divided into CM treatments (2.02 DDD) and 
dry cow therapy (1.56 DDD) (Pol and Ruegg, 2007a). Drug use is similar in Canada; a study on 
89 farms measured and calculated the overall antimicrobial drug use rate, or the number of 
animal defined-daily doses per 1,000 cow-days. For IMM treatment of CM, the antimicrobial 
drug use rate was 3.52 animal defined-daily doses per 1,000 cow-days, with penicillin having the 
highest rate at 2.20 per 1,000 cow-days (Saini et al., 2012). Antimicrobial drug use rate was not 
found to be related with BTSCC, herd size, barn type, or geographical region and was positive 
but weakly correlated with herd level milk production in the study. Finally, a study that used 
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empty drug containers rather than treatment records to estimate drug use on Canadian dairy 
farms found that treatment records vastly underestimated drug use; the use for mastitis products 
was an average daily dose per 100 cow-years of 6,084 (Nobrega et al., 2017). 
 
Concerns of Antibiotic Usage 
There is increased public awareness and scientific interest regarding the administration of 
therapeutic doses or preventative doses of antimicrobials to animals, some of which include 
classes critical to human medicine. For example, 3rd and 4th generation cephalosporins, which 
include the very commonly used IMM ceftiofur product, are on the World Health Organizations 
list of critically important antimicrobials for human medicine (WHO, 2017). Concerns include 
the development of antimicrobial resistance and the sequelae: zoonotic potential of resistant 
pathogens and loss of effectiveness of antibiotics for their intended use(s). Several groups have 
explored the relationships between antimicrobial drug use for the treatment of CM and the 
development of resistance in North America. In a study of gram-positive pathogens by Pol and 
Ruegg (2007), a dose-response relationship between exposure to antimicrobials and bacterial 
susceptibility was observed for some pathogen-antimicrobial combinations (pirlimycin, 
penicillin, ampicillin, erythromycin, and tetracycline), but other antimicrobials commonly used 
as IMM preparations for CM (ceftiofur, cephapirin) were not associated with resistance (Pol and 
Ruegg, 2007b). However, this was a cross sectional study; longitudinal studies have assessed the 
development of antimicrobial resistance over 6, 7 or 9 years and have found no associations with 
common use (Erskine et al., 2002; Makovec and Ruegg, 2003; Lindeman et al., 2013). Despite 
lack of findings for isolates found in diagnostic settings, molecular evidence indicates that some 
methicillin resistant Staph. aureus found in humans may have arisen in cattle (Holmes and 
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Zadoks, 2011) and extended-spectrum beta-lactamase producing coliforms in mastitic milk have 
been linked to the use of cephalosporins in the UK and the Netherlands (Gonggrijp et al., 2016). 
Another public health concern is the presence of antibiotic residues in animal products. The 
frequency of IMM antibiotic treatments is directly associated with increased risk of antibiotic 
residues in milk (McEwen et al., 1991). Taking into account concern for overuse, antimicrobials 
still serve a crucial need for decreasing mortality and morbidity and when used appropriately in 
agricultural systems they have profound effects on animal health and productivity (Johnston, 
1998). 
 
Intramammary Antimicrobial Availability and Efficacy 
Few drug classes are approved and currently available in IMM formulations for use in 
lactating cattle with CM. These classes include the β-lactams that target bacterial peptidoglycan 
cell walls such as penicillin, ceftiofur, cephapirin, amoxicillin, hetacillin, and cloxacillin; and the 
lincosamide pirlimycin which interferes with bacterial protein synthesis (US-FDA, 2017). Label 
indications are similar for each drug formulation, with all achieving approval for at least one 
staphylococcal organism and one streptococcal organism. The hetacillin and ceftiofur-based 
products are the only IMM antimicrobials that hold label claims for efficacy against a gram-
negative organism (E. coli). However, labels claims do not necessarily indicate that efficacy is 
not achieved against additional non-listed organisms. Research groups have performed field 
trials to determine if treatment strategies for CM are more effective than others by comparing 
several different outcomes between treatment groups. These can include subjective measures 
such as time until clinical cure or objective measures such as whether or not the quarter 
experienced a microbiological cure. The latter can also be somewhat subjective as the definition 
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of microbiological cure is dependent on the method used to diagnose and the number of days 
between sample retrieval. Outcomes that are more visible to the producer and more pertinent to 
farm economics include post-mastitis milk production and SCC (or linear score; LS), number of 
days that milk is withheld, recurrence of mastitis in the same quarter, and retention in the herd 
(Lago et al., 2011a; b; Pinzón-Sánchez and Ruegg, 2011). Well-designed field trials can assess 
the efficacy of IMM antimicrobials for CM. However, most published studies lack an untreated 
control group and either do not evaluate cure at the microbial species level or do not have a large 
enough sample size to make claims regarding species-level success as compared with untreated 
controls. The following sections evaluate the findings of field studies regarding the IMM 
treatment of specific pathogens or pathogen groups. 
 
PATHOGEN CHARACTERISTICS AND RESPONSE TO ANTIMICROBIALS 
Gram-Negative Mastitis Pathogens 
Lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, is the 
virulence factor that is responsible for the pathophysiologic release of inflammatory mediators 
and subsequent clinical signs detected in gram-negative CM cases (Burvenich et al., 2003). For 
coliforms such as E. coli, current recommendations include the treatment of the sequelae of 
infection, rather than the infection itself as the presence of bacteria is usually transient and has 
high spontaneous cure rates. Duration of infection for E.coli is less than 10 days (Leininger et al., 
2003), with peak bacterial numbers and subsequent rapid drops in counts occurring in less than 
24 h, often prior to clinical recognition of the disease (Hill et al., 1979). As spontaneous cure is 
also high, ranging from 74% to 86.8%, scientists and experts in the industry question whether 
there is an advantage to antibacterial therapy (Pyörälä and Pyörälä, 1998; Suojala et al., 2010). 
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There are few peer-reviewed papers with a non-treated control group that evaluate 
bacteriological cure differences between E. coli-positive quarters treated with FDA-approved 
IMM antimicrobials and those that are not. One such study was performed by Schukken et al. 
(2011). The group found that a 5 day IMM treatment with ceftiofur resulted in a statistical 
difference in bacteriological cure for the 48 cows included in the analysis (89% cure in treated 
animals versus 53% in control animals)(Schukken et al., 2011). However, cows in either group 
missing follow-up samples were classified as treatment failures, resulting in some bias. 
Bacteriological and clinical cure did not differ between treatment groups when comparing 
amoxicillin, cephapirin, or oxytocin (no antibiotics) for CM caused by coliforms in a trial by 
Guterbock et al. (1993). Similarly, a comparison of IMM amoxicillin, frequent milkout, IMM 
amoxicillin and frequent milkout, and no treatment by Roberson et al. (2004) showed little effect 
of treatment on clinical cures, bacteriologic cures, and milk production for E.coli positive cows 
(Roberson et al., 2004). In a longitudinal study by Ganda et al. (2016), natural E.coli IMIs 
receiving treatment with ceftiofur were not different in respect to clinical cure, pathogen 
clearance rate, or bacterial load when compared to untreated controls. Additionally, the milk 
microbiome of mastitic quarters was reflective of adjacent healthy quarters within 14 days post-
mastitis regardless of treatment group (Ganda et al., 2016a). A challenge trial by the same group 
(n=12 cows) showed a significant decrease in log of bacterial CFUs in the ceftiofur treated cows 
but no effect on milk microbiome, rate of pathogen clearance, or SCC (Ganda et al., 2017). 
These many findings indicate that treatment of E. coli mastitis with antimicrobials may not be 
prudent. 
Duration of Klebsiella IMI is longer than for E. coli, averaging 21 days, and quarters 
infected with Klebsiella have a low chance of spontaneous cure, ranging from 19-37% (Smith et 
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al., 1985; Roberson et al., 2004; Schukken et al., 2011). Milk production losses are highest for 
this pathogen as compared with other gram-negative and gram-positive mastitis-causing 
organisms (Gröhn et al., 2004). Cure for Klebsiella cases in Schukken et al. (2011) was low for 
ceftiofur-treated quarters (57%) as well as for untreated quarters (19%). In the 2004 Roberson 
trial that assessed no treatment, IMM amoxicillin, and frequent milkout, none of the treatments 
used provided satisfactory cure rates for Klebsiella cases (n=18). This is similar to a Wisconsin 
study that reported 0/3 cases cured after treatment with intramammary cephapirin, and to another 
study that reported 50% bacteriologic cure at 3 weeks post-treatment after parenteral antibiotics 
(Timms and Schultz, 1984; Pyörälä and Pyörälä, 1998). 
Increased duration of infection, particularly for non-E. coli gram-negative pathogens, 
might provide reason for IMM treatment. However, beta-lactam antimicrobials target 
peptidoglycans, and gram-negative bacteria have the complexity and decreased permeability of 
an outer LPS layer (Schukken et al., 2012). This might explain the lack of differences between 
antimicrobial and untreated cases as well as the reduced clearance of the organism by the 
immune system. There are no clinical or challenge trials that evaluate treatment versus non-
treatment of less frequently isolated gram-negative pathogens; however, cure rates for treated 
Proteus infections vary between 78 and 86% (Christie et al., 1973; Lee et al., 1980; Ratnakumar 
et al., 1996). Other gram-negative bacteria such as Pseudomonas, Pasteurella or Serratia persist 
into multiple lactations, and are refractory to several different antibiotics (O’Sullivan et al., 1971; 
Hogan et al., 1989; Anderson et al., 1997) 
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Gram-Positive Mastitis Pathogens 
As beta-lactam antibiotics must enter and deactivate penicillin-binding-proteins 
responsible for assembly of the peptidoglycan cell wall and the knowledge that gram-positive 
bacterial cell walls are composed almost entirely by peptidoglycan layers, gram-positive CM 
infections are often sensitive to IMM antimicrobials. In vitro susceptibility of individual 
Streptococcal pathogens varies among species and is related to herd-level SCC (higher SCC 
associated with lower susceptibility), stage of lactation (mid-lactation isolates were more 
susceptible than early lactation isolates), and severity of mastitis (isolates from clinical samples 
were more susceptible than those from non-clinical quarters)(Cameron et al., 2016). Cure rates of 
89-98% have been reported for IMM treatment of the contagious pathogen Strep. agalactiae 
(Weaver et al., 1986; Yamagata et al., 1987; Erskine and Eberhart, 1990). Additionally, post 
milking teat dipping and antibiotic dry cow treatment reduced the proportion of quarters infected 
with Strep. agalactiae from 21.8% to 1.6% over 2 years in a trial including 120 cows (Eberhart 
and Buckalew, 1972). High cure rates and adequate post milking teat dipping likely explain why 
prevalence is low on North American dairies. 
 The cure rate for streptococci other than Strep. agalactiae was 66% overall for untreated 
quarters when over 1000 quarters were analyzed from dairy herds in New York and 
Pennsylvania and less than 30% for 50 quarters from a herd in California (Wilson et al., 1999; 
Pearce et al., 2016). This compares to antimicrobial treated quarters at 90%, 100%, 79%, 100% 
and 82% for amoxicillin, cephapirin, cloxacillin, hetacillin, and penicillin, respectively (Wilson 
et al., 1999). A study on the university dairy at Illinois assessed two different treatment groups: 
antibiotic (IMM ± systemic) and supportive therapy (oxytocin ± anti-inflammatories) or 
supportive therapy alone. When mastitis was caused by Streptococcus spp., clinical cure rate and 
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bacteriologic cure rate was statistically higher when antibiotics were used (Morin et al., 1998). 
This differs from a study by Van Eenennaam et al. (2005) who found no differences in clinical 
cure between Streptococcus-positive cows treated with either oxytocin only, IMM amoxicillin, 
or IMM cephapirin. Cows treated with oxytocin only, however, experienced more CM relapses 
(Van Eenennaam et al., 1995). 
When the group of non-agalactiae streptococcal organisms are studied individually, 
antibiotic therapy continues to show benefits. For example, untreated cure rates for Strep. uberis 
CM range from 0% to 42% (Chamings, 1984; McDougall, 1998; St Rose et al., 2003; Deluyker 
et al., 2005). Strep. uberis is usually susceptible to commonly used antimicrobials such as 
penicillin, cephalosporins, and lincosamides, achieving cure rates of up to 95% dependent on 
treatment duration (Erskine et al., 2002; Guérin-Faublée et al., 2002; Deluyker et al., 2005). 
However, some report low response rates of 50%, and resistance to lincosamides is not 
uncommon (Erskine et al., 2002; Guérin-Faublée et al., 2002; St Rose et al., 2003; Milne et al., 
2005). Many have found increased cure rates with extended therapy for Strep. uberis (Gillespie 
et al., 2002; Deluyker et al., 2005; Loch et al., 2005). Regardless, waiting 48 hours before 
commencement of treatment led to deterioration of infected quarters (Hillerton and Kliem, 
2002). Cure rates for Strep. dysgalactiae during the dry period is expected to be close to 100%, 
and treatment of the organism during lactation is greater than 80% (Østerås et al., 1991; St Rose 
et al., 2003; Oliver et al., 2004; Scillieri Smith et al., 2017). Erskine et al. (2002) reported that 
94.5%, 99.2%, 99.7%, 82.0%, and 89.0% of Strep. dysgalactiae strains from bovine mastitis 
were susceptible to penicillin, ampicillin, cephalothin, erythromycin, and pirlimycin, in vitro, 
respectively (Erskine et al., 2002).  
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Lactococcus spp. have been recently identified as mastitis pathogens; a majority of 
isolates from bovine mastitis milk samples were initially phenotypically identified as 
Streptococcus spp. (Werner et al., 2014). In an investigation of NY herds, 13% of farms had at 
least one case of Lactococcus lactis and it contributed to 24% of gram-positive non-Strep. 
agalactiae, coccal infections (Scillieri Smith et al., 2016). Only 59% of cases (n = 66) from 5 
New York farms and 41.2% (n = 17) of cases from Wisconsin farms experienced bacteriological 
cure after IMM antimicrobial therapy (Lima et al., 2014; Scillieri Smith et al., 2017). In vitro 
studies are conflicting. One study including 92 isolates in New York found no resistance in 
Lactococcus isolates for the beta-lactam antibiotics penicillin, ampicillin, and amoxicillin 
(Plumed-Ferrer et al., 2015). Another study including 32 isolates in Canada reported that only 
46.9%, 40.6%, and 0% were sensitive to ampicillin, pirlimycin, and penicillin, respectively 
(Cameron et al., 2016). Enterococcus spp. are also commonly misidentified mastitis pathogens, 
accounting for 24-30% of all bovine IMIs classified as environmental streptococcal infections 
(Devriese et al., 1999). Spontaneous cure rate of CM caused by these organisms is 27% (Pearce 
et al., 2016). In vitro analysis of Enterococcus spp. is more difficult due to lack of breakpoints as 
well as intrinsic resistance to many antimicrobials; intrinsic resistance of certain Enterococcus 
spp. might contribute to treatment failure if diagnosis does not go beyond the group level 
(Rossitto et al., 2002; Cameron et al., 2016). For example, these organisms possess an efflux 
pump that renders them resistant to lincosamides (Moellering, 2000). However, the susceptibility 
of isolates to ampicillin and penicillin was 100% (Cameron et al., 2016).  
The contagious pathogen Staph. aureus behaves very differently from environmental 
streptococcus and streptococcus-like species and is known to evade the immune system (White 
et al., 1980). While most management practices including parlor procedures and segregation or 
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culling of Staph. aureus cases contribute to successful control, some producers still elect to treat 
positive cows. Cure rates vary greatly from 4% to 92% (Barkema et al., 2006). Treatment 
regimens and pathogen- and cow-related factors impact the probability for cure, with older 
animals, cows with higher SCC and longer durations of high SCC, and cows with a greater 
number of infected quarters experiencing lower cure rates (Barkema et al., 2006). Increased 
duration of treatment is associated with increased chance of cure (Pyörälä and Pyörälä, 1998; Sol 
et al., 2000). 
CNS, unlike Staph. aureus are considered minor environmental mastitis pathogens. 
Species-specific characterization within this group is lacking and differences between species 
and between strains within species exist (De Vliegher, 2015). Additionally, distribution of CNS 
species seems to be highly herd-dependent. CNS are able to cause persistent IMI with moderate 
to no elevations in SCC and rarely affect milk production; S. chromogenes is most frequently 
represented in persistent IMI (Taponen et al., 2006). A meta-analysis on CNS IMI discredited the 
idea that natural CNS IMIs were protective of infections with major mastitis pathogens. 
However, challenge studies showed that the organisms have significant protective effects against 
major pathogens such as Staph aureus (Reyher et al., 2012). Spontaneous elimination rates for 
CNS IMIs are approximately 60 to 70% (McDougall, 1998; Wilson et al., 1999). In regards to 
antimicrobial treatment, 44.4%, 44.4%, and 22.2% of CNS isolates from milk (n = 9) were 
sensitive to amoxicillin, ampicillin, and penicillin, respectively (Srinivasan et al., 2006). 
However, antimicrobial susceptibility differs between the CNS species. 90% of S. simulans cases 
and 2/3 of S. chromogenes isolates are pansusceptible to antibiotics (Taponen et al., 2014). On 
the contrary, S. haemolyticus and S. epidermidis are often resistant to one or several 
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antimicrobials (Taponen et al., 2014). In general, one fourth to one third of CNS isolates are 
resistant to penicillin (Sawant et al., 2009).  
 
Other Mastitis Pathogens 
 Antimicrobial treatment is not recommended for Mycoplasma spp., Prototheca spp., and 
yeast. Mycoplasma spp. are bacteria that lack a cell wall around their cell membrane and are able 
to invade host cells and form biofilms (McAuliffe et al., 2006). As such, they are able to evade 
antibiotic therapy and are inherently unaffected by beta-lactam antibiotics. Additionally, in vitro 
resistance has been detected to all main antibiotic classes, which might explain lack of effect in 
vivo (Waites et al., 2014). Finally, Mycoplasma spp. have the ability to infect different body sites 
enabling them to maintain a reservoir outside of the mammary gland. Due to their contagious and 
refractory characteristics, current strategies include testing and subsequent culling of positive 
animals (Nicholas et al., 2016).  
Prototheca spp. are algae for which there are no known effective or approved therapies 
and current recommendations include segregation and culling as most infections become chronic 
with periodic shedding of organisms (Moroni et al., 2015). Prototheca spp. are environmental, 
opportunistic pathogens, however, once a critical number of infections is established within the 
herd, cow to cow transmission during milking becomes the dominant cause of new infections 
(Moroni et al., 2015). 
Yeast or fungal mastitis has been attributed to treatment directed against other pathogens 
using contaminated syringes or antibiotic applicators, however, infections can occur in untreated 
glands and teat injuries may predispose to establishment of a yeast infection (Dworecka-Kaszak 
et al., 2012). There is no clear evidence of the effectiveness of antimicrobial therapies.  
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Culture-Negative Samples 
Culture negative outcomes occur in 10-40% of CM cases (Roberson, 2003; Lago et al., 
2011a). These results have been attributed to concentrations of pathogens that are lower than the 
detection-limit of the diagnostic tool, presence of inhibitory substances in milk, or clearance of 
the pathogen by the host’s immune system (Taponen et al., 2009). Through sequencing of 
mastitis milk samples, several groups have shown that known mastitis pathogens can be present 
in culture-negative quarters at low relative abundances. However, these same pathogens can also 
be present in healthy milk at low levels (Kuehn et al., 2013; Oikonomou et al., 2014). 
Regardless, when considering prudent use of antimicrobials, treatment of a quarter without a 
confirmed etiology is not justifiable. 
 
PATHOGEN-BASED TREATMENT 
Antimicrobials should only be used for pathogens where there is strong evidence of their 
benefits. As outlined above, this includes gram-positive, non-contagious pathogens. “Culture-
based,” “selective,” or “pathogen-based” therapy is the use of diagnostic culture results to 
manage a case of CM. Culture methods using selective media for gram-negative or gram-positive 
pathogens have been evaluated for on-farm use and have achieved high sensitivities and 
specificities for their abilities to correctly classify samples into their respective gram-status 
(McCarron et al., 2009; Keefe et al., 2010; Godden et al., 2007). Additionally groups have shown 
that the 24 hour delay for those cases that subsequently receive treatment does not contribute to 
recurrence of CM (Wagner et al., 2007). In a pathogen-based protocol, the number of clinical 
cases requiring the use of IMM antibiotics can be reduced by up to 80% (Hess et al., 2003). In 
the study by Hess et al. (2003), statistical comparisons were not made between a treated and non-
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treated group, though anecdotally, withholding of treatment did not lead to decrease severity, and 
cows assigned to treatment in the “no growth” category did not return to normal milk quicker 
than those that were not treated. Days in the treatment pen was equivalent to the withholding 
period for the drug used; clinical signs were similar for cows treated and those that were not. 
Additionally, a study including 54 Canadian dairy farms evaluated the utility of an on-farm 
culture (OFC) system (Petrifilm) for selective therapy. No differences in clinical or 
bacteriological cure rates were observed for the culture and blanket treated groups when 631 
cases were assessed (Keefe et al., 2010). Pathogen-based protocols can be dairy specific; not all 
protocols specify treatment of only gram-positive pathogens (Wagner et al., 2007).  
Two peer-reviewed manuscripts were published describing the use of culture to drive 
pathogen-based therapy in 2011 and 2018 (Lago et al., 2011a; b; McDougall et al., 2018). In the 
earlier study, 422 cows from 8 commercial dairy farms were randomly assigned to blanket 
therapy with cephapirin sodium or a culture-based treatment program using the Minnesota Easy 
Culture System in which only cows with cultures positive for gram-positive pathogens were 
treated with IMM cephapirin sodium (Lago et al., 2011a;b). The group found a reduction in 
antibiotic use by 50% without differences in days to clinical cure, bacteriological cure risk, new 
IMI risk, treatment failure risk, recurrence of CM, linear SCC, daily milk production, and risk 
and days for culling or death events. McDougall et al. evaluated a culture-based system (Check-
up; Farm Medix Ltd., Aukland, NZ) versus blanket therapy on 4 herds in New Zealand. Cows in 
the selective group with no-growth or gram-negative culture results received no treatment. Those 
cows within the selective group that were treated received IMM cloxacillin (Staph. aureus) or 
IMM penicillin (non-aureus gram-positive pathogens), and cows in the blanket group received 
IMM penicillin. A reduction of 0.66 daily doses (25% lower antimicrobial use) was experienced 
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for the selective group, with no differences found between blanket and selectively treated cattle 
in the proportion retreated for CM (McDougall et al., 2018).  
In addition to validated culture-systems, success of an on-farm selective protocol requires 
that herd owners and staff have the time to inoculate and interpret agar plates, are confident in 
their interpretation, and can tolerate leaving cows untreated for 24 hours (Neeser et al., 2006). 
For those who are less confident in culture-based diagnostics, an opportunity exists for the 
submission of mastitis samples to a diagnostic or veterinary laboratory that offers prompt 
turnaround of results for decision-making. No recent studies have evaluated this opportunity. 
 
Economics of Pathogen-Based Treatment 
Cow factors such as days in milk and milk production at the time of CM onset, the 
number of CM events within the lactation, the number of days of milk withheld from sale, loss of 
reproductive efficiency, and milk production losses for the remainder of the lactation contribute 
to the variability of the CM cost (Fetrow, 2000; Hertl et al., 2011; Hertl et al., 2014; Rollin et al., 
2015). Using dynamic programing, the average expense per case of CM is highest for gram-
negative cases ($211) with the major contribution being costs associated with milk production 
loss (Cha et al., 2011). This compares with gram-positive and “other” cases where the major 
contributor to costs was treatment. The findings of Cha et al. indicated that optimal economic 
profitability occurred when 93.1% of gram-positive CM cases, 93.1% of gram-negative CM 
cases, and 94.6% of “other” CM cases were treated. However, response of individual pathogens 
to antimicrobials, which can also factor into treatment costs, was not considered in the model 
(Cha et al., 2011). The same group estimated the value of information in knowing the causative 
agent of CM and determined whether obtaining that information was economically justified by 
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using a dynamic programming model. The primary finding was that the value of information was 
greatest when identifying CM at the generic level (clinical symptoms only) and treating based on 
the highest incidence pathogen. However, all information-based treatment decisions involved use 
of an antimicrobial; no untreated groups were considered in the analysis (Cha et al., 2016). It 
would be interesting to determine the behavior of selective protocols in these models. 
Pinzón-Sánchez et al. used decision tree modeling (which included pathogen, probability 
of cure, and probability of recurrence, among other variables) to evaluate economics of treatment 
practices. The group found that when comparing 2, 3, and 5 day protocols, the most cost-
effective strategy when implementing OFC was to treat gram-positive pathogens for 2 d while 
permitting culture-negative and gram-negative results to “self-cure” (Pinzón-Sánchez et al., 
2011). In the same year, Monte-Carlo modeling was used to determine the economics of a 3M 
Petrifilm on-farm system, considering cow factors as well as accurate versus inaccurate 
diagnoses. The greatest potential for economic return in selective protocols that use on-farm 
diagnostics is in herds with accurate diagnosis of cases and in herds with higher incidences of 
coliform and culture-negative cases (MacDonald et al., 2011). Costs in these herds amount to 
$539 for Staph. aureus, $518 for other gram-positive organisms, $346 for coliform cases, and 
$326 for culture negative cases. This compares to $402, $460, $461, and $452, respectively, 
when all cases are treated with antimicrobials. Finally, Down et al. (2017) used probabilistic 
sensitivity analysis to evaluate the cost-effectiveness of using an on-farm culture approach and 
found that an OFC approach is not cost-effective in many circumstances, in particular not for 
those in which gram-positive pathogens are responsible for more than 20% of all cases. 
However, many inputs for the model were based upon findings from other models in the 
literature rather than findings from clinical trials (Down et al., 2017). Regardless, the cumulative 
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findings of the economic models outline the need for farm-specific evaluation of pathogen 
prevalence prior to implementation to determine returns.  
 
DRY COW ANTIMICROBIAL USE 
Dry-cow IMM antimicrobials were developed in the 1950s; their use was recommended 
in the 1960s as part of the National Institute for Research into Dairying’s 5-point plan (United 
Kingdom). Blanket dry cow therapy (BDCT), or the treatment of every quarter of every cow 
with a long-acting antimicrobial at dry-off, was instituted to combat the high rate of CM 
observed within the 2-weeks post-calving (Green et al., 2002) as well as to cure existing 
infections at dry-off. Research groups have demonstrated that a majority of CM cases during this 
time are contributed by organisms that were present at dry off or newly acquired over the dry 
period (Todhunter et al., 1991; Bradley and Green, 2000; Green et al., 2002). However, 
management and control of mastitis pathogens during the dry and lactating periods have been 
widely successful as indicated by the increase in negative quarter-level culture results at dry-off 
from 44% in 1985 to between 73% and 95% of quarters within the last decade (du Preez and 
Greeff, 1985; Pantoja et al., 2009; Rajala-Schultz et al., 2011). The prevalence of contagious 
pathogens such as Strep. agalactiae and Staph. aureus and reduction of bulk tank somatic cell 
counts (BTSCC) from 295,000 cells/mL in 1997 to 193,000 cells/mL in 2014 also suggest that 
BDCT is currently not a necessity in all herds (Ekman and Østerȧs, 2003; Robert et al., 2006). 
Additionally, only 11.1% of overall test days were greater than 400,000 cells/mL in 2016; this 
compares to 30.3% of test days in 1998 (Miller and Normal, 1999; Norman et al., 2017).  
Regardless of these improvements after the implementation of BDCT, over 90% of cows 
are treated and 90% of operations use antimicrobial products at dry-off in the US according to a 
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survey by the National Animal Health Monitoring System in 2014 (USDA NAHMS, 2016b). 
There are several reasons why a producer/management might elect to not use IMM antibiotics at 
dry-off: 1) economic returns via decreased labor and dry-tube costs; 2) public or government 
policy: for example, Nordic countries have adopted restrictions that permit only selective use of 
antimicrobials, leading to reductions of approximately 80% and 40% for dry-cow and CM 
treatments, respectively (Ekman and Østerȧs, 2003); 3) the introduction of an applicator into the 
teat end is not risk-free (Leelahopongsathon et al., 2016); 4) alternative/adjunct products to 
antibiotics including teat sealants are reported to have success decreasing the risk of new 
infections (Godden et al., 2003; Rabiee and Lean, 2013); and 5) consequences related to public 
health such as accidental residues in the bulk tank or the development of antimicrobial 
resistance. For these reasons, selective treatment of cows at dry-off is an opportunity that is 
being considered by producers and veterinarians. 
 
SELECTIVE DRY COW THERAPY 
Selective dry cow therapy (SDCT) is the identification and treatment of only 
cows/quarters having an infection at dry-off or at high risk for acquiring an infection during the 
dry period. The clinical, health, and microbiological outcomes resulting from the use of specific 
strategies have been explored by research groups over the past few decades. Most practitioners 
and researchers wish to address the following question: “Are cows in selective treatment 
protocols, or cows that are not treated with dry-cow antimicrobials at higher risk for 
experiencing negative outcomes?” This question has been interrogated using field trials and 
subsequent statistical models to compare treatment groups when evaluating outcomes such as 
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risk of CM, bacteriological cure, new infection risk, early lactation milk production, early 
lactation SCC/LS, and risk of culling.  
 
Current Strategies for Selective Dry Cow Therapy 
Identification of the cows or quarters that would benefit from antimicrobial treatment is 
the cornerstone of SDCT protocols and can be performed in several manners. The diagnostics 
elected for use can be performed at the quarter or cow level, and treatment decisions in regards to 
dry cow therapy can be made similarly. Accuracy, costs, labor, and ease of use/implementation 
should be considered when selecting tools to identify cows/quarters to be treated within SDCT 
programs. The following paragraphs describe strategies for SDCT and the respective results of 
field trials. The selected trials considered all mastitis pathogens in their microbiological and 
statistical analysis; all trials were published after 1990. 
Use of a Bulk Tank SCC or Single Composite SCC Prior to Dry-Off. The first studies 
on decreased IMM antibiotics at dry-off were performed in herds with low bulk tank somatic cell 
counts (BTSCC). These studies randomly assigned cows or quarters to either blanket-treatment 
or to no treatment; cows/quarters were not separated based on risk or infection status. This often 
resulted in an increased incidence rate of CM or risk of new IMIs in cows/quarters not receiving 
treatment. For example, Hogan et al. (1995) performed a study on 4 US herds with BTSCC < 
250,000 cells/mL where cows were randomized into 4 groups: (i) antibiotic dry cow therapy, (ii) 
antibiotic dry cow therapy and Propionibacterium acnes injections (PAI), (iii) PAI only, and (iv) 
no treatments. A statistically higher percentage of cured quarters and lower percentage of new 
IMIs were found in cows that received IMM antibiotic versus those that had not (Hogan et al., 
1995). However, statistical comparisons between groups that did not receive PAI were not 
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provided. Schukken et al. (1993) performed a study on one Dutch herd with a BTCC of 140,000 
cells/ml (50 cows) in which 2 quarters were treated and 2 quarters remained untreated within 
each cow. This resulted in a 10-fold increased risk of CM, or 10 cases of CM in uninfused 
quarters versus one case in a quarter that was infused with dry-cow antibiotics (Schukken et al., 
1993). In the same trial, no statistical differences were found between groups for new IMI or 
bacteriologic cure of major pathogens. Minor pathogens were reduced in quarters that were 
treated with antimicrobials. When treatment was performed on the cow level in a California herd 
(233 cows; 240,000 cells/mL) with a low prevalence of contagious mastitis pathogens, no 
statistical differences were found between groups for culling, CM risk, or SCC in the first 120 
days of the subsequent lactation, even when cows were stratified into high and low (≤500,000 
cells/mL) SCC groups (Berry et al., 1997). Scherpenzeel et al. (2014) used a split-udder design 
(2 quarters received treatment, 2 did not) and evaluated use of an individual-cow SCC threshold 
rather than use of a bulk-tank threshold. Primiparous animals with SCC <150,000 cells/mL and 
multiparous animals with SCC <250,000 cells/mL were included; 1,657 cows had 2 quarters that 
were treated and 2 that were not. In the trial, the incidence of CM was 1.7 times higher in 
quarters dried without antimicrobials (95% CI: 1.4-2.1). SCC was higher in non-treated quarters 
and a higher percentage of the quarters were culture positive at calving and at 14 DIM.  
Culture Only Method. The current gold standard for diagnosing an IMI is aerobic 
culture. However, the time, labor, and materials associated with culturing cows can be an added 
cost, and this diagnostic tool, when used in a SDCT protocol, can identify infected 
cows/quarters, but will not determine cows at higher risk for acquiring infections during the dry 
period. The effects of culture-driven antibiotic use at dry-off were determined by Browning et al. 
(1990) in an Australian field trial including 1044 cows from 12 herds. Culture-negative cows 
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were randomly allocated to receive blanket therapy or no treatment, while culture-positive cows 
were randomly allocated to receive blanket therapy or treatment of only infected quarters. No 
statistical differences were detected in CM risks between the groups within the first 5 months of 
lactation. No differences were found for new infection risk in the cows that were culture-
negative at dry-off; however, new infection risk was 4 times higher in selectively treated culture-
positive cows versus blanket treated culture-positive cows (Browning et al., 1990). Only cows 
infected with a major pathogen (n=608) were enrolled in a Norwegian study that assessed the 
effects of SDCT on culling, mastitis, milk yield, and SCC (Østerȧs and Sandvik, 1996). Cows 
were randomly allocated into a placebo group, control group, or one of two IMM antibiotic 
treatments. Cows within the antibiotic groups only received treatments in quarters experiencing 
IMIs. It should be noted that quarters known to have an IMI in the placebo and control groups 
were not treated with antibiotics. There were 21% less cases of mastitis in antibiotic treated 
quarters (P = 0.09). Treated quarters also had lower SCC and a higher lactational milk yield. 
There was no effect of therapy on culling rate. Patel et al. (2017) used quarter-level treatment of 
culture-positive quarters in addition to internal teat sealant (1 herd, 56 cows) and described no 
statistical differences between BDCT and selective quarter treatment when assessing 
bacteriological cure and new infection risks (Patel et al., 2017).  
Cow Records Only: SCC and/or Mastitis Events. Though not presented as a SDCT trial, 
Huxley et al. (2002) evaluated the use of a teat sealant in cows with routine composite SCC 
below 200,000 cells/mL with no previous cases of mastitis and a projected dry period of >51d. 
Comparisons were made between cows only receiving internal teat sealant and cows receiving 
only blanket antibiotic therapy. No statistical differences were found for CM cases, new 
infections with minor pathogens, nor overall bacteriologic cure. While new infection risk for 
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major pathogens was lower in antibiotic-treated cows, bacteriologic cure rates were only higher 
for the minor pathogens Corynebacterium spp. in antibiotic-treated cows (Huxley et al, 2002). 
Another trial evaluating internal teat sealant in the UK used a split-udder design with the same 
cow-level criteria. However, in this trial (Bradley et al., 2010) all quarters received the internal 
teat sealant product, even those treated with antibiotics. No statistical differences were described 
between groups of quarters for bacteriologic cure and new infection risks and no differences 
were found in CM risk.  
In a noninferiority study comparison, McDougall (2010) assigned cows (~900 cows from 
6 New Zealand herds) with SCC ≤ 150,000 cells/mL and no history of CM in the current 
lactation to no treatment, a novel antibiotic, or a reference antibiotic at dry-off. When analysis 
was performed on the quarter level, there were fewer IMIs characterized by any pathogen at 
freshening in antibiotic treated groups; when analysis was performed on the cow level, there was 
only a difference seen for major pathogens. SCC was lower in treated groups, and there was a 
lower hazard of CM during the dry period and in early lactation for treated groups (McDougall, 
2010). A study performed in the US by Rajala-Schultz et al. (2011) on 4 herds (~400 cows) also 
used computer records and mastitis events to determine which cows to enroll. Cows had to have 
a SCC ≤ 200,000 cells/mL over the last 3 tests with no cases of mastitis in the current lactation. 
If the cow met the criteria but there was one case of mastitis, the cow had to maintain a SCC < 
100,000 cells/mL until dry-off. Cows were then randomly assigned to receive IMM antibiotics or 
no treatment. No statistical differences were described for new infection risk or early lactation 
milk production. Overall, there was a lower SCC in the treated cows; however, when evaluated 
on the herd level, only one herd had a statistical difference between groups for this outcome 
(Rajala-Schultz et al., 2011).  
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N-Acetyl Beta-Glucosaminidase (NAG-ase). Hassan et al. (1999) used levels of NAG-
ase, a lysosomal enzyme with elevated levels during infection, in a SDCT protocol on 3 dairy 
farms in Australia (150 cows). Cows were randomized into one of 4 groups: comprehensive 
treatment (IMM antibiotics in all 4 quarters), selective treatment (IMM antibiotics only in NAG-
ase-positive quarters), or no treatment in all 4 quarters. Milk samples retrieved two and six 
weeks into the dry period showed that the proportion of infected quarters differed significantly 
between groups (untreated > selectively treated > comprehensively treated); however, after 6 
weeks, at calving, and at 3 weeks into lactation there were no significant differences in infection 
status between groups. Clinical cases of mastitis occurred only in the untreated and selectively 
treated groups (P < 0.01). Using cultures at dry-off as a reference, NAG-ase values did not 
accurately define infections (Hassan et al., 1999). 
Cow-side Tests Only. Though no randomized field trials have assessed the performance 
of only rapid cow-side tests such as the CMT and milk leukocyte differential (MLD) tests in a 
SDCT protocol, they have been evaluated to determine the infection status of a cow at dry-off. 
CMT and MLD have fair to good sensitivities and specificities for late lactation animals, but are 
dependent upon cut-point and interpretation (Godden et al., 2017). 
Combination of Culture and Cow-Level Data. A teat-sealant study on 482 low SCC (< 
200,000 cells/mL), culture-negative cows was performed using a randomized quarter-level study 
design and 4 different treatments: control (no treatments), IMM antibiotic, IMM antibiotic and 
internal teat sealant, and teat sealant only (Woolford et al., 1998). The number of clinical IMIs 
during the dry period was higher in the control quarters than the infused quarters, but not 
different between the teat sealant only and control quarters. The same findings were found for 
new IMIs at calving.  
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A BTSCC requirement of <250,000 cells/ml (4 herds) was combined with individual 
culture data at dry-off to evaluate new infection and CM risks (Berry and Hillerton, 2002). The 
group found a 9% difference in cases of CM between the untreated and treated cows (P = 0.001). 
However, cows randomized into treatment groups were those with negative, CNS-positive, or 
Corynebacterium-positive culture results one week prior to dry-off. The overall new IMI risk 
was statistically higher in the untreated versus treated cows; the greatest contribution to this 
finding was for major pathogens (Strep. uberis) in quarters already infected with minor 
pathogens. No statistical differences were found in the prevalence of CNS post-calving between 
treated and untreated groups (Berry and Hillerton, 2002). 
Cameron et al. (2013, 2014) used culture in addition to several other screening tools on 
16 Canadian herds: cow level inclusion criteria in the study consisted of a dry period between 30 
and 90 days, 3 serial SCC <200,000 cell/mL prior to dry-off, no CM in the 90 days prior to dry-
off, and a CMT score of <2 on the day prior to dry-off. Cows were then randomized to BDCT or 
SDCT. While cows within the BDCT were all treated with antimicrobials, only culture-positive 
cows within the SDCT group were treated. All cows also received internal teat sealant. No 
statistical differences were found for bacteriological cure and new IMI risks at calving, normal 
logarithm of SCC over the first 180 d, CM risk within 120 d, or test day milk production between 
SDCT and BDCT cows.  
 
Making Sense of Discrepant Data 
In trials that did not use a combination of tools, cows at risk due to historically higher 
SCC or multiple mastitis events, and currently infected cows (if culture was not used) were 
among the cows included in the non-treated group. Dissimilarities between findings could also 
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be due to the presence of higher levels of major pathogens on the included dairies, the lack of 
teat sealant use, or the inclusion of herds with BTSCC >250,000 cells/mL.  
In an effort to generate an overall outcome for trials that evaluated treatment protocols at 
dry-off, two groups performed meta-analysis on previously published research. One analysis by 
Halasa et al. (2009a) was performed on 4 SDCT trials (SDCT protocol versus BDCT protocol) 
and 13 BDCT trials (BDCT versus no-treatment). In it, the meta-analytic pooled relative risks for 
bacteriological cure were 1.76 and 1.78, respectively. For new infection, pooled relative risks of 
0.58 and 0.55 were described for BDCT versus SDCT in the 2 meta-analyses (Robert et al., 
2006a; Halasa et al., 2009b). While statistical differences in relative risk were seen for protection 
against new quarter IMI, no statistical differences were calculated when the selection unit was 
the cow (Halasa et al. 2009b). In the Robert et al. (2006a) meta-analysis, pooled differences in 
new IMI risk were statistically significant for streptococcal and Staph. aureus IMIs and not for 
IMIs caused by CNS or coliforms. Statistically different findings for BDCT versus SDCT in 15 
of the 25 studies could be due to the fact that contributions of streptococcal species and Staph. 
aureus represented more than 35% of IMIs in 50% of the studies included.  
 Readers will note that the main objective of many of the studies described here was not 
to compare a selectively treated or untreated group of cows/quarters to a blanket-treated group of 
cows or quarters, rather the data comparing these groups could be extracted from the results 
presented in each manuscript. Overall, there are limited studies that adequately capture the best 
comparisons in regards to sample size, study design and statistical evaluations. These include 
Sherpenzeel et al., 2016 (Netherlands), Cameron et al., 2013 and 2014(Canada), and Rajala-
Schultz et al., 2007 (US). The differing findings in each of these trials dictate the need for more 
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research on the subject. However, we do know that selection of farms for SDCT should be 
dependent on pathogen prevalence and SDCT protocols should be implemented on the cow level.  
 
Economics of Selective Dry Cow Therapy 
An economic analysis comparing BDCT to no dry-cow therapy of all cows within a herd 
concluded that dry-cow therapy was advantageous. However, the modeled costs of not using dry-
cow antibiotics always included lower milk production and higher SCC for these cows, with 
values retrieved from regression analyses with suboptimal R2 values (McNab and Meek, 1991). 
More recently, stochastic modeling was used to evaluate the economics of SDCT by Huijps and 
Hogeveen (2007). The economic parameters associated with the greatest influence on costs were 
antibiotics, milk losses, and the hourly rate for labor. The infection parameters that produced the 
most influence on costs were CM, the probability of culling, and infection rate over the dry 
period. When infection rate and antibiotic costs are low, no DCT might be best, but variation is 
high; in scenarios where selection criteria has high sensitivity, there will be lower average costs. 
Default values of the input variables and probabilities in this Dutch model showed that SDCT 
economically is the best option (Huijps and Hogeveen, 2007). In studies where “economic” 
outcomes were similar between groups (milk production, infection risk, CM risks, and culling 
risks) partial budget analysis can easily be performed. A net benefit of $2.62 per cow was 
calculated for the pilot study performed at the University of Minnesota by Patel et al. (2014). 
This accounted for the cost of labor and supplies to segregate, sample, and culture all cows at the 
quarter-level (Patel, 2014). As cure and infection risks were similar between groups, the authors 
did not account for additional cases of mastitis experienced by one group over another. The 
economic analysis performed by Scherpenzeel et al. (2016) used computer modeling to predict 
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economic outcomes using 7 different SDCT scenarios. These models assumed higher subclinical 
and CM prevalence and decreasing total antimicrobial usage for each scenario of decreasing 
sequential SCC thresholds. Two of 7 programs produced an economic advantage of SDCT over 
BDCT: 1. using 50,000 cells/mL for 1st lactation and higher animals and 2. using 150,000 
cells/mL for first lactation animals and 50,000 cells/mL for >1st lactation animals (Sherpenzeel et 
al., 2016). Subsequent to this analysis, the same group (Sherpenzeel et al., 2018) used 
mathematical modeling to determine the effect of individual-farm BTSCC and CM incidences on 
economic values (costs associated with CM or subclinical mastitis in early lactation). BDCT was 
compared to a sliding scale of SDCT (100% to 0% antibiotic use) on farms with permutations of 
low, high, and average BTSCC and low, high and average CM incidences. The authors 
concluded that for all evaluated BTSCC levels, SDCT was more economically beneficial than 
BDCT, with greater profits occurring in herds with lower incidences of CM; all types of herds 
can reduce dry-cow antimicrobial use without negative economic consequences (Sherpenzeel et 
al., 2018). 
 
Application of Selective Dry Cow Therapy 
 Herds with a bulk tank SCC ≤250,000 cells/mL, hygienic dry-off procedures, and very 
low prevalence of contagious pathogens could be considered for SDCT (Ekman and Østerås, 
2003; Cameron et al., 2014). Treatments should be on the cow level: many groups have also 
shown that due to interdependence of quarters, split-udder or quarter-level treatment design 
might contribute to negative outcomes, and quarters do not act independently when considering 
infection risk (Robert et al., 2006b; Paixão et al., 2017). 
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Cow-side or record-based tests such as CMT, CM history, and Dairy Herd Information 
Association (DHIA) SCC offer the convenience of readily accessible data, but if using 
microbiological culture as a reference gold-standard, these methods will result in more 
misclassifications. High sensitivity will minimize the potential risk of not treating a cow that 
might benefit from treatment. Sensitivity can be increased by using lower SCC thresholds to 
define “at risk” cows. With a more sensitive test, more cows will be treated. Regardless, lower 
thresholds will result in more prudent use of antimicrobials than in a BDCT system. Sensitivities 
and specificities of using monthly SCC and CM events as treatment criteria for SDCT range 
from 58.4% to 69.4% and 62.7% to 71.5%, respectively (Torres et al., 2008; McDougall, 2010; 
Rajala-Schultz et al., 2011). As described by the referenced field trials, aerobic culture can be 
used on all cows or a subpopulation of cows (e.g. cows with SCC below a certain threshold) to 
screen cows or quarters for treatment. This generates additional costs and the need for reliable 
and conscientious sampling as well as trained personnel or external laboratory staff to define an 
infected quarter. Additionally, cows need to be segregated for sampling at least one day prior to 
dry-off and again when animals to be treated are identified.  
 
SUMMARY 
 Public health concerns, the risk for the development of resistant pathogens, and the many 
trials that indicate that particular cow and/or pathogen traits contribute to treatment failure all 
support the need to use antimicrobials responsibly and prudently. Producers are aware of this 
need: over 70% of dairy farmers in the UK said that reducing antibiotic usage would be “a good 
thing to do” (Jones et al., 2015). BDCT is a means to reduce new IMI and increase bacteriologic 
cure in subclinical and clinically infected cows at and during dry-off. IMM antimicrobials for 
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lactating cows also have their place in treating susceptible infections; however, selective use of 
IMM antibiotics for those cows that will likely benefit can produce similar results when applied 
in appropriate herds. Selective antimicrobial use at dry-off and pathogen-based therapy protocols 
create opportunities to practice good drug stewardship and in some situations these programs 
have shown to offer economic benefits. Research indicates that success is farm specific. 
Veterinarians should remain abreast of current research findings and consider farm management 
and pathogen presence as they work with producers to develop the best strategies. Further 
research on pathogen-based treatment can create an armory of information to help veterinarians 
and producers guide treatment decisions, particularly when more than half of cultures from CM 
cases yield no growth or gram-negative organisms and up to 90% of dry cow cultures yield no 
growth. 
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ABSTRACT 
The purpose was to evaluate two intramammary treatments for mild-to-moderate cases of 
clinical mastitis in a noninferiority comparison. Noninferiority trials are intended to show 
whether a given treatment, hetacillin potassium, has at least comparable efficacy as the reference 
treatment, ceftiofur hydrochloride. Treatments can be deemed inferior to the reference treatment 
by an amount less than the margin of noninferiority, or inconclusive if the confidence interval 
crosses the margin of noninferiority. Cows with clinical mastitis from 6 farms were considered 
for enrollment. Using a randomized design, cows with mild or moderate mastitis in one quarter 
were assigned to on-label treatment with either ceftiofur or hetacillin. A total of 596 cows met 
the criteria needed for continued enrollment. Treatment distribution resulted in 309 cows in the 
ceftiofur group and 287 cows in the hetacillin group. Mixed regression analysis was performed 
for the following outcomes: bacteriological cure, pathogen cure, clinical cure, postevent milk 
production and linear score, and survival to day 30 and 60. Cox proportional hazards analysis 
was used to describe treatment effect on survival and mastitis risks. Bacteriological cure, defined 
as absence of causative organism in samples retrieved at days 14 and 21 post-mastitis, was 
similar between groups. No significant statistical differences were found in cure risk, and 
noninferiority of hetacillin relative to ceftiofur for bacteriological cure was conclusive (hetacillin 
= 67%, ceftiofur = 72%). Absence of a pathogen on both follow-up samples designated a cow as 
a pathogen cure. Pathogen cure was similar between treatment groups and noninferiority of 
hetacillin relative to ceftiofur was shown (hetacillin = 35%, ceftiofur = 32%). Clinical cure 
(hetacillin = 68%, ceftiofur = 64%), postevent milk production (hetacillin = 37.0 kg, ceftiofur = 
38.2 kg), and linear scores (hetacillin= 3.4, ceftiofur =3.1) were also not statistically different 
between treatment groups. Noninferiority of hetacillin relative to ceftiofur was shown for 
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survival to d 30 and survival to d 60, while hetacillin was more likely to have a clinical cure than 
ceftiofur by day 4. No differences were seen between groups when Cox proportional hazards 
were performed: for exit from the herd in the 60 d following the event or in the risk for a 
subsequent mastitis event. These findings can be used to develop farm-specific protocols for 
clinical mastitis treatment. 
Key words: clinical mastitis, hetacillin, noninferiority, ceftiofur  
 
INTRODUCTION 
The antimicrobial treatment options available to dairy producers for clinical mastitis 
(CM) are required by United States agencies to exhibit efficacy relative to a non-treated negative 
control. Very few studies have rigorously compared available treatments to positive controls 
using appropriate on-farm trials. It would be of benefit to perform controlled trials comparing 
two existing treatments. 
In the US, only two classes of antimicrobials are commercially available for 
intramammary (IMM) treatment of CM; beta-lactams and lincosamides (Baynes and Riviere, 
2014). In this study, we compared two beta-lactams. Hetacillin potassium (Hetacin K®, 
Boehringer Ingelheim, St Joseph, MO) is a broad-spectrum IMM antibiotic approved to treat 
gram-negative and gram-positive mastitis-causing pathogens such as Streptococcus agalactiae, 
Streptococcus dysgalactiae, Staphylococcus aureus, and Escherichia coli (Food and Drug 
Administration; FDA, 2010). It is chemically related to ampicillin and was shown to maintain 
necessary minimum inhibitory concentrations in a three times per day milking regime (Lindquist 
et al., 2015). Ceftiofur hydrochloride (Spectramast® LC, Zoetis, Kalamazoo, MI) is a broad 
spectrum third generation cephalosporin indicated to treat mastitis associated with CNS, Strep. 
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dysgalactiae, and E. coli (FDA, 2005). While both drugs have an established milk withdrawal 
time of 72 h, average length of recommended treatment varies. While the label indication for 
ceftiofur is administration every 24 h for 2-8 days, the hetacillin label states a three day duration 
at the same daily interval. The average duration for the use of ceftiofur for mild, moderate, and 
severe CM was 4.0, 4.4, and 4.5 d in a recent Wisconsin survey, respectively (Oliveira and 
Ruegg, 2014). 
 A two-sided comparative study must prove a higher defined efficacy for the proposed 
treatment over the current standard-of-care treatment in a clinical setting with the purpose to 
reject the null hypothesis that the therapies are not different; if the evidence is not strong enough 
to favor the tested product, the researcher cannot rule out nor conclude equality. Noninferiority 
of a therapy is established when the data provide evidence to conclude that its efficacy is within 
a certain amount of the equivalence margin of the comparison therapy (Walker and Nowacki, 
2011). If a researcher can hypothesize and confirm that a therapy is equivalent or superior to the 
reference, benefits to the patients can include convenience, lower costs, fewer side effects, 
improved delivery systems, and better integration into a current protocol (Piaggio et al., 2006; 
Walker and Nowacki, 2011).  
In regards to mastitis research, three major studies involving FDA-approved IMM 
preparations have been previously performed as noninferiority trials. Schukken et al. (2013), 
concluded noninferiority between a first-generation cephalosporin and a third-generation 
cephalosporin when considering both clinical cure of all non-severe CM cases and 
bacteriological cure of gram-positive cases. The specific interest was to determine if there was a 
difference in efficacy given that first generation cephalosporins have limited gram-negative 
activity while third-generation products have broader activity claims (Hornish and Kotarski, 
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2002;  Guérin-Faublée et al., 2003; Pfeifer et al., 2010). The second and third noninferiority trials 
performed by Arruda et al. (2013) and Johnson et al. (2016) on dry-cow therapy treatments 
determined noninferiority when considering various indices including post-calving new infection 
risk. No similar comparison has been made between a third generation cephalosporin, ceftiofur, 
and a semi-synthetic penicillin, hetacillin, in the treatment of mild to moderate CM. A Northeast 
survey study comparing bacteriological cure rates for 7 mastitis drugs was performed by Wilson 
et al. (1999). While cure rates for cephapirin rather than ceftiofur were analyzed, hetacillin cure 
rate was comparable to the cephalosporin product (62%, n = 35/56 versus 68%, n = 152/222, 
respectively). However, given its comparable cure rate, a 2014 study on 51 large dairy herds in 
Wisconsin indicated that only 3.3% (n = 21/645) of CM cases were treated with IMM hetacillin 
while 71.6% (n = 462/645) of cases were treated with ceftiofur (Oliveira and Ruegg, 2014). 
This study compared the treatment efficacy of a 3 day administration of intramammary 
hetacillin to a 5 day administration of the reference treatment ceftiofur. The objective of the trial 
was to evaluate whether noninferiority of the test product against the reference product can be 
established.  
 
MATERIALS AND METHODS 
Study Design 
 This was a randomized noninferiority study. The concept of a noninferiority trial is 
formalized in the term equivalence margin, which defines a range of values for which the 
efficacies or margins between differences in clinical outcome are close enough to be considered 
equivalent (Walker and Nowacki, 2011). A pre-stated margin of noninferiority is chosen as the 
smallest value that would show a clinically important effect. This margin is also used in a 
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statement of hypothesis: in this study, the null hypothesis was that a 3 d treatment with hetacillin 
is inferior compared with an extended 5 d treatment with ceftiofur when considering 
bacteriological cure, clinical cure, pathogen cure, and survival indices. The alternative 
hypothesis was that a 3 d treatment with hetacillin is noninferior compared with an extended 
treatment with ceftiofur by more than the equivalence margin of 15%. The choice of equivalence 
margins is often less than half of the expected effect in a traditional study. In a trial comparing 
treatment of gram-negative CM cows, bacteriological cure was ~35% greater for cows treated 
with ceftiofur than for cows receiving no treatment (ceftiofur n = 41/56; control n = 18/48; 
Schukken et al., 2011). Additional assessment of differences in postevent milk production, 
postevent linear score, and days in the treatment pen (hospital days) was evaluated using 
traditional hypotheses rather than noninferiority comparisons. 
 
Study Farms 
 This trial was conducted between September 2014 and June 2015 at 6 commercial dairy 
farms in major dairy-producing regions of New York State. Farms eligible for inclusion in the 
study met the following criteria: herd size >500 lactating cows; participation in monthly Dairy 
Herd Information Association (DHIA) testing; accurate recording of CM cases; and willingness 
to participate and follow standard operating procedures, which included not wavering from 
treatment plans for 7 days. A known presence of streptococcal CM was also required to ensure 
appropriate representation of gram-positive and gram-negative etiologies. Medians for this 
sample of herds were: 1057 lactating cows (range: 524 to 1466), 12,150 kg per cow per year of 
milk (range: 11,773 to 13,091 kg), and a bulk tank somatic cell count (SCC) of 140,500 cells/mL 
(range: 100,000 to 267,000 cells/mL).  
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Case Definition  
All cases of CM at each of the 6 Holstein dairies were assessed for enrollment at the time 
of occurrence. A cow was defined as having CM if milk was abnormal from one or more 
quarters. A clinical scoring system (CS) adapted from Wenz et al. (2001) was used to classify 
CM cases based on severity and only cows with clinical scores of 1 or 2 were included. Severity 
of clinical signs was scored as mild (CS = 1), moderate (CS = 2), or severe (CS = 3). A score of 
1 was assigned if the milk was visually abnormal; a score of 2 was assigned if the milk was 
visually abnormal and there was firmness or swelling of the affected quarter; and a score of 3 
was assigned if the milk was grossly abnormal, there was firmness or swelling of the affected 
quarter, and there were signs of systemic disease (e.g. fever, dehydration, or depression).  
In addition to a CS < 3, a cow needed to meet the following criteria: less than 300 days in 
milk (DIM), neither CM nor antimicrobial administration in the last 30 d, parity < 6, only one 
quarter exhibiting signs of CM, and no previous enrollment in the trial.  
 
Treatment Groups 
At each farm location, lactating cows with CM that met the inclusion criteria were 
randomly allocated to one treatment group via Dairy Comp 305 (DC305, Tulare, CA; four 
farms) or via randomized envelopes containing treatment assignment (two farms). Treatment 
groups were as follows: the test treatment group consisting of cows receiving one treatment of 
hetacillin once per day for 3 d into the affected quarter and a reference treatment group 
consisting of cows receiving one treatment of ceftiofur once per day for 5 d into the affected 
quarter. Intramammary treatments were administered using partial insertion technique by trained 
farm personnel.  
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Timing of Events 
The day of enrollment, also the first day of treatment, was defined as day 1 and 
commenced upon randomized allocation of treatment group. Before treating a cow, the teat of 
the affected quarter was thoroughly disinfected and 3 streams of milk from the affected quarter 
were discarded. A milk sample was taken using aseptic technique and immediately placed in the 
on-farm freezer. After the sample was taken, the teat end was disinfected again and treated with 
the allocated treatment. The cow was marked as treated using a leg band, per standard on-farm 
protocol. For each treatment, a dated and signed treatment confirmation was completed. A CS 
for cows in both groups was also obtained on days 2-5 following the initial score on day 1. 
Approximately 14 d (±4 d) and 21 d (± 5 d) after the onset of treatment, a milk sample was 
collected from the enrolled quarter and a CS was determined. Resamples were obtained at least 7 
d apart for each cow. If at any time an animal became systemically ill following randomization 
and treatment, farm personnel was advised to remove the animal from the study and initiate 
additional treatments. In these cases, a milk sample and CS were collected before additional 
treatments were provided. If a cow sustained mastitis in another quarter, it was removed from the 
trial with the same requirements. 
 
Bacteriological Culture 
Standard culture technique was performed on all samples according to National Mastitis 
Council guidelines for identification of aerobic organisms (National Mastitis Council, 1999). 
Briefly, 0.01 mL of milk was streaked on trypticase soy agar containing 5% sheep blood and 1% 
esculin (PML Microbiologicals, Mississauga, ON, Canada), and plates were incubated 
aerobically at 37°C for 18-24 h. After observations of colony morphology and hemolytic 
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patterns, isolates were examined further by means of 3% potassium hydroxide, gram staining, 
catalase and indole testing, and additional biochemical and metabolic evaluations as needed. 
Gram-negative organisms were identified by colony morphology on MacConkey’s agar (Hardy 
Diagnostics, Santa Maria, CA). Diagnosis and confirmation of IMM infection by culture was 
based on standard published definitions and assessed at the quarter level. Briefly, an 
intramammary infection was defined as one or more colonies isolated from the ten microliter 
milk sample for all pathogens except for CNS. For CNS, 2 or more colonies isolated from the ten 
microliter milk sample were needed to establish presence of an infection (Dohoo et al., 2011). 
When two different types of bacteria were identified, the result was classified as a mixed 
infection. When at least one colony each of 3 or more of types was isolated, the sample was 
considered contaminated. 
 
Data Capture 
Sampling and clinical data collection was performed by farm staff (5 farms) or a support 
technician (one farm). Farm staff was trained by Quality Milk Production Services (QMPS, 
Ithaca, NY) personnel and veterinarians to identify mastitis, assign severity scores, enroll cases, 
collect samples, and complete paper records. Quality assurance audits were performed by QMPS 
and herd veterinarians and regular visits were performed by the first author.  
 
Sample Size Determination 
The required sample size was determined using the confidence interval approach, 
considering where the confidence interval for the treatment effect lies with respect to both the 
margin of noninferiority (Δ), and a null effect (treatments are equal). Sample size depends on the 
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level of confidence chosen, the risk of Type II error (or desired power), and Δ. Here we specified 
Δ as the difference in cure risk ratios between the two treatments. A binomial distribution was 
performed assuming a ceftiofur cure risk of 65% based on a randomized clinical efficacy trial 
(Schukken et al., 2011), plotting Δ as the independent variable and power and sample size as 
dependent variables. This was used to find the sample size (n = 250 per group) with a chosen 
value for power (0.9) and a chosen value of Δ (0.15), which is less than half of the expected 
effect of ceftiofur in a traditional clinical trial (Schukken et al., 2011). The total study size is then 
twice this number, or 500. We enrolled 600 cows to ensure adequate study power while 
accounting for loss to follow-up and a Type I error risk of 5%. 
 
Primary and Secondary Outcomes 
Primary outcomes were bacteriological cure, clinical cure, and pathogen cure. A quarter 
was defined as a bacteriological cure when there was a pathogen present in the pretreatment 
sample and this pathogen was absent from both post-treatment samples (days 14 and 21). Cows 
that initially cultured with no growth or contamination were not included in analysis for 
bacteriological cure. If one of the follow-up samples contained the same organism as the 
pretreatment sample, the quarter was defined as a non-cure. If a cow left the trial due to mastitis 
reasons and her exit sample revealed the same organism as the pretreatment sample, the quarter 
was defined as a non-cure. If none of the present samples cultured with the enrollment organism, 
but a cow was missing one or both follow-up samples or a removal sample, the cow was deemed 
lost to follow-up for bacteriological cure. If none of the present samples cultured with the 
enrollment organism and one of the samples was contaminated, the cow was also lost to follow-
up for this outcome. Samples were missed due to treatment for other ailments, input error, or 
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early dry/sale. If no exit sample was present before the 21 d sample collection period, the cow 
was lost to follow-up for bacteriological cure. Differences in frequencies of lost to follow-up 
between treatment groups were noted for each outcome.  
A quarter was defined as a clinical cure within the first 5 days and for the follow-up 
records when its CS became and remained zero. Clinical cure was dichotomized to include two 
groups: those cows that cured by day 4 and those that did not. Day 1-5 trial records were 
considered sufficient to determine clinical cure.  
When both follow up samples contained no growth, the cow was defined as a pathogen 
cure. A pathogen did not need to be present in the pretreatment sample to be defined as a 
pathogen cure. Cows with contaminated samples were lost to follow-up and not considered for 
pathogen cure analysis. If a cow had one of two follow-up samples with no growth, but was 
missing a second sample, the cow was also lost to follow-up. 
Secondary outcomes were extended clinical cure, number of clinical days, post treatment 
milk production and linear score, survival of the cow in the herd, occurrence of another mastitis 
event in the same quarter, and hospital days. A quarter was defined as an extended clinical cure 
when its CS was 0 on d 14 and 21 after the event. The clinical days outcome was defined as the 
time to clinical cure and was calculated as the number of days from entrance into the treatment 
pen until clinical signs were undetectable. Hospital days were defined as the number of days (in 
24 h intervals), between entrance dates and exit dates into or from the treatment pen. Previous 
milk production and linear scores (LS) were obtained from the test day data prior to the event 
(range: -8 d to -43 d pre-event). Post event milk production and LS were obtained from the test 
day after the event (range: +8 d to +43 d postevent). LS is a transformation of SCC, calculated as 
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[Ln(SCC / 100) / Ln(2)] + 3 (Ali and Shook, 1980). Survival analysis was evaluated by 
following the cow to dry, cull, or 60 days post-enrollment, whichever came first.  
 
Statistical Analysis  
Noninferiority analysis of binary outcomes was completed using PROC FREQ in SAS® 
version 9.4 (SAS Institute, 2014) with one-sided 95% confidence intervals and noninferiority 
margins. Statistical analysis of the primary and secondary outcomes was performed using 
regression models, taking into account the following covariates: parity, DIM, hospital days, 
previous milk yield, LS, and CM etiology. To select the best model, all possible confounding 
variables were subjected to bivariate analysis by means of Chi-squared, t-tests, or analysis of 
variance tests using PROC FREQ, PROC TTEST, PROC REG, or PROC ANOVA. The primary 
explanatory variable of interest was treatment group; all interactions with this variable were 
tested in a similar manner. Any terms with a P-value < 0.2 were offered into the models. Each 
variable was then examined by manual backwards stepwise elimination in the regression until all 
possible explanatory variables with P < 0.1 were included. In many of the models, the treatment 
variable was forced. Farm was first tested as a fixed effect and if determined not to be significant 
to the level of P < 0.10, it was then included as a random effect. This corrected for any within-
farm clustering that violated the assumptions of independence. Additionally, basic techniques 
were used to assess normality, homoscedasticity, and linearity of variables. Transformations 
were performed and reported as necessary. Not all included animals had complete LS or milk 
yield data as some cows experienced the event in early lactation with no prior test day or late in 
lactation with no post-CM test day. Cows were excluded from hospital days or clinical days 
 68 
 
 
analyses if pen moves were not complete in DC305 records. Where analyses were performed on 
a subgroup of animals, the number of animals with complete data is indicated in the tables. 
Mixed logistic regression models were performed for the binary outcomes bacteriological 
cure, pathogen cure, clinical cure by day 4, survival to day 30, and survival to day 60. Mixed 
linear regression models were performed for postevent milk yield and postevent LS. Time in the 
herd from day 0 to day 60 postevent was evaluated using Cox proportional hazards regression 
(PROC PHREG). Similar analysis was performed to describe the effect of treatment on the 
survival distribution of quarters experiencing another case of mastitis before 60 days post-
enrollment.  
 
RESULTS 
Descriptive Results  
 Enrollment characteristics for each of the 6 farms are shown in Table 2.1. In total, the 
farms experienced 1168 cases of mastitis, 161 of which were severe (13.8%). The number of 
mastitic cows meeting eligibility criteria was 627. Thirty-one cows did not remain in the study 
due to secondary treatment of the quarter or cow within the first 7 d of enrollment (n = 15; 
hetacillin = 12, ceftiofur = 3), mastitis in another quarter within 7 days (n = 8; hetacillin = 4, 
ceftiofur = 4), non-survival of cow or quarter (n = 7; hetacillin = 3, ceftiofur = 4), and input 
errors (n = 1, ceftiofur). The mean time of first follow up sample was 14.1 d postevent (standard 
deviation, SD ± 1.9 d) and second follow-up sample was 21.2 d postevent (SD ± 2.2 d). Eight 
cows did not have enrollment samples, but could be assessed for the following outcomes: clinical 
days, hospital days, postevent milk production and LS, and survival indices. Of the cultures, 63% 
produced diagnostic growth (n = 369/588), 31% resulted in no organism (n = 183/588), and the 
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remaining 6% resulted in no significant growth or contamination (n = 36/588). Of all etiologies, 
the most frequently cultured gram-positive organisms found were Strep. dysgalactiae (14.0%; n 
= 84/588) followed by Staph. aureus (8.0%; n = 47/588) and Strep. uberis (7.8%; n = 46/588). E. 
coli (13.8%; n = 81/588) was the most commonly isolated gram-negative organism followed by 
Klebsiella spp. (5.4%; n = 32/588) and Pasteurella spp. (1.0%; n = 6/588). All etiologies were 
evenly distributed (P > 0.05) except for Strep. uberis, for which 72% (n = 33/46) of cases were 
randomly allocated to the ceftiofur group while 28% (n = 13/46) were allocated to the hetacillin 
group (P < 0.01). Distribution of organisms within each treatment group can be seen in Table 
2.2.  
 The distribution of treatments was nearly equivalent; 48% of cows were assigned to the 
hetacillin group (n = 287/596) and 52% of cows were assigned to the ceftiofur group (n = 
309/596). Distribution of treatment group by farm was also not statistically different (P = 0.68). 
We found no statistical differences in the means of DIM (hetacillin = 130 d, ceftiofur = 129 d; P 
= 0.78), lactation number (hetacillin and ceftiofur = 2.7; P = 0.46), previous test-day linear 
scores (hetacillin = 2.3, ceftiofur = 2.5; P = 0.37), and milk yields (hetacillin = 42.5 kg, ceftiofur 
= 42.7 kg; P = 0.80). The quarter affected did not differ between groups (P = 0.70).  
 
Bacteriological Cure 
 Cases were not eligible for bacteriological cure when the treated quarter had no growth (n 
= 183) or contaminated growth (n = 25) on initial culture. If a case did not meet the appropriate 
collection times for follow-up samples, it was not included in analysis (n = 1). If a cow had any 
of the criteria defined in materials and methods as lost to follow-up, the cow was not included in 
analysis (n = 35). The number of cases meeting inclusion criteria was 353; 164 hetacillin-treated 
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cows and 189 ceftiofur-treated cows had complete data. Bacteriological cure was seen in 250 
cases (71%); 112 (68%) of the hetacillin cows and 138 (73%) of the ceftiofur cows. Differences 
in bacteriological cure percentages based on etiology and treatment group can be seen in Figures 
2.1 and 2.2.  
When stratified by gram-stain classification, 74 of 106 (70%) ceftiofur-treated cows with 
gram-positive mastitis cured while 57 of 90 (63%) of hetacillin cows with gram-positive cultures 
experienced bacteriological cure. Of the cows with gram-negative mastitis, 82% of the ceftiofur 
group cured (n = 49/60) while a similar percentage (79%) of the hetacillin group cured (n = 
42/53).  
Mixed model logistic regression of bacteriological cure produced a model that included 
etiology and treatment group as explanatory variables (Table 2.3). Interactions between 
treatment group and etiology were assessed but any observed interactions were likely due to 
chance assuming the null hypothesis was true. When controlling for treatment, odds of 
bacteriological cure for all CM organisms, except for Staph aureus were higher than the 
grouping of other organisms that included Pseudomonas, Yeast, Prototheca, Corynebacterium, 
and Enterococcus. These increased odds were statistically significant for E. coli and Strep. 
dysgalactiae. The odds ratio (OR) for bacteriological cure between treatment groups was 
approximately 1.3 times higher for ceftiofur-treated cows compared with hetacillin-treated cows 
(95% confidence interval, CI: 0.77-2.1, P = 0.32). Least squares means (LSM) for 
bacteriological cure for hetacillin-treated cows was 67% (95% CI: 59%-75%), while it was 72% 
for ceftiofur-treated cows (95% CI: 65%-79%). 
Calculation of point estimates for cure risk differences can be seen in Figure 2.3. The risk 
difference between the groups was -0.047, with a 95% confidence interval of -0.14 to 0.048. 
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When stratified by gram staining classification (n = 309; gram-positives n = 196, gram-negatives 
n = 113), a larger risk difference was seen in the gram-positive organisms (-0.065; 95% CI:-
0.197-0.068). The risk difference was least negative for gram-negative etiologies at -0.024 (95% 
CI: -0.171-0.122).  
 
Clinical Cure 
 A total of 572 cows met the criteria necessary to assess this outcome (hetacillin = 268, 
ceftiofur = 304). Of the initial 596 cows, 24 cows did not have scores recorded for the required 5 
sequential days and were not included in analysis. Overall, 64% of cows experienced ≤ 4 clinical 
days (n = 366/572). Of the hetacillin-treated cows, 70% experienced ≤ 4 clinical days (n = 
187/268) while 59% of ceftiofur-treated cows experienced ≤ 4 clinical days (n=179/304; P = 
0.007). A noninferiority analysis calculated a proportion difference of 0.12 (95% CI: 0.031-0.19; 
Figure 2.3.).  
A mixed binomial logistic regression model including treatment group and log of hospital 
days resulted in similar LSM of clinical cure for each group (68% for hetacillin, 64% for 
ceftiofur). A total of 352 cows with full data were included in regression analysis. The effects of 
treatment group were not statistically significant in the model (P = 0.65). When hospital days are 
included, the odds ratio of having ≤ 4 clinical days for hetacillin-treated cows versus ceftiofur-
treated cows, although higher (1.2), is not significantly different from 1 (95% CI: 0.62-2.2; P = 
0.57). As interpreted, an increase in hospital days leads to a decrease in the log-odds for the 
outcome of clinical days ≤ 4.  
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Pathogen Cure 
Absence of a pathogen on both follow-up samples designated a cow as a pathogen cure. 
To be considered a pathogen cure, both follow-up samples as well as the enrollment sample had 
to be present and not contaminated (missing, n = 23; contaminated, n = 39). If a cow had any of 
the criteria defined in materials and methods as lost to follow up, it was not included in analysis 
(n = 11). If a case did not meet the appropriate collection times for follow-up samples, the case 
was not included in analysis (n = 2). A total of 521 cows were used in the analysis (ceftiofur = 
271, hetacillin = 250) and 462 cows had full data for modeling. A cow with a no-growth or 
growth result upon enrollment had to maintain a no-growth result in both of its follow-up 
samples to be considered a pathogen cure. Overall, 44% of cows experienced a pathogen cure, 
45% of hetacillin-treated cows and 43% of ceftiofur-treated cows. Mixed model logistic 
regression resulted in a numerically better pathogen cure (OR = 1.1) for hetacillin-treated cases 
as compared with the ceftiofur cases, but the observed difference was likely due to chance (P = 
0.57). Least square means for hetacillin-treated cows was 35% in the model while 32% cured for 
ceftiofur (95% CI: hetacillin, 22%-50%; ceftiofur, 20%-47%). Variables significant in the model 
were etiology, previous LS, and previous milk yield (Table 2.4).  
No-growth results were exempt from the analysis described by Table 2.3. However, the 
effects of this etiology were reflected in the logistic model for pathogen cure: when all other 
variables were held constant, odds of pathogen cure for all etiologies except for E. coli were 
trending lower or significantly lower than no-growth results, indicating that cows experiencing a 
no-growth result were likely to remain no-growth at both resample dates. While E. coli CM had 
an increased odds of pathogen cure, it was not statistically significant (P = 0.93). Interactions 
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between treatment group and etiology were assessed but not statistically significant to the level 
of P < 0.05. As milk yield or LS increased, the odds of pathogen cure decreased.  
Point estimates for pathogen cure risk differences with confidence intervals can be seen 
in Figure 2.3. The risk difference between the groups was 0.020, with a 95% confidence interval 
of -0.065 to 0.11.  
 
Extended Clinical Cure and Clinical Days 
Using resample CS at days 14 ± 4 and 21 ± 5 (n = 520), bivariate analysis shows 92% (n 
= 221/241) of hetacillin-treated cows with clinical cure and 91% (n = 253/279) of ceftiofur-
treated cows with clinical cure. A Chi-square comparison indicates no differences between 
treatment groups (P = 0.68). Noninferiority analysis confirms that the treatments are noninferior 
when assessing this outcome (risk difference = 0.010, 95% CI: -0.039-0.059). 
Any cow experiencing 5 or more clinical days was given a value of 5. Bivariate analysis 
indicates a difference in clinical days between treatment groups (P = 0.0026), with the hetacillin-
treated cows experiencing overall less days (3.4 d; 95% CI: 1.3-1.5) versus ceftiofur-treated 
cows (3.7 d; 95% CI: 1.3-1.5). Lack of normality of clinical days did not permit linear regression 
modeling.  
 
Postevent Milk Yield 
 All cows with milk yield values at 8-43 days post-mastitis event were included in the 
analysis. The mean number of days between mastitis event and test date for data retrieval was 
23.6 d with a median of 24 d. The total number of included cows was 542, with 261 in the 
hetacillin group and 281 in the ceftiofur group. Average postevent milk yield between the groups 
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was similar; the average test-day milk for hetacillin-treated cows was 38.2 kg while the average 
milk for ceftiofur-treated cows was 38.7 kg (bivariate analysis, P = 0.54). A mixed linear 
regression model used 484 observations and included DIM category, previous test-day milk 
yield, and etiology. The LSM for hetacillin-treated and ceftiofur-treated cows was 37.0 kg and 
38.2 kg, respectively (P = 0.09). In the model, as expected, as previous milk yield increased, 
postevent milk yield increased. Cows lower in DIM had significantly greater milk production 
than those > 200 DIM, and the LSM for milk yield decreased with increasing DIM category. All 
etiology groups had lower milk production than those with no-growth results (Table 2.5).  
 
Postevent LS 
All cows with LS values at 8-43 days post-mastitis event were assessed for analysis (n = 
531; hetacillin = 251, ceftiofur = 280). The mean number of days between mastitis event and test 
date for data retrieval was 23.6 d with a median of 24 d. Average postevent LS for hetacillin-
treated cows and ceftiofur-treated cows was 3.4 and 3.1, respectively (bivariate analysis, P = 
0.66). A mixed linear regression model included previous LS, parity, and etiology. The LSM for 
hetacillin-treated and ceftiofur-treated cows was 3.4 and 3.1, respectively (P = 0.086). A total of 
466 cows were included in the model. As expected, previous LS was significant in the model; as 
previous LS increased, postevent LS increased. In the model, each earlier parity had a lower LS 
than the third and greater parity when other variables were accounted for (P = 0.0032). All 
culture results had higher LS than those cows culturing with no-growth results. P-values and 
LSM for each etiology can be found in Table 2.6. 
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Survival to d 30 
 A cow not surviving was defined as having experienced culling or death. A total of 585 
cows were included in the analysis, 284 hetacillin-treated cows and 301 ceftiofur-treated cows. 
Overall, 95% of cows survived to day 30. Of the hetacillin-treated cows, 12 (4.2%) did not 
survive to 30 d compared with 15 (5.0%) of ceftiofur-treated cows. In a mixed logistic regression 
model with 521 observations, the odds of survival were higher in the hetacillin group (OR = 1.2) 
but treatment group was not statistically significant (P = 0.73). The only significant variable was 
previous milk yield (P = 0.022), which showed an increased odds of survival with increasing 
previous milk yield (OR = 1.05; 95% CI: 1.01-1.1). Noninferiority analysis resulted in a risk 
difference of 0.0076 (95% CI:-0.026-0.042; Figure 2.3). 
 
Survival to d 60 
The same cow inclusions were made as for survival to day 30 (n = 585; hetacillin = 284; 
ceftiofur = 301). Overall, 91% of cows survived to day 60. Of the hetacillin-treated cows, 22 
(7.8%) did not survive to 60 d compared with 30 (10.0%) of the ceftiofur-treated cows. In a 
mixed logistic regression model, the odds of survival were higher in the hetacillin group (OR = 
1.4) but the P-value = 0.26. In the model, the odds of survival increased as previous milk yield 
increased (OR = 1.04; 95% CI: 1.01-1.07; P = 0.012). The risk difference was 0.022 (95% CI:-
0.024-0.068; Figure 2.3).  
 
Time-to-Event: Survival Analysis and Mastitis Recurrence 
 The same cows included in logistic analysis of survival to 30 and 60 d were included in 
the time-to-event analysis for overall survival (n = 585; hetacillin = 284; ceftiofur = 301). A total 
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of 521 observations were included in Cox proportional hazards regression. Modeling for overall 
survival in time-to-event analysis provided a hazard ratio of 0.74 when comparing hetacillin-
treated cows to ceftiofur-treated cows, indicating a reduction in risk of 26% for that group. The 
treatment group P-value was 0.27. The only variables that remained in the model were parity (P 
= 0.086) and previous milk yield (P = 0.0010).  
Modeling for time-to-mastitis event in the same quarter provided a hazard ratio for the 
hetacillin group over the ceftiofur group of 1.1 (P = 0.73) when controlling for milk yield. One 
farm did not reliably record mastitis at the quarter level, leading to removal of 104 cows from 
analysis. Three cows were not included because their quarter ceased production within 7 d of 
enrollment. The total number of cows eligible for analysis was 478 (hetacillin = 229; ceftiofur = 
249). A total of 421 observations were included in a Cox proportional hazards regression model. 
Only previous milk yield was significant in the model (P = 0.0004).  
 
Hospital Days 
 A cow was eligible for hospital days analysis when there was a pen move indicating exit 
from the treatment pen in both DC305 and the written record (n = 351). Four of six of the dairies 
reliably recorded pen moves; cows enrolled from two of the dairies did not contribute to analysis 
of this outcome. The number of cows meeting criteria was 344 (hetacillin = 164; ceftiofur = 
180). Data was normalized by using the log of hospital days as the outcome. Bivariate analysis 
revealed a greater number of hospital days for the ceftiofur-treated group (8.0 d) versus the 
hetacillin-treated group (6.2 d; P < 0.001). A mixed linear regression model included etiology as 
the only significant covariate, but values for LSM remained constant (ceftiofur = 8.0 d, hetacillin 
= 6.2 d; P < 0.001). Table 2.7 describes the model of log of hospital days. On average, all 
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etiologies aside from Klebsiella spp. and other experienced more hospital days than no-growth 
cows. Using no-growth as the base in the model, only Staph. aureus differed statistically in 
hospital days. 
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Table 2.1. Basic description (numbers) of clinical mastitis (CM) cases and enrolled cases on 6 
commercial dairy farms (A-F) in New York during the trial period 
1Culture results falling into this category are defined in Table 2.2. 
  
Item A B C D E F Total 
Total CM cases  110 335 138 198 168 219 1,168 
Total nonsevere CM cases  94 226 132 183 161 211 1,007 
Number meeting eligibility criteria 74 130 84 105 129 105 627 
Number of cases maintaining enrollment 71 119 78 99 125 104 596 
Hetacillin  28 55 40 50 62 52 287 
Ceftiofur 43 64 38 49 63 52 309 
Culture results (pretreatment)        
No growth 30 53 11 18 40 31 183 
Gram-positive 17 29 48 44 43 41 222 
Gram-negative 8 17 8 35 29 16 113 
Other1 16 20 11 2 13 16 78 
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Table 2.2. Distribution of organisms between treatment groups for pre-treatment samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Included in other category of Table 2.1. 
2Includes non-Strep. uberis/non-Strep. dysgalactiae Streptococcus spp., Enterococcus spp., and 
Lactococcus spp. 
  
Organism 
Hetacillin, 
no. 
(n = 282) 
Ceftiofur, 
no. 
(n = 306) 
No growth 95 88 
No significant growth1 17 11 
Escherichia coli 36 45 
Klebsiella spp. 17 15 
Streptococcus dysgalactiae 47 37 
Streptococcus uberis 13 33 
CNS 5 6 
Staphylococcus aureus 21 26 
Other cocci2 20 26 
Other Enterobacteriaceae  6 2 
Other organisms 21 29 
Pseudomonas spp.1 0 1 
Pasteurella  1 5 
Proteus spp. 0 1 
Yeast1 4 8 
Prototheca spp.1 1 0 
Trueperella 
pyogenes1 
3 5 
Gram-positive 
bacillus 
1 1 
Contamination1 0 2 
Missing sample1 5 3 
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Table 2.3. Parameter estimates, SE, statistics, and odds ratios (OR) for fixed effects of a mixed 
logistic regression model evaluating bacteriological cure = true1 (n = 353) 
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis 
event, etiology, and linear score and milk production at test day previous to event. Farm was 
included as a random effect but had no contribution to variance. 
2Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, 
Prototheca spp., Trueperella pyogenes, Corynebacterium spp., Enterobacter spp., and 
Enterococcus spp. 
  
Parameter Description Estimate SE P-value OR 95% CI 
Intercept  0.79 0.28 0.037   
Treatment Hetacillin -0.25 0.26 0.32 0.78 0.47-1.3 
 Ceftiofur Referent     
Etiology Streptococcus uberis 0.28 0.42 0.50 1.3 0.58-3.0 
 Streptococcus spp. 0.0065 0.48 0.99 1.0 0.39-2.6 
 Streptococcus dysgalactiae 0.92 0.41 0.024 2.5 1.1-5.6 
 Staphylococcus aureus -1.48 0.42 0.0005 0.23 0.10-0.52 
 Klebsiella spp. 0.11 0.48 0.82 1.1 0.44-2.9 
 Escherichia coli 1.4 0.45 0.0023 4.0 1.6-9.7 
 Other2 Referent     
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Table 2.4. Parameter estimates, SE, statistics, and odds ratios (OR) for fixed effects of a mixed 
logistic regression model evaluating pathogen cure = true1 (n = 462) 
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis 
event, etiology, and linear score and milk production at test day previous to event. Farm was 
included as a random effect. 
2Milk production (kg) on test d 8 to 43 d before clinical mastitis event. 
3Linear score on test day d 8 to 43 d before clinical mastitis event. 
4Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, 
Prototheca spp., Trueperella pyogenes, Corynebacterium spp., Enterobacter spp., and 
Enterococcus spp. 
  
Parameter Description Estimate SE P-value OR 95% CI 
Intercept  1.5 0.61 0.054   
Treatment Hetacillin 0.12 0.21 0.57 1.1 0.75-1.7 
 Ceftiofur Referent     
Milk2  -0.027 0.01
1 
0.014 0.97 0.95-1.0 
Linear Score3  -0.10 0.05 0.037 0.90 0.82-0.99 
Etiology Streptococcus uberis -0.80 0.40 0.047 0.46 0.20-1.0 
 Streptococcus spp. -1.76 0.54 0.0011 0.18 0.063-0.51 
 Streptococcus 
dysgalactiae 
-0.75 0.33 0.026 0.49 0.25-0.94 
 Staphylococcus aureus -2.37 0.55 <0.0001 0.094 0.032-0.28 
 Klebsiella spp. -0.86 0.48 0.075 0.44 0.17-1.1 
 Escherichia coli 0.029 0.34 0.93 1.1 0.54-2.1 
 Other4 -0.61 0.33 0.066 0.56 0.29-1.1 
 No Growth Referent     
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Table 2.5. Parameter estimates, SE, statistics, and LSM for fixed effects of a mixed linear 
regression model evaluating postevent milk production (kg)1 (n = 484) 
1Within 8 to 43 d postevent. Parameters evaluated for potential confounding included cow 
parity, DIM at clinical mastitis event, etiology, and linear score and milk production at test 
day previous to event. Farm was included as a random effect. 
2Milk production (kg) at previous test-date (8-43 d premastitis event). 
3Included nonsignificant growth, Pseudomonas spp., 
Proteus spp., gram-negative bacillus, yeast, Prototheca 
spp., Trueperella pyogenes, Corynebacterium spp., 
Enterobacter spp., and Enterococcus spp. 
  
Parameter Description Estimate SE P-value LSM (kg) 95% CI 
Intercept  11.3 1.7 0.0011   
Treatment Hetacillin -1.2 0.68 0.091 37.0 35.9-38.2 
 Ceftiofur Referent   38.2 37.1-39.3 
Previous Milk2 (kg)  0.56 0.035 <0.0001   
       
Days in Milk 1-100 10.2 0.92 <0.0001 43.0 41.8-44.3 
 101-200 4.2 0.89 <0.0001 37.0 35.8-38.2 
 >200 Referent   32.8 31.3-34.3 
Etiology Streptococcus 
uberis 
-1.7 1.4 0.20 37.9 35.5-40.4 
 Streptococcus spp. -0.85 1.6 0.59 38.8 35.9-41.7 
 Streptococcus 
dysgalactiae 
-3.2 1.1 0.0033 36.5 34.6-38.3 
 Staphylococcus 
aureus 
-1.8 1.4 0.18 37.8 35.4-40.3 
 Klebsiella spp. -1.4 1.6 0.39 38.3 35.4-41.2 
 Escherichia coli -4.2 1.1 0.0002 35.4 33.6-37.3 
 Other3 -3.3 1.1 0.0026 36.4 34.5-38.2 
 No Growth Referent   39.7 38.4-40.9 
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Table 2.6. Parameter estimates, SE, statistics, LSM for fixed effects of a mixed linear regression 
model evaluating postevent linear score (LS)1 (n = 466) 
1Within 8 to 43 d postevent. Parameters evaluated for potential confounding included cow parity, 
DIM at clinical mastitis event, etiology and LS and milk production at test day previous to 
event. Farm was included as a random effect. 
2Linear score at previous test-date (8-43 d premastitis event) 
3Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, 
Prototheca spp., Trueperella pyogenes, Corynebacterium spp., Enterobacter spp., and 
Enterococcus spp. 
 
 
 
 
 
Parameter Description Estimate SE P-value LSM  95% 
CI 
Intercept  2.41 0.28 0.0004   
Treatment Hetacillin 0.36 0.21 0.086 3.4 3.0-3.8 
 Ceftiofur Referent   3.1 2.7-3.5 
Previous 
LS2 
 0.21 0.049 <0.0001   
Parity 1 -0.85 0.31 0.0064 2.9 2.3-3.5 
 2 -0.64 0.23 0.0065 3.1 2.7-3.6 
 ≥3 Referent   3.8 3.4-4.1 
Etiology Streptococcus uberis 0.92 0.41 0.024 3.5 2.7-4.3 
 Streptococcus spp. 0.082 0.48 0.87 2.7 1.7-3.6 
 Streptococcus dysgalactiae 0.76 0.33 0.024 3.3 2.8-3.9 
 Staphylococcus aureus 1.8 0.44 <0.0001 4.3 3.5-5.1 
 Klebsiella spp. 0.69 0.48 0.15 3.3 2.4-4.2 
 Escherichia coli 0.60 0.35 0.085 3.2 2.6-3.8 
 Other3 0.68 0.33 0.039 3.3 2.7-3.8 
 No Growth Referent   2.6 2.1-3.0 
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Table 2.7. Parameter estimates, SE, statistics, and LSM of a mixed linear regression model 
evaluating log(hospital days)1 (n = 344) 
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis 
event, etiology, and linear score and milk production at test day previous to event. Farm was 
included as a random effect. 
2Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, Yeast, 
Prototheca spp., Trueperella pyogenes, Corynebacterium spp., Enterobacter spp., and 
Enterococcus spp. 
 
 
 
  
Parameter Description Estimate SE P-value LSM (d) 95% CI 
Intercept  2.0 0.14 0.0007   
Treatment Hetacillin -0.26 0.03 <0.0001 6.2 4.7-8.1 
 Ceftiofur Referent   8.0 6.1-10.4 
Etiology Streptococcus uberis 0.05 0.08 0.50 7.0 5.1-9.4 
 Streptococcus spp. 0.11 0.072 0.11 7.4 5.6-10.0 
 Streptococcus dysgalactiae 0.087 0.058 0.14 7.23 5.5-9.6 
 Staphylococcus aureus 0.22 0.062 0.0004 8.3 6.2-11.0 
 Klebsiella spp. -0.055 0.068 0.42 6.3 4.7-8.4 
 Escherichia coli 0.017 0.050 0.74 6.8 5.2-8.9 
 Other2 -0.0025 0.054 0.96 6.6 5.0-8.7 
 No Growth Referent   6.6 5.1-8.7 
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Figure 2.1. Bacteriological (Bact.) and clinical (Clin.) cure percentages for the following 
mastitis etiologies on aerobic culture:  CNS, Staphylococcus aureus, Streptococcus 
dysgalactiae, Streptococcus uberis, and other streptococcal organisms. Error bars indicate 95% 
CI based on SE of the mean proportion. 
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Figure 2.2. Bacteriological (Bact.) and clinical (Clin) cure percentages for the following mastitis 
etiologies on aerobic culture: Escherichia coli, Klebsiella spp., and other defined as 
Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella 
pyogenes, Corynebacterium spp., Enterobacter spp., and Enterococcus spp. No significant (Sig) 
growth and no growth also included. Cows with no growth results were not included in 
bacteriological cure analysis. Error bars indicate 95% CI based on SE of the mean proportion. 
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Figure 2.3. Representation of outcome probability differences for hetacillin versus ceftiofur in a 
noninferiority comparison. The gray boxes represent the point estimates for each difference. 
Arrowheads indicate a 95% CI. Shaded area is representative of noninferiority. Intervals falling 
in the area >0 conclude superiority of hetacillin to ceftiofur. Values crossing -0.15 (the 
noninferiority margin) are inconclusive. Overall bacteriological cure = all etiologies. Pathogen 
cure is defined as absence of a pathogen on both follow-up samples (d 14 and 21). Pcure = 
Probability of cure. 
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DISCUSSION 
Using a noninferiority comparison, this study evaluated the efficacy of two IMM 
antibiotic preparations for the treatment of mild to moderate CM. The most important findings 
are summarized in Figure 2.3; the current study found that hetacillin was noninferior to ceftiofur 
in the primary outcomes of bacteriological, pathogen, and clinical cures and secondary outcomes 
describing survival to 30 and 60 d. Hetacillin was superior to ceftiofur when clinical days was 
dichotomized to less than or equal to 4 d. 
The overall bacteriological cure risk difference between the groups was -0.047. 
Noninferiority could be stated as the 95% confidence interval, -0.143 to 0.048, falls above the 
noninferiority margin of -0.15. When comparing gram-positive to gram-negative etiologies, a 
larger risk difference than for an overall comparison was seen in CM caused by gram-positive 
organisms. Upon further examination of the risk difference for gram-positive etiologies, it was 
noted that although numerically higher cure rates for hetacillin-treated CNS and hetacillin-
treated Staph. aureus cows than the respective ceftiofur-treated cows, ceftiofur had higher cure 
rates in the more represented culture outcomes such as Strep. dysgalactiae (Figure 2.1). The 
bacteriological cure risk difference was lowest (least negative) for gram-negative etiologies, 
resulting from a numerically higher but non-significant cure rate for ceftiofur-treated E. coli and 
Klebsiella cows versus the respective hetacillin-treated cows. The confidence intervals of the risk 
differences for gram-positive and gram-negative etiologies cross both the noninferiority limit and 
zero, suggesting that we lacked the power to identify an observed difference smaller than our 
declared margin. This may have been due to the smaller sample size when culture results were 
separated by gram-negative and gram-positive status.  
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Despite the large difference seen in bacteriological cure of Strep. dysgalactiae CM 
between hetacillin and ceftiofur-treated cows (ceftiofur having a greater cure), the rate of clinical 
cure by day 4 for this organism was greater for hetacillin-treated cows. The same could be seen 
for the gram-negative organisms E. coli and Klebsiella spp.: despite a numerically greater 
bacteriological cure for ceftiofur, this drug had a lower percentage of clinical cures for these 
organisms as compared to hetacillin. Analysis of the binary outcome “clinical cure in less than 4 
days” resulted in a positive risk difference of 0.119; a confidence interval beyond both the 
noninferiority limit, -0.15, and zero, indicates superiority of hetacillin over ceftiofur for this 
outcome (Figure 2.3). One could speculate that clinical cure rates may be higher for hetacillin 
cows due to bias: CS is a subjective measure and having to treat ceftiofur cows two additional 
days may have led observers to be more critical of symptoms before administration of 
medication. Blinding in regards to treatment was not performed in this trial, but producers and 
researchers were unaware of objective primary outcomes, including bacteriologic and pathogen 
cures and the quantitative secondary outcomes LS and milk production. 
In order to obtain the power and numbers needed to evaluate CM treatment efficacy, 
trials that use bacteriological cure as a primary outcome must restrict treatment assignment to 
cases in which bacteria are isolated. This then determines the need to wait for culture results 
prior to administration of the product (Schukken and Deluyker, 1995). In this study, we used a 
pathogen cure outcome, following and modifying the ideas outlined in Pinzón-Sánchez and 
Ruegg (2011) and Oliveira et al. (2013) to facilitate the inclusion of no-growth results. This 
allows researchers to analyze the risk of remaining pathogen free. Our values of 43% and 45% 
for pathogen cure of ceftiofur and hetacillin-treated cows, respectively, were lower than the 65% 
(n = 276/427) found in the Oliviera et al. study (IMM treatment with any antimicrobial). Low 
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values for pathogen cure may be due to the large number (~25%) of Strep. spp. positive cows in 
the trial. While the cure rate for CM caused by environmental streptococci may exceed 50%, 
cows can suffer frequent relapses (Guterbock et al., 1993; Van Eenennaam et al., 1995; Morin et 
al, 1998). The delay of treatment may have impacted these cows as aggressive IMM treatment of 
Strep. uberis CM has been shown to result in cure rates that exceed 90% (Hillerton and Kleim, 
2002).  
Our average clinical days, 3.4 and 3.7 for hetacillin and ceftiofur-treated cows, 
respectively, are lower than the ceftiofur-treated cows (4.5 d, n = 262) and cephapirin treated 
cows (4.9 d, n = 49) in a 2014 CM study performed by Oliveira and Ruegg. Our results were also 
less than cephalosporin treated cows in an earlier study (2011) by Pinzón-Sánchez and Ruegg 
(5.4 d, n = 143). This is likely due to our assignment of 5 clinical days to those cows that 
exhibited clinical signs beyond the initial observation period. An additional study detected lower 
values than found in the present study for clinical days, at 2.7 d and 3.2 d for blanket-treated 
cephapirin and selectively treated cephapirin cows, respectively (Lago et al., 2011a). Despite 
these deviations from our findings, all authors referenced concluded no statistical differences 
between treatment groups in days to clinical cure.  
For extended clinical outcome comparisons, 92% of hetacillin-treated cows and 91% of 
ceftiofur-treated cows retained their cured statuses on days 14 and 21 post-enrollment. This 
differs from the Schukken et al. (2013) study that found an overall clinical cure of 62% (n = 
184/296) at days 10 and 17. This may be due to the clinical scoring system in that study, which 
included rectal temperature, hydration scoring, and attitude assessment. 
The model for postevent milk production included etiology as a significant variable. 
When the causative microorganism was absent on initial culture (a no-growth result), cows 
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responded with a significantly higher milk production than those with growth. Mastitis is 
associated with losses in milk production, particularly for coliform cases (Grӧhn et al., 2004). 
Our data indicates that cows with E. coli average the greatest loss in milk production at next test 
day relative to other etiologies. Values were similar to a change of -4.62 kg found in a 2004 
study by Grӧhn et al. for cows 15-21DIM. In the latter study, however, Klebsiella affected cows 
suffered the greatest loss with an average change of -6.24 kg of milk per day during this time 
period. Our differences may be reflective of the few numbers of Klebsiella cases or the various 
genetic strains found on six dairies (Grӧhn et al., 2004).  
Parity, previous LS, and etiology were significant in a model for postevent LS. Inclusion 
of these variables agreed with known risk factors associated with short-term post-treatment 
outcomes ( Pinzón-Sánchez and Ruegg, 2011). In regards to etiology, Staph. aureus cows 
experienced the highest postevent LS. This is supported by the fact that Staph. aureus is 
commonly cultured in dairies with high bulk tank SCCs (Barkema et al., 1997). Treatment was 
not significant in the model. No comparisons have been described in recent literature between 
hetacillin and ceftiofur for post-treatment milk quality and quantity indices. However, a 2011 
trial performed by Schukken et al. concluded no significant differences in SCC nor milk yield for 
the remainder of the lactation when considering ceftiofur-treated gram-negative cases and 
untreated gram-negative cases.    
Noninferiority was described for hetacillin in both survival indices (Figure 2.3). 
Historically, the culling rate for CM cows was estimated to be more than twice that of non-CM 
cows; the risk of culling is highest in the period immediate to the mastitis event (Barkema et al., 
1997; Grӧhn et al., 2004). For this reason, we used a 60 d interval for event analysis, but 
expected to find similar results had we followed the cows for a longer period of time. Though 
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this is the first trial comparing IMM hetacillin to ceftiofur, recent selective treatment trials have 
reported no statistical differences in removal from the herd within the weeks after CM when 
cows were treated with different cephalosporin products or protocols (Lago et al., 2011a; Lago et 
al., 2011b). The costs of culling contribute to the total costs of CM and also influence the 
benefits returned from intensive antimicrobial treatments; knowledge of noninferiority of one 
product to another for survival indices is economically important (Steeneveld et al., 2011).  
Milk yield was similarly significant in Cox proportional hazards analysis when assessing 
survival in the herd and time-to-next-mastitis in the same quarter. However, the recurrence risk 
of CM was not dependent on etiology in our analysis. While this model agreed with a previous 
study performed by Lago et al. (2011b) in which the effect of organism was not significant, 
etiology was a sensitive indicator for recurrence risk in a streptococcal CM study (Van 
Eenennaam et al., 1995). The uneven distribution of Strep. uberis may have precluded the 
detection of an effect of etiology in survival analysis. Additionally, the larger percentage of these 
cows in the ceftiofur-treated group may introduce bias when assessing etiological analysis for 
each of the treatment outcomes, particularly if ceftiofur cows generally experience higher cure 
rates for this etiology.  
The only significant difference between treatment groups was for hospital days, with a 
difference in LSM of 1.8 d, favoring hetacillin. This difference results from two less treatment 
days for hetacillin cows while maintaining the same 72-hour milk withhold for each product. 
Within the design of the study, although milk withhold times were the same, treatment duration 
protocols for the drugs were not identical. Based on a recent Wisconsin study, which 
characterized an average duration for IMM ceftiofur use between 4 and 5 days, 5 days was 
selected for treatment length in this trial (Oliveira and Ruegg, 2014). The authors felt that 
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selection of this duration 1) reflected current farm use, and 2) permitted ceftiofur the best chance 
to display better efficacy over hetacillin. The hetacillin label indication dictated the 3 day 
treatment period for this drug. While the difference may be evident to readers, as producers are 
simply following the pasteurized milk ordinance, we were unable to assume that hetacillin-
treated nor ceftiofur-treated cows would experience unresolved clinical signs beyond the 
withhold date without actually testing it. Cows in the study remained in the hospital pen until 
their milk was no longer violative and symptoms of CM were resolved. Initial study design 
considered that clinical days may have been a more important factor in hospital day analysis than 
both the withhold and treatment durations. An economic analysis for hetacillin treatment in 
regards to decreased labor costs and increased days of saleable milk was not performed. 
When assessing severity of CM, approximately 14% of cows did not qualify due to 
systemic signs. This was similar to the 15.3% value found in a survey of 50 Wisconsin dairy 
farms (Oliveira et al., 2013), but higher than values found on a smaller survey (8%, n=266) and 
in a recent Canadian survey (10%, n=2,311; Olde Riekerink et al., 2008; Pinzón-Sánchez and 
Ruegg, 2011). Exclusion of severe CM cows limits the generalizability of our results to cows 
with nonsevere mastitis. Due to individualized farm-specific treatment for severe mastitis, 
additional trials would need to be performed to assess differences in the two antibiotic products.  
 
CONCLUSIONS 
 A CM trial comparing a 5 d treatment with ceftiofur to a 3 d treatment with hetacillin 
showed noninferiority of the latter in regards to bacteriological cure, clinical cure, pathogen cure, 
and survival to 30 and 60 days. When noninferiority analysis is applied to gram-positive and 
gram-negative etiological groups, the data is inconclusive. However, results are consistent with 
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the fact that these two IMM products are effective against one or more gram-positive organisms 
as well as the gram-negative E. coli. No statistically significant differences in continuous 
outcomes such as clinical days, postevent milk yields, and postevent linear scores were found 
between treatment groups. Hospital days differed favorably for hetacillin versus ceftiofur, 
allowing milk from hetacillin-treated cows to contribute to the bulk tank 1.8 days earlier than the 
respective ceftiofur-treated cows. No effect of treatment was observed on risk of leaving the herd 
in 60 d or on risk of experiencing a new mastitis event in the same quarter. Differences in 
bacteriological cure profiles, however, determine the importance of pre-treatment diagnostics. 
Farms with access to culture results may benefit most from our results. Our findings can aid in 
herd-specific decisions, specifically in developing treatment protocols for nonsevere CM. 
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ABSTRACT 
The purpose was to compare immediate intramammary antimicrobial treatment of all 
cases of clinical mastitis to a selective treatment protocol based on 24 h culture results. The study 
was conducted at a 3500 cow commercial farm in NY. Using a randomized design, mild to 
moderate clinical mastitis cases were assigned to either the blanket therapy or pathogen-based 
therapy group. Cows in the blanket therapy group received immediate on-label intramammary 
treatment with ceftiofur hydrochloride for 5 d. Upon receipt of 24 h culture results, cows in the 
pathogen-based group followed a protocol automatically assigned via Dairy Comp 305: 
Staphylococcus spp., Streptococcus spp., or Enterococcus spp. were administered on-label 
intramammary treatment with cephapirin sodium for 1 d. Others, including cows with no-growth 
or gram-negative results, received no treatment. A total of 725 cases of clinical mastitis were 
observed; 114 cows were not enrolled due to severity. An additional 122 cases did not meet 
inclusion criteria. Distribution of treatments for the 489 qualifying events was equal between 
groups (pathogen-based, n = 246; blanket, n = 243). The proportion of cases assigned to the 
blanket and pathogen-based groups that received intramammary therapy was 100% and 32%, 
respectively. No significant differences existed between blanket therapy and pathogen-based 
therapy in days to clinical cure; means were 4.8 d and 4.5 d, respectively. The difference in post-
event milk production between groups was not statistically significant (blanket therapy = 34.7 
kg; pathogen-based = 35.4 kg). No differences were observed in test-day linear scores between 
groups; least squares means of linear scores was 4.3 for pathogen-based cows and 4.2 for blanket 
therapy cows. Odds of survival 30 d post-enrollment was similar between groups (odds ratio of 
pathogen-based as reference = 1.6; 95% confidence interval: 0.7-3.7) as were odds of survival to 
60 d (odds ratio = 1.4; 95% confidence interval: 0.7-2.6). The one significant difference found 
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for the effect of treatment was in hospital days; pathogen-based cows experienced, on average, 3 
fewer days than blanket therapy cows. A majority (68.5%) of moderate and mild clinical cases 
would not have been treated if all cows on this trial were enrolled in a pathogen-based protocol. 
The use of a strategic treatment protocol based on 24 h post-mastitis pathogen results has 
potential to efficiently reduce antimicrobial use. 
Key words: clinical mastitis, cephapirin, ceftiofur, no treatment 
 
INTRODUCTION 
Clinical mastitis (CM) is defined by visible signs of inflammation in an affected 
mammary gland such as redness, swelling, pain or heat, and alterations such as clots, flakes, 
discoloration, or abnormal consistency of secretions. Clinical mastitis has a high incidence on 
North American dairy farms, ranging from 20% to 51% of cows (Sargeant et al., 1998; Olde 
Riekerink et al., 2008). This disease can create severe economic losses due to discarded milk, 
reduced production, decreased conception, premature culling, transmission to other cattle, and 
treatment costs (Fetrow, 2000; Hertl et al., 2014). Current practice on many farms is treatment of 
all CM cases or “blanket treatment” with intramammary (IMM) antimicrobials. In a previous 
Wisconsin study, 80% of all antimicrobial drugs used on dairies were used for treatment or 
prevention of mastitis (Pol and Ruegg, 2007a). Problems attributed to the use of antimicrobials in 
animals include potential drug residues in the food supply, possible development of 
antimicrobial resistance, and monetary losses associated with treatment and discarded milk 
(Owens et al., 1997; Barton, 2000).  
A recent economic deterministic approach estimated financial losses for CM during the 
first 30 days of lactation at $444 per case, accounting for diagnostics, antimicrobial costs, non-
 101 
 
 
saleable milk, veterinary costs, milk and reproductive losses, and replacement costs (Rollin et al., 
2015). Pathogen-specific treatment may be preferential in an economic model as it has the ability 
to decrease the use of antimicrobials, leading to reduced risks of residues and lower treatment 
and milk-discard costs (Schukken et al., 2011; MacDonald et al., 2011).   
Targeted therapy of CM using on-farm culture (OFC) results or other accurate diagnostic 
tools can replace the routine use of broad-spectrum antimicrobials, replacing the dated practice 
of treating without diagnosis (Hogeveen et al., 2011). Selective treatment of CM is defined as the 
use of antimicrobials only for cases that may benefit from them; outcomes regarding 
antimicrobial usage in specific pathogen groups have been studied in depth. Differences in cure 
rates between etiological bacteria may be attributed to the targeting of components of bacterial 
cell walls (Pyörälä et al., 1994) . This proves difficult in gram-negative bacteria due to their 
complex additional lipopolysaccharide layer, likely reflected in the failure of efficacy for 
antimicrobial products in induced coliform mastitis trials (Lago et al., 2014). Where 
antimicrobials are not used, 85% spontaneous bacteriological cure rates for experimentally 
induced gram-negative Escherichia coli have been observed by day seven (Leininger et al., 
2003). Furthermore, 30% or greater of CM cases exhibit culture-negative outcomes when 
sampled, for which the use of antimicrobials can be difficult to justify (Lago et al., 2011a; 
Oliveira and Ruegg, 2014).  
Contrary to gram-negative CM, many IMM products are labeled for the treatment of 
gram-positive bacteria. Aggressive intramammary treatment of clinical and subclinical cows 
infected with coagulase-negative Staphylococcus spp. (CNS) and experimentally induced cases 
of environmental Streptococcus uberis, for example, is often successful with some cure rates 
exceeding 90% (Oliver et al., 2004; Hillerton and Kleim, 2002). Alternatively, the spontaneous 
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cure rate for CM caused by environmental Streptococcus spp. may exceed 50% but these cows 
can suffer frequent relapses (Morin et al., 1998).  
 Subsequent to the publication of studies analyzing “gram-specific” treatment response, 
farms gravitated toward a “treat or no-treat” system: gram-positive environmental pathogens 
were treated with IMM antimicrobials and gram-negative and no-growth culture cows remained 
untreated. No significant differences were seen in probability of bacteriological cure of a culture-
based system versus blanket therapy when such a protocol was employed (Keefe et al., 2010). 
Likewise, Lago et al. (2011a,b) showed no significant differences between blanket treatment and 
selective treatment groups in CM recurrence, days to clinical cure, bacteriological cure risk, 
treatment failure risk, somatic cell count (SCC), culling, or milk production when 24-hour 
culture results were used to make treatment decisions on eight commercial farms.   
 Antimicrobial products currently available for IMM use not only have varying label 
claims that include effectiveness against gram-negative organisms, but also have diverse 
durations of use, formulations, and withdrawal periods, making it difficult to determine whether 
a treat or no-treat regimen is beneficial. Cephapirin sodium, a first generation cephalosporin, was 
recently described as noninferior to ceftiofur hydrochloride, a third generation cephalosporin, 
when considering bacteriological cure of gram-positive etiologies and clinical cure of all CM 
cases (Schukken et al., 2013). Results of this study led to speculation of how cephapirin would 
perform in a treat or no-treat pathogen-based system, as treatment time would result in three less 
antimicrobial treatments and four less treatment days per cow as compared to the more widely 
used ceftiofur: a Wisconsin survey of 51 dairies found of the cows receiving only IMM treatment 
for CM, 74.9% received ceftiofur and 13.7% received cephapirin (Oliviera and Ruegg, 2014). 
Economic benefits could be realized with reduction in treatment time, duration, and product cost. 
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The current trial is not a comparison of two different antimicrobials. Our objective, rather, was to 
determine if a protocol based on culture results, specifically treating gram-positives with 
cephapirin, offered similar outcomes to treating all cows with ceftiofur. To compare, we 
investigated differences in days to clinical cure, milk production, linear score (LS), risk of 
culling post-CM event, and hospital days. Our hypothesis is that a pathogen-driven treatment 
protocol as used in the current trial, may not only decrease the use of antimicrobials and protect 
aspects of public health, but also create economic benefits for the farm.  
 
MATERIALS AND METHODS 
Study Animals 
Clinical mastitis cases were assessed for inclusion at a 3500 Holstein-cow commercial 
dairy in central New York between December 2014 and April 2015 under Institutional Animal 
Care and Use Committee approval. This farm was chosen due to its large herd size, a monthly 
incidence of five to six percent CM, availability of reliable health records, consultation 
opportunity with management and veterinarians, and access to microbiological diagnosis of milk 
samples within 24 h of collection. This farm used Dairy Herd Information Association (DHIA) 
services, which included monthly SCC and milk weights. Health records included treatment, 
treatment pen moves, time to resolution of clinical signs, and culling data.  
 
Case Definition 
Each CM case was detected by trained on-farm employees by observing abnormalities in 
milk such as changes in consistency and color or “udder” signs including hard, swollen, or red 
quarters. Cows exhibiting severe symptoms such as depression, anorexia, dehydration, or fever 
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received systemic antimicrobials and anti-inflammatories and were excluded from the study. 
Other exclusion criteria were treatment with antimicrobials or anti-inflammatories in the 
previous 15 d or impending sale of the animal. Multiple quarters and subsequent cases from an 
individual cow were included. A cow was not excluded if it had multiple cases of mastitis before 
enrollment.  
 
Sample Collection and Treatment Assignment 
Using sterile technique, a milk sample was collected from each affected quarter into a 
milk culture tube. The tube was labeled and promptly placed in a 5°C refrigerator. Severity, 
quarter, and date entering hospital were recorded in Dairy Comp 305 (DC305). Culture results 
within 24 h of sample collection were achieved through the use of daily sample pick-up via the 
Quality Milk Production Services (QMPS) program at the Animal Health and Diagnostic Center 
in Ithaca, NY. The study was a randomized design with cows in the herd assigned by DC305 to 
either the blanket therapy group or the pathogen-based treatment group. If a cow was enrolled a 
successive time, the same treatment group was assigned.  
 
Microbiological Methods 
Standard culture technique was performed on all samples by QMPS employees according 
to National Mastitis Council guidelines for identification of aerobic organisms and Mycoplasma 
spp. (National Mastitis Council, 1999). Briefly, 0.01 mL of milk was streaked on trypticase soy 
agar containing 5% sheep blood and 1% esculin (PML Microbiologicals; Mississauga, ON, 
Canada) and MacConkey’s agar (Hardy Diagnostics; Santa Maria, CA) for identification of 
gram-negative organisms, and plates were incubated aerobically at 37°C for 18-24 h. After 
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observation of colony morphology and hemolytic patterns, isolates were examined further by 
means of 3% potassium hydroxide, gram staining, catalase and oxidase testing, PathoDx® Strep 
Grouping Latex tests (Thermo Fisher Scientific; Lenexa, KS), and additional biochemical and 
metabolic evaluations as needed. Mycoplasma spp. were identified using a dissection microscope 
after anaerobic incubation at 37°C for seven days on Mycoplasma agar (Sigma-Aldrich LLC; St. 
Louis, MO). 
Diagnosis and confirmation of IMM infection by culture of a single quarter milk sample 
was based on standard published definitions (Dohoo et al., 2011). Confirmation of etiologic 
cause was defined as the isolation of one or more colonies from ten microliters of milk for all 
pathogens except for CNS. For CNS, two or more colonies isolated from the sample were needed 
to establish the presence of an infection. When two or more different bacterial pathogens were 
identified in the same sample, the result was classified as a mixed infection. If one non-
pathogenic or ≥ two dissimilar non-pathogenic colony types were present in low levels (one to 
five colonies), the culture was defined as having “no significant growth” (i.e., the cow is unlikely 
to have an intramammary infection). Contamination was defined as the isolation of three or more 
different colony types (> five colonies each) from the milk sample.  
A cow in either treatment group with positive cultures for Prototheca spp., Mycoplasma 
spp., Staphylococcus aureus, or Streptococcus agalactiae was culled when its meat residue was 
no longer violative. This practice was standard herd policy before the start of the trial. Secondary 
IMM treatment after the eighth day of enrollment was allowed in cases that did not respond to 
initial treatment. Any cow not following protocol was excluded from analysis. Each cow was 
followed until the end of its current lactation, the date it was culled, or 60 d post-enrollment, 
whichever arrived first.  
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Treatment Groups 
Blanket Therapy Group (BT). Immediately after enrollment, cows received one tube of 
ceftiofur hydrochloride into the affected quarter(s) (Spectramast LC®; Zoetis, Florham Park, 
NJ). The treatment was repeated once every 24 h for five days according to label directions. 
Pathogen-Based Treatment Group (dPB). Direct upload of culture results to the on-farm 
computer was performed daily. Dairy Comp 305 automatically assigned the following treatment 
regimen based on pathogen: cows positive for CNS, Streptococcus grp G, Streptococcus grp C, 
Streptococcus dysgalactiae, Strep. uberis, or Enterococcus spp. were administered one IMM 
tube of cephapirin sodium (ToDAY®; Boehringer Ingelheim, St. Joseph, MO) every 12 h for 
two treatments according to label directions. A cow positive for any other organism or no growth 
on culture plates was assigned to no treatment. If two organisms were present or mastitis 
occurred in two quarters, the presence of CNS or Strep. spp. determined treatment in all CM 
quarters with cephapirin. 
All CM cows remained in the treatment pen until milk withdrawal times were met and 
milk returned to normal visual appearance. Entrance and exit dates, as well as the date that 
clinical signs became absent were recorded by trained on-farm personnel. Any cow that 
graduated to severe clinical signs exited the trial and was treated systemically according to 
veterinary recommendations.  
 
Treatment Outcomes  
Cows in the study were followed up for: clinical days, post-treatment milk production, 
post-treatment LS, survival in the herd, and hospital days. The clinical days outcome was defined 
as the time to clinical cure and was calculated as the number of days from entrance into the 
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treatment pen until milk, udder, and systemic abnormalities associated with CM were 
undetectable. Linear score is a transformation of SCC, calculated as [Ln(SCC / 100) / Ln(2)] + 3 
(Ali and Shook, 1980). Post-treatment LS and milk production were obtained from the test day 
8-43 d post-CM event. The hospital days outcome was defined as the time in the treatment pen 
and was calculated as the number of days between entrance and exit into and from this pen. All 
values and dates were retrieved from farm management (clinical days), DHIA test-day records 
(LS and milk production), and DC305 (culling and hospital days).  
 
Data Analysis  
The effects of selected explanatory variables on post-treatment outcomes were analyzed 
using general linear models for continuous variables and binomial logistic regression models for 
dichotomous outcomes. Continuous outcomes included clinical days, post-treatment milk 
production, post-treatment LS, and hospital days. Dichotomous outcomes included retention in 
the herd 30 d post-enrollment and retention in the herd 60 d post-enrollment. Continuous 
explanatory variables included milk production and LS at previous DHIA test (8-43 days before 
the event). Explanatory categorical variables tested were mastitis event (1st, 2nd, or >2nd), parity 
(1st, 2nd, or ≥3rd), and days in milk (0-100 DIM, 101-200 DIM, and >200 DIM). All analyses 
were performed in SAS© version 9.4 (SAS Institute, 2014) using PROC GLM and PROC 
LOGISTIC. To select the best model, all possible confounding variables were subjected to 
bivariate analysis by means of Chi-squared, t-tests, or analysis of variance tests using PROC 
FREQ, PROC TTEST, PROC REG, or PROC ANOVA. Interactions of each variable with the 
main effect of treatment group were assessed in a similar manner and any terms with a P-value < 
0.2 were offered into the models. Each variable was then examined by manual backwards 
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stepwise elimination in the regression until all possible explanatory variables with P < 0.1 were 
included. In many of the models, the treatment variable was forced (P > 0.1). We used least 
squares means (LSM) and α = 0.05 to describe means and confidence intervals (CI), 
respectively, unless otherwise noted. Additionally, basic graphing techniques were used to assess 
normality, homoscedasticity, and linearity of variables. Data transformations were performed 
and reported as necessary. 
Six final models were established describing 1) the average number of clinical days, 2) 
post-event milk production, 3) post-event LS, 4) the odds of survival at 30 d, 5) the odds of 
survival at 60 d, and 6) the average number of hospital days. Not all included animals had 
complete LS or milk yield data as some cows experienced the event in early lactation with no 
prior test day or experienced the event late in lactation with no post-CM test day. Cows were 
excluded from clinical days or hospital days analyses if pen moves were incomplete in the 
records. An animal was not included in a model if it was missing a data point for a parameter 
offered the model; the number of animals with complete data for each analysis is indicated in 
each table.  
 
RESULTS 
Descriptive Data 
A total of 725 cases of CM were observed. Of those, 489 cases were enrolled in the 
study. Distribution between groups was similar with 50% cows (n = 246/489) assigned to the 
dPB protocol and 50% of cows (n = 243/489) assigned to the BT group. Cows with severe 
mastitis, amounting to 16% (n = 114/725; dPB, n = 62; BT, n = 52; P = 0.33), were not eligible 
for enrollment. Cows were excluded from analysis if they received: the wrong treatment (n = 24; 
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dPB, n = 14; BT n = 10, P = 0.68), treatment with an additional antimicrobial within 7 d of 
enrollment (n = 57; dPB, n = 35; BT n = 22, P = 0.17), or an event entry error (n = 4; dPB, n = 1; 
BT, n = 3, P = 0.35). Cows excluded due to Staph. aureus positive and Mycoplasma spp. 
positive cultures were 4% (n = 28/725; dPB, n = 15; BT, n = 13, P =0.85) and 1% (n = 9/725; 
dPB, n = 8; BT, n = 1, P = 0.04), respectively. Of the 489 cases enrolled in the study, parity 
distribution was 19% (n = 93/489), 30% (n = 147/489), and 51% (n = 249/489) for first, second, 
and third lactation and greater. The overall mean and median for DIM was 165 d and 151 d, 
respectively. Sixty percent of cows (n = 294/489) were experiencing their first mastitis event of 
the current lactation; this number was greater in the BT group than the dPB group (dPB, n =137; 
BT, n =157; P = 0.05). The relationship is reversed in those cows experiencing their >2nd mastitis 
event (dPB, n = 57; BT, n = 35; P = 0.02). Distribution of these descriptors by treatment group 
can be seen in Table 3.1. The mean and median number of days between enrollment and retrieval 
of test day data was 23 d (S.D.=10 d) and 21 d, respectively.  
On a herd level, 70% (n = 340/489) of cultures produced diagnostic bacterial growth. The 
most commonly isolated pathogens at 24 h post-incubation were gram-negative bacilli (34%; n = 
164/489), followed by Streptococcus spp. (32%; n = 155/489) and CNS (2%; n = 10/489). At 48 
h post incubation, gram-negative organisms were further defined: 23% of all CM etiologies were 
Escherichia coli (n = 113/489), 6% Klebsiella spp. (n = 30/489), and 1% Pasteurella (n = 8/489). 
Among the gram-positive organisms, Strep. uberis was most commonly isolated (14%; n = 
66/489) followed by S. dysgalactiae (13%; n = 63/489), other Streptococcus spp. (4%; n = 
21/489), and CNS (2%; n = 11/489). The remaining 48 h diagnoses (gram-positive bacilli, 
Enterococcus spp., Corynebacterium spp., Enterobacter spp.) each represented less than 1% of 
all CM cases. Distribution of 24 h culture results by treatment group are listed in Table 3.2. 
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Treatment assignment and pathogen diagnostics resulted in 79 of 246 cows in the dPB 
treatment group receiving cephapirin, leaving 68% of CM cases (n = 167/246) in the dPB group 
not treated with IMM antimicrobials.  
 
Effect of Treatment Protocol 
Effect on Clinical Days. Cases were only eligible for clinical days analysis if they had a 
recorded date for when milk and udder signs returned to normal. Exactly 59 dPB cows were lost 
to follow up for clinical days analysis due to placement into a non-hospital pen during the first 
month of the trial. Full data existed for all variables in the model for 150 dPB cows and 219 BT 
cows. Mixed linear regression involved a log transformation of the clinical days outcome to 
provide normality of the variance. The resulting model provided a numerically lower number of 
clinical days for the dPB group, however, this difference was not statistically significant (LSM 
for dPB group = 4.5 d, BT = 4.8 d; P = 0.12). The results of the final regression model are shown 
in Table 3.3. The noticeable parameter in the model was milk production (P = 0.02), which 
indicated a decrease in clinical days as production increased. There was a trend for clinical days 
to increase with increasing DIM and increasing parity categories.  
Effect on Test-Day Milk. The average post-CM test-day milk for all cows with test-day 
data (n = 440) was 34.5 kg. Full data existed for 202 dPB cows and 206 BT cows in the model. 
Although not statistically significant, the mixed linear regression model indicated +0.7 kg milk 
for the dPB group (LSM dPB = 35.4 kg, BT = 34.7 kg; P = 0.48). As expected, pre-CM milk 
production had an effect on post-event milk production. Cows earlier in lactation (0-100 DIM), 
on average, produced 5 kg more milk than those later in their lactations (>200 DIM), P < 0.0001. 
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In this herd, parity was important with 1st and 2nd parities producing more milk than those ≥3rd 
parity (+2.8 kg; P = 0.04; +2.2 kg; P = 0.04, respectively).  
Effect on Test-Day Linear Score. No statistically significant difference existed in LS 
post-CM between cows assigned to either treatment program; BT cows experienced a lower 
numerical LS than dPB cows (n = 200 for BT, n = 196 for dPB; LS = 4.2 and 4.3, respectively; P 
= 0.58). As expected, LS before CM event was an important variable; as pre-CM LS increased, 
post-CM LS increased (P < 0.0001). Two other parameters remained important in the model: 
parity and mastitis event. These effects can be seen in Table 3.4. 
Effect on Probability of Survival at 30 d. A total of 451 observations were used in logistic 
analysis to model the probability of survival at 30 d post-event; 5% of CM cows with full data (n = 
23, BT = 14/226; dPB = 9/225) did not remain in the herd beyond this time point. No significant 
difference was detected in odds of survival 30 d post-CM event between the treatment groups 
(ORdPB = 1.6, 95% CI: 0.7-3.7; P = 0.31). The only variable that remained in the model was pre-
CM milk production. The odds ratio of this effect was 1.05 (95% CI: 1.02-1.26).  
Effect on Probability of Survival at 60 d. Similar to 30 day odds, no significant difference 
existed in odds of survival 60 d post CM event between the treatment groups (ORdPB = 1.4, 95% 
CI: 0.7-2.6; P = 0.29). Out of 451 CM cows, 11% (n = 50, BT = 27/226, dPB = 23/225) were 
culled by 60 d. Estimates that remained significant in the model were those describing milk 
production, parity, and mastitis event. Similar to the 30 d model, cows had increased odds of 
survival as milk production increased (ORdPB = 1.09; 95% CI: 1.02-1.17). Parities 1 and 2 had 
increased odds of survival over parity ≥3, and as the number of mastitis events in the current 
lactation increased categorically, odds of survival decreased. The logistic regression model 
describing ORs and CIs is shown in Table 3.5. 
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Effect on Hospital Days. Hospital days data was recorded for 424 CM cases, 184 in the 
dPB and 240 in the BT group; 57 dPB cows were lost to follow up for clinical days analysis due 
to placement into a non-hospital pen during the first month of the trial. The number of cows with 
full data that were included in the regression model was 388 (dPB = 166, BT = 222). A linear 
regression model for hospital days was also log-transformed for normality of variance and is 
shown in Table 3.6. After transformation of the estimates, LSM for hospital days was 5.8 d for 
the dPB group and 8.8 d for the BT; the BT group spent three additional days in the hospital pen 
(P < 0.0001).  
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Table 3.1. Cow-level descriptors for each treatment group 
1P-values based on bivariate analysis (t-test, Fisher exact) of each variable by treatment group 
2Cow-level mastitis event at time of enrollment for the current lactation 
3At test d 8 to 43 before enrollment  
 Treatment Group     
 Pathogen 
Based  
(n = 246) 
Blanket 
Therapy 
 (n = 243) 
 
Total 
 
Overall 
 
% of group 
P-value1 
Parity, no.      0.39 
1st  48 45 93   0.82 
2nd  67 80 147   0.20 
≥3rd  131 118 249   0.32 
DIM       
Mean 169 161  165  0.43 
Median 154 150  151   
Mastitis Event,2 no.      0.04 
1st  137 157 294   0.05 
2nd  52 51 108   > 0.99 
>2nd  57 35 92   0.02 
Milk yield,3 kg n = 232 n = 219  n = 451   
Mean 35.0 34.0  34.5  0.90 
Median 35.5 33.2  35.0   
Linear Score3  n = 231 n = 216  n = 447   
Mean 3.8 3.5  3.6  0.22 
Median 3.2 2.8  3.0   
Intramammary 
treatment, no. 
      
Ceftiofur  0 243   100  
No treatment 167 0   68  
Cephapirin  79 0   32  
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Table 3.2. Cow-level etiology of infection at detection1 
 Treatment Group  
 Pathogen- Based 
(n = 246) 
Blanket Therapy 
(n = 243) 
 
24 h Culture Result no. % no. % P-value2 
  No Growth  65 26 51 21 0.28 
  No Significant Growth 16 7 17 7 0.86 
  CNS 4 2 6 3 0.54 
  Streptococcus spp. 75 31 80 33 0.63 
  Gram-negative bacillus3 84 34 80 33 0.77 
  Yeast spp. 1 0.4 5 2 0.12 
  Trueperella pyogenes 1 0.4 2 0.8 > 0.99 
  Corynebacterium spp. 0 0 2 0.8 0.25 
1Etiological classification is based on aerobic culture results performed by Quality Milk and 
Production Services. 
2P-values based on bivariate analysis (Fisher exact) of each etiology by treatment group. 
3Postancillary testing, these organisms were further characterized as Escherichia coli, Klebsiella 
spp., Pasteurella, Citrobacter spp., or remained gram-negative bacillus at 48 h reading. 
 
 
 
Table 3.3. Parameter estimates and statistics for fixed effects of a linear regression model 
evaluating log(clinical days)1; n = 369 
Parameter Description Estimate  
 
LSM CD2 SE P-value 
Intercept  1.90  0.09 <0.0001 
Treatment Pathogen-based -0.06  4.5 0.04 0.12 
 Blanket Therapy Referent 4.8   
Milk production,3 kg  -0.005   0.002 0.02 
DIM4 0-100 -0.11  4.4 0.05 0.04 
 101-200 -0.08  4.5 0.05 0.08 
 >200 Referent 4.9   
Parity  1 -0.15  4.3 0.06 0.01 
 2 -0.07  4.6 0.04 0.10 
 ≥3 Referent 5.0   
1Parameters evaluated for potential confounding included parity, DIM at the clinical mastitis 
(CM) event, previous occurrence of a clinical mastitis case in the present lactation, and linear 
score and milk production at test day previous to event. 
2Least squares means for clinical days. 
3On test d 8 to 43 d before CM event. 
4At time of CM event.  
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Table 3.4. Parameter estimates and statistics for fixed effects of a linear regression model 
evaluating Linear Score (LS) on test day post clinical mastitis (CM) event (8-43 d)1; n = 396 
Parameter Description Estimate SE P-value 
Intercept  4.21 0.38 <0.0001 
Treatment Pathogen-based 0.12 0.21 0.58 
 Blanket Therapy Referent   
Parity  1 -0.95 0.30 0.002 
 2 -0.24 0.24 0.31 
 ≥3 Referent   
LS2  0.26 0.05 <0.0001 
Mastitis event3 1st case -1.06 0.30 <0.0001 
 2nd case -0.75 0.33 0.02 
 >2nd case Referent   
1Parameters evaluated for potential confounding included parity, DIM at CM event, previous 
occurrence of a CM case in the present lactation, and LS and milk production at test day 
previous to event.  
2On test day 8-43 d before CM event.  
3At time of CM event. 
 
 
 
Table 3.5. Logistic regression for survival to 60 d after clinical mastitis (CM) 
event1; n = 451 
Parameter Description Estimate SE P-value Odds 
Ratio 
95% CI 
Intercept  -0.53 0.66 0.42   
Treatment Pathogen-
based 
0.33 0.31 0.29 1.4 0.7-2.6 
 Blanket 
Therapy 
Referent     
Milk production,2 kg  0.08 0.03 0.01 1.09 1.02-
1.17 
Parity 1 0.64 0.47 0.17 1.9 0.8-4.7 
 2 0.87 0.40 0.03 2.4 1.1-5.2 
 ≥3 Referent     
Mastitis event 1st 0.98 0.38 0.01 2.7 1.3-5.6 
 2nd 0.40 0.41 0.32 1.5 0.7-3.3 
 >2nd Referent     
1Probability modeled was “alive” at 60 d. Covariates evaluated for potential confounding 
included parity, DIM at CM event, previous occurrence of a CM case in the present lactation, 
and linear score and milk production at test day previous to event.  
2On test d 8 to 43 before CM event.  
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Table 3.6. Parameter estimates and statistics for fixed effects of a linear regression model 
evaluating log(hospital days)1; n = 388 
1Parameters evaluated for potential confounding included parity, DIM at the clinical mastitis 
event, previous occurrence of a clinical mastitis (CM) case in the present lactation, and linear 
score and milk production at test day previous to event.  
2On test d 8 to 43 before the CM event. 
  
Parameter Description Estimate  
 
LSM SE P-value 
Intercept  2.38   0.09 <0.0001 
Treatment Pathogen- based -0.41 5.8 0.04 <0.0001 
 Blanket Referent 8.8   
Milk production,2 kg  -0.005  0.002 0.01 
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DISCUSSION 
We found that using a pathogen-based treatment protocol compared with a blanket 
therapy protocol for mild to moderate clinical mastitis resulted in no significant differences in 
days to clinical cure, post-event milk production, test-day linear score, and survival to 30 and 60 
d. Our study did not provide a direct comparison between a first generation cephalosporin, 
cephapirin, and a third generation cephalosporin, ceftiofur, as was done in the noninferiority 
comparison performed by Schukken et al. in 2013. Instead, we described an overall comparison 
of two distinct protocols; assessments between antimicrobial products were not included nor 
were important to our objectives. While no differences existed between treatment groups for 
many of the evaluated outcomes, we found an advantage to the use of a protocol that selectively 
treated 32% of cows with IMM cephapirin while not treating a majority of others: a significant 
decrease in the average number of hospital days (three days). No-growth, no significant growth, 
and gram-negative bacillus together accounted for more than 60% of mild to moderate cases of 
CM in this trial, meeting the described patterns in recent studies (Schukken et al., 2013; Oliveira 
and Ruegg, 2014).  
Our average clinical days, 4.7, and clinical days by group (4.8 and 4.5) are comparable to 
the respective nonsevere ceftiofur-treated (4.5 d, n = 262) and cephapirin-treated cows (4.9 d, n = 
49) in a recent Wisconsin mastitis survey (Oliveira and Ruegg, 2014). Our result was less than 
the ceftiofur-treated cows in an earlier study performed by the same group (Pinzón-Sánchez and 
Ruegg, 2011). The authors expressed that the large value, 5.4 clinical days, was due to the 
administration of IMM antimicrobials until the complete resolution of clinical signs. Another 
study detected lower values than those found in the present study, at 2.7 d and 3.2 d for blanket-
treated cephapirin and selectively treated gram-positive cases, respectively (Lago et al., 2011a). 
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Sixty-seven percent of CM cows treated with cephapirin and an equivalent percentage of 
oxytocin-only treated cows exhibited clinical cure by 4.5 d after treatment in a study by 
Guterbock et al. (1993). In the current study, 52% (n = 85/163) and 39% (n = 92/235) exhibited 
clinical cure by 4.5 d for dPB and BT therapies, respectively. The Schukken et al. study (2013) 
analyzed this outcome using a different method; the authors described noninferiority for overall 
clinical cure when comparing on-label IMM cephapirin versus 5 d IMM ceftiofur. The 2013 
study described no absolute difference (0%) when considering clinical observations at days 10 
and 17 post-CM. Our risk difference for a clinical cure by day 4.5 was noted above as 13% 
between treatments and reflects observations performed at earlier time points. Despite deviations 
from our findings, all authors referenced concluded no statistical differences between treatment 
groups in days to clinical cure.  
Several reasons influenced our choice of evaluating clinical cure as an index of outcome. 
While the “gold standard” approach in research studies to evaluate treatment efficacy is serial 
culture for bacteriological cure, many initial cultures can return negative results, limiting the 
ability to determine cure. Follow-up samples also may result in a different pathogen or 
contamination. Bacteriologic cure rates at 14 and 21 days in CM cows treated with pirlimycin 
were not significantly different for cows with mastitis caused by susceptible or resistant bacteria, 
indicating that this index of cure may not always be valid (Hoe and Ruegg, 2005). An indirect 
assessment such as LS or SCC as well as simple assessment of resolution of clinical signs 
provides a reliable perception of treatment success (Lago et al., 2004; Bradley and Green, 2009; 
Bradley et al., 2012). In fact, most producers pursue a remission of clinical signs foremost over 
immediate elimination of the causative organism; when the owner is not actively engaged in 
milking, the decision-making process is based on evaluation of individual-cow milking 
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performance and observations by the milking staff (Roberson, 2003; Pinzón-Sánchez and Ruegg, 
2011). For these reasons, we measured the number of days to resolution of clinical signs. 
Resolution of clinical signs is a subjective measure and blinding in regards to treatment was not 
performed in this trial. However, producers and researchers were unaware of objective primary 
outcomes, including LS, culling, and milk production. We acknowledge that normal milk may 
not constitute elimination of the infection, and likewise, the clinical phase may extend beyond 
the time of bacteriological cure. These are disadvantages to the use of a clinical scoring system 
(Roberson, 2003). Bacteriological cure using serial cultures can provide an additional indicator 
of efficacy and could be pursued to quantify differences in response between protocols. 
Furthermore, bacteriological culture of post-mastitis samples would be advantageous for 
determining the presence and comparison of new and chronic intramammary infections between 
groups. 
Previous and current research has established that differences in cure rates are associated 
with etiology, previous milk yield, previous SCC, previous occurrence of CM, treatment 
duration, parity or lactation of the animal, and stage of lactation (Pinzón-Sánchez and Ruegg, 
2011). As the decision to treat BT cows was independent of pathogen result (these cows were 
treated immediately), a valid comparison of the treatment groups did not include pathogen in the 
model for clinical days. At diagnosis of CM, milk samples were retrieved and cultures were 
performed for cows in both groups to ensure that: randomization occurred without creating bias 
for individual etiologies, cows with contagious organisms were identified, and cows in the dPB 
group received their treatment assignment. Objectives did not include assessing the impact of 
culture results on treatment outcomes, but rather the impact of the selected protocols. Subsequent 
mastitis events at the quarter-level were not followed; this is a limitation of the current study. 
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Analysis and interpretation of follow-up mastitis events between groups would be difficult to 
assess as an unequal distribution in the categories of mastitis event number at enrollment existed 
(Table 3.1). More cows experiencing their first case of mastitis were allocated to the BT group, 
while more animals experiencing their 3rd or greater event were allocated to the dPB group. 
Cows with previous cases of CM are less likely to respond to therapy: a previous study by 
Pinzón-Sánchez et al. (2010) including 143 cases of CM showed that cows treated in the current 
lactation for the first time were 11 times less likely to have a recurrence than those experiencing 
a previous case of CM. Also, an increase in mastitis events during a lactation can result in 
decreased milk production, increased LS, increased risk of culling, and an increase in hospital 
and clinical days, creating a bias away from the null when considering differences in outcomes 
between groups. In this trial, any contribution of selection bias creates more opportunity for the 
dPB cows to experience these negative outcomes. Variables listed in the Pinzón-Sánchez study, 
including mastitis event number, were initially included as potential confounders when 
constructing a model and no statistical differences between treatments were observed.  
Milk production and LS post-CM event were not significantly different between 
treatment groups in the current study. Our results were consistent with three previous mastitis 
trials comparing blanket treated to selectively treated cows (“no growths” and coliform-positive 
cows did not receive antimicrobials). No significant differences in LS or milk production were 
detected between groups (Van Eenennaam et al., 1995; Roberson et al., 2004; Lago et al., 
2011b). A fourth study depicted no significant differences in post-event LS or in milk production 
between first and third generation cephalosporin treatments (Schukken et al., 2013). Conversely, 
a study by Shim et al. (2004) reported a continued loss of production for cows that were not 
treated with antimicrobials; in comparison, treated animals suffered 1/3 of the stated loss. 
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Approximately 40% of the cows in the 2004 study were experiencing their second or greater case 
of mastitis and distribution of cases between treatment groups was not described. Additionally, 
the author recognized that the continued milk loss in CM cases may have resulted from persistent 
subclinical mastitis.  
 The current study found no significant differences between treatment groups when 
assessing survival in the herd to 30 and 60 d. Similarly, Lago et al. (2011a) found no statistical 
differences in removal from herd within 21 d when assessing outcomes for blanket-treated 
cephapirin cows versus a protocol treating only gram-positive CM cows. A subsequent time-to-
event analysis from the same data set concluded that days to culling between groups was similar 
(Lago et al., 2011b). Previous to both studies, a 1995 trial assessing two different IMM 
treatments versus non-treatment of CM resulted in no differences in removal from the herd, an 
outcome that was independent of etiology (Van Eenennaam et al., 1995). In our study, milk yield 
at test was the most important predictor for retention in the herd when assessing survival indices. 
This agreed with a recent study assessing risk factors associated with short-term post-treatment 
outcomes (Pinzón-Sánchez and Ruegg, 2011).  
Approximately 60 untreated dPB cows were placed into a non-hospital pen at time of 
diagnosis, creating potential bias in the models for clinical and hospital days. These cows exited 
the hospital pen at day zero; time to resolution of clinical signs is difficult to determine. Despite 
omission of these cows from clinical and hospital day analysis, the mean number of hospital days 
for those cows included was significantly different between groups. The authors were aware of 
the possibility of a three day difference in outcomes when the trial commenced. Drug labels 
designate that using an antibiotic with a one-day treatment and 96 h milk withhold versus using 
an antibiotic with a five-day treatment and 72 h milk withhold would result in a three day 
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difference. However, dPB cows had a delay in treatment by 24 hours, resulting in a projected 
difference of two days. Also, we could not assume that ceftiofur-treated cows, cephapirin-treated 
cows (16% of the 489 enrolled cows; n = 79) nor untreated cows (34%; n = 167) would 
experience resolution of clinical signs before the withhold date. Cows with etiologies known to 
have a longer duration of clinical signs at this farm (E. coli, Klebsiella spp.) were not treated in 
the dPB protocol; it was anticipated that these cows would contribute a higher number of clinical 
days to this group. Additionally, clinical signs proceeded beyond the withhold date for 52% of 
cephapirin-treated cows with full data (n = 38/73), which included a large percentage of 
Streptococcus spp. positive mastitis cases (n = 36). Of all cows experiencing greater than six 
clinical days, 56% had Streptococcus spp. positive cultures (n = 56/100). Of the cows in the dPB 
group, 33% (n = 54 of 163 with full data) experienced unresolved clinical signs by day six. 
  The three day difference in days out of the tank between the BT and the dPB groups is an 
important attribute when considering economics. Pinzón-Sánchez et al. (2011) performed a 
decision tree analysis on treatment strategies for mild and moderate first-case CM in early 
lactation and found that the most cost-effective strategy when implementing OFC was to treat 
gram-positive pathogens for two days (one treatment per day) while permitting culture-negative 
and gram-negative results to “self-cure.” The mentioned study did not investigate the economics 
of treating twice daily for one day, which would involve the same costs for treatments and labor, 
but dependent upon withdrawal time of product used, may decrease costs associated with 
discarded milk. Regardless, when modeling for pathogen, probability of recurrence, and 
probability of cure, routine extended therapy ( ≥ five days) was not economically optimal under 
any circumstance (Pinzón-Sánchez et al., 2011). Extended antimicrobial treatments, defined as 
greater than three days of IMM treatments with or without systemic antimicrobials or anti-
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inflammatories, did not result in outcome benefits (i.e., fewer follow up treatments, less milk 
production, less culling) in excess of treatment costs (Steeneveld et al.; 2011).  
 Until recently, the impact of delaying CM treatment for 24 h to allow for culture was not 
well defined; the idea that use of a pathogen-based system produced undesirable outcomes as 
compared with implementation of immediate treatment was a valid consideration. However, 
several studies have addressed this question, particularly for the delayed treatment of gram-
positive CM etiologies. Immediate versus delayed treatment of all CM cases producing growth 
on agar or delayed treatment of only gram-positives cases indicated no differences in survival 
indices (Wagner et al., 2007; Lago et al., 2011b), LS and milk production (Lago et al., 2011b), 
clinical and bacteriological cures (Lago et al., 2011a), or mastitis recurrence (Wagner et al., 
2007; Lago et al., 2011b). Conversely, these cases tended to have shorter milk discard time while 
decreasing antimicrobial use (Lago et al., 2011a). The majority of the referenced studies include 
data from multiple dairies. The authors recognize that trials using more than one herd may 
provide additional data that includes or accounts for variation among herds; a weakness in the 
current study exists if this study population is not representative of an external population. 
Certainly one should not generalize the results of this study to dairy farms that are not like this 
one. Despite the use of one dairy, ad-hoc power analysis produced confidence in our results: with 
a power of 90% and a Type I error rate of .05, we were able to detect differences in clinical and 
hospital days of 1.2 days or more, a 0.2 or more kg difference in milk yield, odds ratios of 1.2 or 
greater for 30 and 60 d survival, and differences in linear score of 0.22 or more. While a large 
sample from one herd may impact external validity and generalizability to heterogeneous dairies, 
it likely increases the reliability of application of the results to similar dairy farms. 
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Resistance to antimicrobials may contribute to the similarities found between treatment 
groups in the current study. Previous research indicates that resistance to cephalosporins may be 
more prevalent in gram-negative versus gram-positive mastitis-causing pathogens. Ruegg et al. 
(2015) analyzed phenotypic profiles of gram-positive, mastitis-causing organisms and 
determined that while ceftiofur and cephapirin were the most commonly used IMM products in 
the enrolled herds, almost none of the pathogens were phenotypically resistant to those 
compounds. The latter study agreed with the results of a European trial performed by Thomas et 
al. (2015). Particularly, among clinical mastitis isolates of Strep. uberis and Staph. aureus, 
resistance to beta-lactam antibiotics was absent. For E. coli, there was an absence of resistance 
for ceftiofur and minimal resistance for cephalexin (Thomas et al., 2015). Alternatively, 
Srinivasan et al. (2007) and Erskine et al. (2002) found cephalosporin resistance in 15.5% and 
25.5% of E. coli isolates from cows with mastitis, respectively. As over 20% of cows in the 
current trial were culture-positive for E.coli, ceftiofur-treated resistant isolates may have 
decreased any differences in outcomes that could be realized. Regardless, the objectives of this 
trial were to compare treatment protocols and the cow-level response for each protocol; despite 
any resistance in mastitis isolates, benefits to the use of blanket therapy in regards to the 
explored outcomes were not found. Additionally, herds that use systemic ceftiofur for the 
treatment of various health conditions are more likely to have cows with less susceptible fecal 
isolates of E. coli than those that did not report ceftiofur use (Tragesser et al., 2006), suggesting 
that on a herd level, reduction of antimicrobials can decrease the potential for development of 
resistance.  
Protocols that practice judicious and targeted use of antimicrobials by rapid identification 
and diagnosis not only decrease the potential for development of antimicrobial resistance, but 
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also address a concern with violative residues. The risk of a residue violation is directly 
associated with IMM antimicrobial use (McEwen et al., 1991). It has been reported that drugs 
used for the treatment of CM contribute the highest average daily dose per cow per year (DDD) 
at 2.0 followed by drugs used for dry cow therapy at 1.58. These numbers compare with doses 
for the treatment of other ailments such as foot rot (0.39 DDD), metritis (0.32 DDD), and 
respiratory illness (0.14 DDD). The mean overall density of ceftiofur use in the report was 
significantly greater than the density of use for other compounds labeled for IMM CM treatment 
(Pol and Ruegg, 2007b). In the current trial, the assignment and administration of an IMM 
cephalosporin product based on pathogen results apportioned the antimicrobial to less than 40% 
of nonsevere mastitis cases.  
 
CONCLUSIONS 
Many organisms that cause mastitis are successfully cleared by a cow’s immune 
system—a shift in etiologies of current dairies to mostly gram-negatives or “no growths” rather 
than contagious or gram-positive organisms creates a large opportunity to reduce the use of 
antimicrobials. Greater than 65% of moderate and mild CM cases would not have been treated if 
all cows on this trial were enrolled in a pathogen-based protocol. This strategic method of 
treatment decreased milk withholding time by three days for those cows on a pathogen-based 
treatment protocol, with no significant differences in days to clinical cure, milk yield, and LS 
post-mastitis event; nor additional odds of culling in the two months following. If mastitis 
treatment decisions are based on scientific reasoning and data indices, economic returns and 
aspects of public health will be protected. 
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ABSTRACT 
 
 The purpose was to determine if a pathogen-based treatment protocol for nonsevere 
clinical mastitis could be effectively implemented on moderate-sized dairies that might not have 
daily access to a professional diagnostic laboratory. The study was conducted at 8 commercial 
dairy farms in central New York (500-1,000 milking cows). Two different “diagnostic” groups 
were investigated. Dairies in the on-farm culture group (n = 2) were trained to use Minnesota tri-
plates to diagnose every case of nonsevere clinical mastitis. Dairies in the 5-day pickup group (n 
= 6) submitted milk samples from all nonsevere mastitis cases to Quality Milk Production 
Services at the Cornell Animal Health and Diagnostic Laboratory 5 days per week and waited 24 
h for diagnostic results prior to the treatment of clinical cases. Upon receipt or interpretation of 
results, dairies in both groups followed a treatment protocol decided upon by management and 
the herd veterinarian. Briefly, all dairies chose to treat non-contagious gram-positive pathogens 
with an intramammary antibiotic according to the manufacturer’s label. All dairies chose not to 
treat any quarter with a negative culture result. Variation existed in regards to treatment of gram-
negative pathogens.  A total of 1,031 cases of nonsevere mastitis were enrolled. Compliance to 
the protocol ranged from 59% to 96% and was higher for the dairies in the 5-day-pickup group. 
When delayed pathogen-based treatment was practiced, no important changes were noted in 
monthly mastitis incidence on seven of the dairies. Bulk tank somatic cell count was also similar 
before and after the study for these dairies. No changes in mature equivalent milk production 
were observed for the 8 dairies. One dairy experienced a drop in the bulk tank somatic cell count 
of 100,000 cells/mL, which can be explained by their apparent increase in monthly mastitis 
incidence. This suggests improved proficiency in mastitis detection for this herd. Overall, 
inconsistencies and irregularity of data recording, in respect to mastitis events and treatments 
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was drastically improved with implementation of the program.  Reductions in antimicrobial 
usage ranged from 6.8% to 92.5% dependent on farm protocol and pathogen profile of the herd. 
Decreased antibiotic use resulted in savings between $2,200 and $4,600 per dairy per year when 
cost of cultures was accounted for. The use of a pathogen-based treatment protocol based on 5-
day per week results or on farm-culture results has the potential to decrease antimicrobial use, 
promote product sustainability, and protect aspects of public health.  
 
INTRODUCTION 
Clinical mastitis (CM) is defined as inflammation or infection of the mammary gland and 
is detected by visible signs of inflammation such as redness, swelling or pain, and alterations in 
milk such as clots, flakes, discoloration, or abnormal consistency. This disease remains the most 
common bacterial disease on dairies and its high incidence (20.4-51.0%) accounts for the 
majority of antimicrobials administered to lactating dairy cattle (Pol and Ruegg, 2007, Olde 
Riekerink et al., 2008). This disease can incur severe economic losses due to discarded milk, 
reduced production, decreased conception, premature culling, transmission of infection to other 
cattle, and treatment costs (Fetrow, 2000, Hertl et al., 2014a, b). Current practice on many dairy 
farms is treatment of all CM cases or “blanket treatment” with intramammary (IMM; into the 
mammary gland) antimicrobials. In a Wisconsin study (Pol and Ruegg, 2007), 80% of 
antimicrobial drugs used on dairies were for treatment or prevention of mastitis. However, many 
organisms that cause mastitis are successfully cleared by a cow’s immune system—a recent shift 
in etiologies to a majority of gram-negatives or “no growths” rather than contagious or gram-
positive organisms creates an opportunity to reduce the use of antimicrobials. Multiple “treat” 
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and “no-treat” CM regimens have been tested using on-farm clinical trials; results describe no 
important differences in clinical outcomes between groups (Lago et al., 2011b, a, McDougall et 
al., 2018). 
 A recent study by our group (Vasquez et al., 2017) used a randomized field trial to assign 
nonsevere CM cases to either the blanket therapy group (BT) or the delayed pathogen-based 
therapy group (dPB). This work was performed on a 3,500 cow dairy with a 5-6% monthly 
incidence of CM. Cows in the BT group received immediate IMM treatment with a 3rd 
generation cephalosporin every day for 5 days. Upon receipt of 24 h culture results, cows in the 
dPB group followed a protocol automatically assigned via the dairy computer: gram-positive 
organisms such as Staphylococcus spp. and Streptococcus spp. were administered IMM 
treatment with a first generation cephalosporin for 1 day. Others, including cows with negative 
cultures or gram-negative pathogens received no treatment. Statistical comparisons were 
performed between treatment groups for clinical outcomes. The strategic method of treatment 
decreased the time that milk had to be discarded by 3 d for those cows in the dPB group, with no 
significant differences in days to clinical cure, milk yield, and linear score post-mastitis event; 
nor additional odds of culling in the 2 months following. Greater than 65% of moderate and mild 
CM cases would not have been treated if all cows were enrolled in a pathogen-based protocol. 
An additional economic analysis performed on the same data established that greater than 
$30,000 per 1,000 cows would be returned if this protocol was used at similar dairies. If mastitis 
treatment decisions are based on scientific reasoning and data indices, economic returns and 
aspects of public health will be protected. Non-prudent use of antimicrobials as therapeutics can 
have a negative impact on sustainable agriculture by reducing drug efficacy, as pathogenic 
microorganisms can develop resistance, leading to cycles of prolonged use of the same drug or 
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supplemented use of alternative antimicrobials. Use of antimicrobials on dairies has been shown 
to have a direct positive correlation to the risk of drug residues in fluid milk sold to processing 
entities (McEwen et al., 1991).  
Our trial was unique in that it involved a 24 h turnaround of culture results 7 d per week. 
Cows experiencing mastitis that eventually went on to be treated (gram-positive culture results) 
were only delayed by this short amount of time. Additionally, cultures were performed at a 
certified diagnostic laboratory allowing for accuracy of results and confirmation of contagious 
and more obscure organisms. However, many smaller, widespread dairies may not have access to 
a reference laboratory with a 24 h turnaround. We intended to continue and evaluate our protocol 
on the more representative, moderate-sized dairies of NY State (500-1,000 cows) using either 
on-farm culture, which has been assessed as a rapid and reliable way of diagnosis (Mansion-de 
Vries et al., 2014, Royster et al., 2014) or a 5 d per-week sample pickup, simulating a veterinary 
facility or diagnostic lab with the capacity to culture less frequently.  
We wished to evaluate the practicality of a pathogen-based treatment protocol on dairies 
that do not have daily access to sample submission. To this end, our objective was to create a 
network of involved and engaged dairy producers to assess 2 alternatives: less frequent sample 
retrieval (simulating a 5 d per-week veterinary laboratory) and on-farm 24 h culture diagnosis, or 
“OFC”. If application of our protocol on these dairies can successfully reduce antimicrobial use 
by greater than 60% without negative outcomes, widespread education of the judicious use of 
antibiotics by dairy farmers in states such as NY, which have prominent contributions to milk 
products, can create positive impacts on sustainability by preventing the selection of resistant 
organisms, thereby increasing product efficacy.  
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MATERIALS AND METHODS 
This study was approved by Cornell IACUC under Quality Milk Production Services 
#2013-064. 
 
Herd Selection 
 The study involved 8 Holstein dairy herds in central New York with a herd size target of 
<1,000 milking cows. Each dairy was targeted to enroll 150 cases of nonsevere clinical mastitis 
between February 2017 and December 2017. Farm characteristics can be seen in Table 4.1. 
Herds were selected based on their willingness to take samples from mastitic quarters and to use 
on-farm culture (OFC), or to refrigerate samples immediately and notify Quality Milk 
Production Service (QMPS) at the diagnostic lab at Cornell University for prompt sample 
retrieval (5 d pickup). Farms had to be using IMM antibiotics for the treatment of the majority of 
mild and moderate mastitis cases to be enrolled.  Farms using QMPS diagnostics had to be 
willing to delay treatment by 24 h and either treat on the days when sample pickup did not occur, 
or to wait two additional days for culture results. Additionally, all herds sending samples to 
QMPS had to use Dairy Comp 305 (DC305) computer recording, as 24 h culture results were 
uploaded to this program.   
 
Enrollment of Cases  
All parlor employees were trained to recognize signs of mild-to-moderate clinical 
mastitis. This included abnormal color or consistency of the milk (flakes, flecks, clots), and/or 
redness and swelling of the quarter. Any cow that was showing systemic illness including 
dehydration, pyrexia, or depression was not enrolled in the trial and was treated according to the 
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herd veterinarian’s instructions. Using aseptic technique, milk samples were retrieved from each 
affected quarter, labeled with the cow number, quarter, and the date, and placed immediately in a 
5°C refrigerator.  
 
Diagnostic Groups 
On-Farm Culture (OFC) Herds. Herds A and B each nominated one person responsible 
for the microbiological procedures. Each herd was provided an incubator that was to be 
maintained at 37°C. Humidity was supplied using a small container of water within the unit. 
Training was provided by the author and was supplemented with color handouts, including the 
Minnesota Easy Culture System guide. Training included inoculating the agar with sterile swabs, 
interpretation of the results, and recording of the data. The media provided was the Minnesota 
Tri-plate (University of Minnesota, St. Paul, Minnesota), which consisted of three different 
media on one plate: selective media for gram-negative bacteria (MacConkey media), selective 
media for Streptococcus and Streptococci-like species (Modified TKT Media), and selective 
media for gram-positive bacteria and yeast/fungi (Factor Media). The nominated person initiated 
cultures on the day that milk samples were collected. A sterile cotton swab was saturated with 
the milk sample prior to inoculating each portion of the plate. The plate was then incubated at 
37°C for 24 h. After 24 h, plates were assessed and the colonies were identified as streptococci, 
Staph. aureus, CNS, Klebsiella spp., E. coli, gram-negative bacteria, or other organisms. Pure 
growth of one or more colonies was indicative of an infection for all organisms except CNS. For 
CNS, more than 3 colonies had to be present to indicate an infection. Growth of two different 
colony types was a mixed infection and was recorded as the two different etiologies. Growth of 
three or more colony types was contamination and management was instructed to sample the 
 138 
 
 
quarter again. Results were recorded on paper and in DC305 (Herd B) or on paper only (Herd 
A). Dependent on result, treatment commenced 24-36 hours after original detection of mastitis. 
The remaining portion of the milk sample was frozen at -20°C until samples were retrieved on a 
weekly basis by the author. Obvious disagreements between QMPS and OFC results were 
addressed with weekly feedback and further training. Technical support was provided throughout 
the study. 
5-Day Sample Pickup Herds. Herds 1-6 were provided instruction for entering culture 
events into DC305 for each individual case of mastitis. This included recording the date, quarter, 
and severity of mastitis. A printed submission list was generated each morning for the courier, 
who retrieved samples for 5 consecutive mornings prior to 10:00am. Results were returned 
within 24 h of retrieval and marked as specific culture code within an individual cow card. 
Laminated copies of culture codes and their corresponding organisms were posted at each dairy. 
Additionally, a printout of each day’s culture results was generated and printed at 11:00am from 
each herd’s computer.  
 
Laboratory Procedures  
Standard culture technique was performed on all frozen samples from herds A and B and 
fresh samples from herds 1-6 according to the National Mastitis Council’s guidelines for 
identification of aerobic organisms (National Mastitis Council, 2017). Briefly, 0.01 mL of milk 
was streaked on trypticase soy agar containing 5% sheep blood and 1% esculin (PML 
Microbiologicals, Mississauga, ON, Canada) and incubated aerobically at 37°C for 18 to 24 
hours. Colonies from pure cultures were subjected to matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) using a Bruker MALDI-TOF Biotyper (version 3.1.66; Bruker 
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Corp. Billerica, MA). Confidence levels were assigned by the machine software by referencing 
the Bruker 5989 RUO bacterial library. Levels accepted for species identification were ≥2.0 and 
for genus identification between 1.8 and 2.0. The same definitions for intramammary infection 
were used as described earlier.  
 
Treatment Protocols  
Managers, owners, and the herd veterinarian determined a treatment protocol specific for 
each dairy. As not important to our objectives, we allowed each herd’s team to decide what IMM 
antibiotic(s) to use. Following assessment of the culture plates at 24 h, quarters to be treated in 
the OFC group were treated with the selected IMM product according to the manufacturer’s 
instructions. For example, all gram-positive organisms on herd A and gram-positive organisms 
and Klebsiella spp. on herd B were treated with an IMM antimicrobial. All other organisms were 
not treated. For the 5 d pickup herds, treatment commenced upon receipt of the computerized 
results the morning after sample submission. If a herd elected not to wait the weekend to treat a 
mastitic cow, IMM treatment could begin immediately, prior to receipt of results. Any cow that 
graduated to systemic clinical signs was removed from the trial and treated according to the 
veterinarian’s recommendations. Farm management was asked to record all treatments in 
DC305.  
 
Questionnaires  
Brief initial and follow-up oral questionnaires were administered to individuals directly 
involved with the treatment decisions on each dairy. The preliminary questionnaire inquired 
about the details and costs of the current mastitis treatment protocol, what factors were involved 
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in selecting cows to treat, the primary reason why management sought to change their current 
program, and what type of program they see as ideal. The final questionnaire asked whether the 
trial program was effective at the dairy, the most helpful and beneficial aspects of the program, 
the cost-savings, whether management thought cows were becoming chronic, and what 
improvements could be made overall. 
 
Analysis  
Initial record analysis prior to the start of the trial revealed that management was not 
consistent in their recording of mastitis cases nor in recording of individual treatments. Many 
dairies did not have established protocols, implemented protocols that included extra-label 
administration of antimicrobials, or had overlapping/redundant protocols within the computer 
system or within individual cow cards. Therefore, monthly mastitis incidence, number of mastitis 
cases, and chronicity of mastitis (the number of retreated quarters) prior to the start of the trial 
are likely inaccurate. As such, any statistical comparison between these benchmarks before and 
after the trial was not performed. For other analyses, the unit of analysis was the quarter. 
Quarters were excluded from analysis if no on-farm culture result was recorded (herds A and B). 
Compliance was calculated as the number of cases for which management followed the decided 
treatment protocol divided by the total number of cases cultured for that herd. Antimicrobial use 
was calculated as the number of cases receiving IMM antibiotics divided by the total number of 
cases cultured for that herd. Chronicity of cases was assessed as the number of repeated mastitis 
cases over the study period (same cow and same quarter), at least 14 days apart, divided by the 
total number of mastitis cases for that period.  
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 For comparison between OFC and QMPS culture results for herds A and B, diagnoses 
were grouped according to the most prevalent mastitis pathogens on the dairy as well as 
according to their treatment protocol. The following categories of growth were described for 
herd A: “no growth”, Staph. aureus, gram-positive, gram-negative, “mixed with gram-positive,” 
and “other”. For herd B: “no growth”,  Klebsiella  spp., E.coli, gram-positive, gram-negative, 
“mixed with gram-positive,” and “other”. Where Staph. aureus (herd A) or Klebsiella (herd B) 
and another organism were cultured, the result was coded as agreed if the respective organism 
was reported by the other methodology, irrespective of the second organism. If a result was 
contaminated, it was classified as “other”. If one result was missing, it was coded as null. The 
percent agreement was calculated as the total number of cultures in agreement over the total 
number of cultures for each herd. Kappa statistics were used to calculate the overall level of 
agreement.  
 
RESULTS 
Individual Farm Characteristics   
Herd size, bedding type, and the number of quarters enrolled for each farm can be seen in 
Table 4.1.  Herds 1, 4, 5, and 6 initially used blanket therapy for all mastitis cases, which was 
defined as treating each case with an IMM antimicrobial on the date of detection.  Herd A treated 
all cows with IMM antimicrobials on the day of detection, but discontinued treatment for gram-
negative and “no growth” cultures when results of the OFC were read.  Herd 2 and herd B both 
used OFC prior to the beginning of the trial, but were not consistent with their treatments and did 
not feel adequately trained on culture plate diagnostics.  Prior to the commencement of the trial, 
herd 3 submitted samples to the diagnostic laboratory once per week; treatment of gram-positive 
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cases was delayed by up to 8 days for some cows.  Only herds 4, 5, and 6 reliably recorded all 
mastitis events, and only herds 4 and 6 reliably recorded mastitis treatments.  Dairies on the 
project were taught to record single mastitis events rather than treatments (as some cows would 
not be treated) and to record all events, regardless of severity.  Consistency was encouraged by 
creating standard protocols within the computer program.  Overall, this allowed for better 
epidemiological analysis of mastitis cases, and easier communication between the herd 
veterinarian and the client.   
 
Initial Questionnaire Responses  
Two of the 8 dairies were unsatisfied with the current mastitis program.  Half of the 
dairies believed that the current protocol worked well, but that the overall mastitis program 
needed improvement. The remaining dairies (n = 2) noted that the current program worked well 
and needed no improvement; however, they were willing to try something new.  Of all dairies on 
the project, the largest dairy had the highest expense for the treatment of CM at $25,000/yr.  
When expenditures per year were standardized for the number of cows per dairy, between $0.83 
and $23.81 was spent on treatments per head, per year.  The most common reason given for 
enrolling in the program was projected savings on treatment costs.  The remaining reasons were 
knowledge of etiology (or knowledge of etiology in a timelier manner), and establishing a more 
effective treatment protocol.  The main factor driving the written mastitis protocols was:  the 
veterinarian (4), the withhold time of the treatment chosen (1), the ease of implementation (1), 
the effectiveness of the treatment chosen (1), or the individual cow characteristics (1).  The main 
factors driving whether a cow was treated or not (assuming culling as an a “non-treatment” for 
those herds using blanket therapy) were: milk production, clinical signs, chronicity, and 
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pregnancy status.  According to management, characteristics of an ideal selective treatment 
protocol would be:  one that offers a prevention strategy or minimizes the need for antibiotics 
and one that offers diagnostic driven decisions with minimal turnaround time for results.     
 
Culture Results  
A total of 1,031 quarters were enrolled in the study.  Using aerobic culture, a pathogen 
was identified in 65.6% of the mastitis cases.  About 1/3 (34.4%) of cases had no-growth on 
culture, about 1/3 had gram-positive organisms (27.3%), and about 1/3 of cultures revealed a 
gram-negative pathogen (30.9%).  Culture results by herd are listed in Table 4.2. 
 
Compliance, Milk Production, and Milk Quality 
Descriptors, including treatment scheme, compliance, and milk quality and production 
indices for each dairy can be seen in Table 4.3.  All herds elected to treat non-contagious gram-
positive organisms and not treat culture-negative cases, but there were several variations on 
treatment of gram-negative pathogens and contagious gram-positive pathogens.  Three dairies in 
the 5 d pickup group extended their “wait-to-treat” period over the days when samples were not 
picked up.  On average, 82.5% of cows were treated according to the established protocol (n = 
851 cases).  Compliance was generally higher for the 5 d pickup herds as compared with herds 
using OFC.  Protocols and compliance by herd is shown in Table 4.3.  The most common form 
of non-compliance was IMM treatment of cows with gram-negative pathogens and cows with 
negative culture results (41.7% of non-compliant cases, n = 75).  These were treated due to 
worsening clinical signs.  The next most common form of non-compliance was non-treatment of 
gram-positive cases (due to resolution of clinical signs during the 24 h waiting period; 30.6% of 
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non-compliant cases, n = 55).  Other reasons for non-treatment of cases that should have been 
treated were: culling of the animal (n = 12, 6.7%), drying the cow early (n = 2, 1.1%), and cases 
refractory to treatment that management elected not to treat (for example, S. aureus; n = 10, 
5.6%).  Finally, 26 culture-negative cows were treated that should not have been in one herd due 
to general miscommunication between management and hospital staff (14.4%). 
Bulk tank somatic cell counts before and after the trial were similar for seven of the 
dairies.  Herd B experienced a dramatic drop in BTSCC over the course of the trial (Table 4.3).  
Similarly, only small changes were noted in mature equivalent milk production (ME305), a 
standardized estimation of how much an average cow in the herd would have produced for 305 
days, in pounds.   
 
Retreatment for Clinical Mastitis/Chronicity 
 Dependent on farm, between 10% and 55% of quarters were retreated for CM over the 
months of the trial and up to 2 months post-mastitis event (Table 4.4).  For half of the farms, the 
percentage of retreats appeared to increase as compared with the percentage of retreats before the 
start of the trial.  Two dairies showed a decrease in the percentage of retreats and one remained 
similar.  However, mastitis event data was not consistently nor reliably recorded prior to the trial 
and these comparisons are likely inaccurate.   Monthly mastitis incidence remained similar or 
decreased for most herds, except for herd B which appeared to increase 1.4 fold.  This is due to 
better detection and separation/treatment of mastitis cases during the study as compared with the 
year before.  This is supported by the large decrease observed in herd B’s BTSCC (Table 4.3).  
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Agreement Between On-Farm and Laboratory Cultures for Herds A and B  
The distribution of results between the culture categories that were used to compare OFC 
diagnoses and QMPS diagnoses for herds A and B can be seen in Tables 4.5 and 4.6.  The 
overall agreement for herd A was 67.3% (kappa = 0.58; 95% C.I. 0.49-0.67), with the highest 
agreement occurring for the gram-positive cultures (80.5% agreement) and lowest for “mixed 
gram-positive” and “other” categories (<10% agreement). For herd B the overall agreement was 
55.9% (kappa = 0.42; 95% C.I. 0.32-0.51), with the highest agreement occurring for negative 
cultures (84.3% agreement) and the lowest for “other gram-negative”, “mixed gram-positive”, 
and “other” categories (<10% agreement).  Combined results for herds A and B resulted in 
188/304 correct diagnoses, or 61.8% agreement.  
 
Antimicrobial Usage  
The average reduction in antimicrobial usage was 46.4% (range = 6.8% to 92.5%).  The 
percentage of mastitis cases treated with IMM antimicrobials before and after the study can be 
seen in Figure 4.1.  As previously stated, prior to the trial, herds 2 and B were practicing 
pathogen-based treatment using OFC without guidance.  Guidance reduced antimicrobial use by 
6.8% and 20% for these herds, respectively.  Herd 3 was also using a pathogen-based treatment 
protocol, but only submitting cultures once per week.  Quicker diagnostic turn-around led to a 
decrease in use of 17.2%.  All other dairies, represented by the dark “before” bars amounting to 
100% (Figure 4.1), were practicing blanket treatment at time of mastitis detection.  
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Table 4.1. Herd characteristics for enrolled dairies.  Herds 1-6 used 24 h sample pickup 5 days 
per week, herds A and B were trained to use on-farm culture to drive treatment decisions 
1Apparent monthly mastitis incidence.  Calculated from computer data at time of enrollment as 
number of treated mastitis cases per month.  For an individual cow, treatments had to occur at 
least 14 d apart to be considered a new case. 
2Number of lactating cows at time of enrollment. 
  
Herd Bedding MMI1 County 
Herd 
Size2 Start Date End Date 
Duration, 
d 
Quarters 
enrolled, 
no. 
1 Sand 2.2 Onondaga 820 1/30/2017 9/21/2017 234 150 
2 Sand 1.8 Cortland 600 1/29/2017 12/20/2017 325 113 
3 Peat Moss 4.6 Cortland 510 1/29/2017 10/28/2017 272 153 
4 Sand 3.0 Onondaga 910 2/1/2017 7/30/2017 179 154 
5 
Sand and 
Sawdust 3.0 Cortland 1,040 2/1/2017 12/21/2017 323 96 
6 Sawdust 5.3 Onondaga 630 10/17/2017 12/6/2017 50 53 
A Sawdust 5.7 Broome 1,050 1/23/2017 3/30/2017 66 159 
B Sand 3.6 Cortland 560 2/21/2017 7/4/2017 133 153 
Total       198 1,031 
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 Table 4.2.  Etiology of infection at time of mastitis detection for each enrolled herd1   
 
 
Herd 
 
 
1 2 3 4 5 6 A B Total 
Culture Result no. (%) no. (%) no. (%) no. (%) no. (%) no. (%) no. (%) no. (%) no. (%) 
Negative 43 (28.7) 42 (37.2) 33 (21.6) 75 (48.7) 26 (27.1) 30 (56.6) 53 (33.3) 53 (34.6) 355 (34.4) 
Gram-negative 51 (34) 34 (30) 64 (41.8) 47 (30.5) 47 (49) 15 (28.3) 24 (15.1) 37 (24.1) 319 (30.9) 
E.coli 15 (10) 13 (11.5) 62 (40.5) 24 (15.6) 21 (21.9) 1 (1.9) 9 (5.7) 5 (3.3) 149 (14.5) 
Klebsiella spp. 23 (15.3) 17 (15) 0 (0) 13 (8.4) 20 (20.8) 6 (11.3) 6 (3.8) 21 (13.7) 105 (10..2) 
Other2 13 (8.7) 4 (3.5) 2 (1.3) 10 (6.5) 6 (6.3) 8 (15.1) 9 (5.7) 11 (7.2) 65 (6.3) 
Gram-positive 42 (28) 33 (29.2) 42 (27.5) 28 (18.2) 13 (13.5) 4 (7.5) 71 (44.7) 48 (31.4) 281 (27.3) 
Staph aureus 2 (1.3) 0 (0) 10 (6.5) 0 (0) 1 (1) 0 (0) 32 (20.1) 0 (0) 45 (4.4) 
Staph spp. 2 (1.3) 7 (6.2) 4 (2.6) 4 (2.6) 1 (1) 0 (0) 7 (4.4) 8 (5.2) 33 (3.2) 
        Strep dysgalactiae 5 (3.3) 6 (5.3) 23 (15) 7 (4.5) 3 (3.1) 0 (0) 21 (13.2) 8 (5.2) 73 (7.1) 
Strep uberis 8 (5.3) 3 (2.7) 4 (2.6) 4 (2.6) 1 (1) 1 (1.9) 4 (2.5) 0 (0) 25 (2.4) 
Strep spp. 5 (3.3) 3 (2.7) 0 (0) 1 (0.6) 1 (1) 0 (0) 3 (1.9) 1 (0.7) 14 (1.4) 
Lactococcus spp. 11 (7.3) 6 (5.3) 0 (0) 5 (3.2) 1 (1) 0 (0) 1 (0.6) 20 (13.1) 44 (4.3) 
Mixed3 6 (4) 4 (3.5) 0 (0) 3 (1.9) 4 (4.2) 1 (1.9) 3 (1.9) 10 (6.5) 31 (3.0) 
Other4 3 (2) 4 (3.5) 1 (0.7) 4 (2.6) 1 (1) 2 (3.8) 0 (0) 1 (0.7) 16 (1.6) 
Other5 13 (8.7) 3 (2.7) 9 (5.9) 0 (0) 3 (3.1) 0 (0) 5 (3.1) 9 (5.9) 42 (4.1) 
Contamination 1 (0.7) 1 (0.9) 5 (3.3) 4 (2.6) 7 (7.3) 4 (7.5) 6 (3.8) 6 (3.9) 34 (3.3) 
Total 150 113 153 154 96 53 159 153 1,031 
 
1Etiological classification is based on aerobic culture results and matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) performed by Quality Milk and Production Services for all dairies. 
2Includes Enterobacter spp., Citrobacter spp., gram-negative bacilli, Pasteurella, Pseudomonas, and Serratia. 
3Had at least 1 gram-positive organism in addition to another organism, dictating treatment. 
4Includes gram-positive bacilli and Enterococcus spp. 
5Includes Trueperella pyogenes and Corynebacterium spp. 
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Table 4.3.  Treatment protocols, compliance, and bulk tank and milk production characteristics 
for moderate-sized NY dairy herds enrolled in a pathogen-based mastitis treatment protocol.  
herds 1-6 used 24 h sample pickup 5 d per week, herds A and B were trained to use on- farm 
culture to drive treatment decisions 
Herd Treatment 
Protocol 
 Compliance1 Wait 
Weekend?2 
BTSCC 
Before3 
BTSCC 
After4 
ME305 
Before5 
ME305 
After6 
1 Gram + UNK7 no 169,000 125,000 32,650 26,083 
2 Gram + 85% yes 188,000 146,000 32,275 31,135 
3 Gram +, cull S. aureus 96% yes 139,000 178,000 30,777 30,793 
4 Gram + 94% yes 90,000 89,000 31,360 31,800 
5 All but “No-Growth” 73% no 109,000 116,000 28,694 28,915 
6 Gram + 85% no 208,000 195,000 27,744 27,744 
A Gram + 59% N/A 184,000 198,000 * * 
B Gram +, Klebsiella spp. 76% N/A 240,000 133,000 33,169 31,218 
Average      165,875 147,500 30,953    29,670  
1The percentage of cases treated according to the treatment protocol agreed upon by 
veterinarians and management; also considers whether farm decided to wait to treat over the 
weekend or not. 
2For 5 d per week herds, whether management waited until results were returned prior to 
treatment.   
3Bulk tank somatic cell count prior to the start of the trial (see Table 4.1 for individual herd 
dates). 
4Bulk tank somatic cell count after the trial was complete (see Table 4.1 for individual herd 
dates). 
5Mature equivalent milk production (lbs.) at the start of the trial. Herd A’s computer program did 
not allow for this calculation.  The average daily production for a cow in herd A was 87.3lbs. 
6Mature equivalent milk production (lbs.) at the end of the trial. Herd A’s computer program did 
not allow for this calculation. The average daily production for a cow in herd A was 86.4lbs. 
7Due to non-compliance of entrance of treatment records into the computer system, we were 
unable to retrieve this information from this dairy. 
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Table 4.4.  Monthly mastitis incidence (MMI) and percentage of cases retreated before and after 
implementation of a pathogen-based protocol for treatment of nonsevere mastitis.  Herds 1-6 
used 24 h sample pickup 5 d per week, herds A and B were trained to use on-farm culture to 
drive their treatment decisions 
1Values are reflective of the number of cows over the identical period as the trial period, but 
from the previous year’s data. These numbers are likely inaccurate as recording of mastitis 
events was inconsistent. 
2Values are reflective of the cases enrolled in the trial (all nonsevere clinical cases).These values 
are appropriate as management was trained to consistently record events. 
aHerd 5 did not submit cultures from all mastitis cases during the trial period. This number 
reflects the number of cases occurring during the trial period, according to computer records.  
 
Prior to Trial1 During/After Trial2 
Herd 
Cows, 
no. 
Cases, 
no. MMI ,% 
Retreats, 
% 
Cows, 
no. 
Cases, 
no. MMI ,% Retreats,% 
1 125 151 2.2 20.8 122 150 2.3 23.0 
2 20 21 1.8 5.0 89 113 1.7 27.0 
3 50 55 4.6 10.0 122 153 3.3 25.4 
4 73 92 3.0 26.0 109 154 2.8 41.3 
5 207 237 3.0 14.5 320 354a 3.2 10.6 
6 54 69 5.3 27.8 48 53 5.0 10.4 
A UNK UNK 5.7 UNK 125 159 6.9 27.2 
B 72 90 3.6 25.0 99 153 6.2 54.5 
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Table 4.5.  Agreement between on-farm culture and Quality Milk Production Services (“Laboratory Culture”) results for herd A. 
Shaded boxes represent agreement between the two methods 
1Culture had at least one gram-positive organism in addition to one other organism. 
2Included contamination and Corynebacterium spp. 
  
 Laboratory Culture 
On-farm culture Negative Staph. aureus Gram-positive Gram-negative Mixed with gram-positive1 Other2 Total 
Negative 34 1 5 3 0 1 44 
Staph. aureus 0 25 1 0 2 0 28 
Gram-positive 12 5 29 1 0 6 53 
Gram-negative 6 0 0 18 1 0 25 
Mixed with gram-positive1 1 1 1 2 0 3 8 
Other2 0 0 0 0 0 1 1 
Total 53 32 36 24 3 11 159 
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Table 4.6.  Agreement between on-farm culture and Quality Milk Production Services (“Laboratory Culture”) results for herd A. 
Shaded boxes represent agreement between the two methods 
1Culture had at least one gram-positive organism in addition to one other organism. 
2Included contamination, Trueperella pyogenes, yeast, and Corynebacterium spp. 
aEight results were not classified due to incubator error (machine was accidentally turned off). 
  
 
Laboratory Culture 
On-farm culture Negative Klebsiella spp. E. coli  Other gram-negative Gram-positive 
Mixed with 
gram-positive1 Other2 Total 
Negative 43 6 1 2 8 1 4 65 
Klebsiella spp. 0 13 0 2 0 1 0 16 
E. coli  1 0 4 2 0 0 1 8 
Other gram-negative 0 0 0 0 0 0 0 0 
Gram-positive 6 0 0 1 21 5 7 40 
Mixed with gram-positive1 0 0 0 0 0 0 1 1 
Other2 1 1 0 3 0 10 0 15 
Total 51 20 5 10 29 17 13 145a 
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Figure 4.1. Percent of nonsevere clinical mastitis cases treated with antimicrobials before and 
after implementation of a pathogen-based treatment protocol by herd. Herds 1-6 used 24 h 
sample pickup 5 d per week, herds A and B were trained to use on-farm culture to drive their 
treatment decisions 
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DISCUSSION 
 This study demonstrated that on on-site farm culture systems or provision of off-site 
culture results 5 d per week can effectively guide pathogen-based treatment decisions for 
nonsevere clinical mastitis cases on moderate-sized dairies.  On average, a reduction in antibiotic 
use of 46.4% was experienced.  The variation between farms in terms of protocol design, 
compliance, and diagnostic accuracy was apparent.  Overall, compliance and satisfaction with 
the program was high.   
As the follow-up questionnaire generates much of the discussion for this project, detailed 
responses are mentioned here rather than in the results section above.  This study was not 
performed as a clinical trial, like the one described in Vasquez et al. (2017); comparisons could 
not be made between outcomes for cows treated according to the pathogen-based treatment 
protocol and cows treated using a blanket therapy protocol.  Originally proposed benchmarks for 
assessment of this program were evaluations of chronicity and monthly mastitis incidences 
before and after the trial period.  What became apparent was the inconsistency regarding the 
recording of mastitis events and treatments.  As such, the best indications for success of the 
program were 1) maintained or decreased BTSCC, which occurred for all dairies during the trial, 
2) maintained or decreasing numbers of mastitis cases in the hospital pen on a monthly basis, 
which was described by similar monthly mastitis incidences over the trial period, and 3) 
anecdotal reports from farm management.  Seven out of eight dairies believed that pathogen-
based treatment was effective at their dairies.  One dairy was not convinced the program was 
helpful, but moving forward was willing to explore not treating culture-negative cows that were 
experiencing mild clinical signs.  This dairy owner admitted that he was informed and surprised 
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about the pathogen distribution on his dairy; a positive aspect of the program would be that 26% 
of his cases would not be treated with antibiotics.   
Compliance ranged between 59% and 96% and was likely influenced on OFC herds by 
confidence in diagnostics.  On-farm culture herds listed the following benefits of the trial: 
continued guidance, knowing etiology quickly, and the ability to compare QMPS results to their 
results.  However, a drawback of the program for OFC herds was the variation in interpretation 
between QMPS and on-farm results.  For herds A and B, the kappa agreement statistics were 
0.58 and 0.42.  These values fall within the “moderate” category of strength of agreement, the 
third category on a 5-point scale (Altmant, 1991). Regardless, the level of agreement is better 
than by chance alone.  Levels of agreement would have been lower if categorization of culture 
data was on the species level.  However, categorization was based on groupings of organisms 
used to guide treatment for each farm.  Errors in diagnosis can lead to different therapeutic 
choices and over- or under-treatment of mastitis cases.  For herd A, 15.7% and 8.0% of cases 
were over- and under-treated, respectively, due to misdiagnosis, assuming that laboratory culture 
is the gold standard. For herd B, 12% and 18% of cases were over- and under-treated, 
respectively.  Evaluation of accurate data would allow one to determine whether under-treatment 
was contributing to chronicity of cases.  However, given that this was not a randomized clinical 
trial, it would be difficult to determine if those cases would become chronic, regardless of 
treatment.  None of the dairies believed that the cows became chronic as a result of 
implementation of the protocol. 
Greater compliance on all farms and agreement between on-farm culture and laboratory 
cultures for OFC herds could have been accomplished with greater levels of veterinary input.  
Also, herd management was instructed to exclude any animal with systemic signs.  A large 
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proportion of gram-negative cases were eventually treated with antimicrobials, indicating that 
perhaps these cases should not have been enrolled.  One must also consider that aside from 
protocol designation, a combination of factors including parity, stage of lactation, CM history, 
and SCC history contribute to the decisions that herd owners make.  Thus the value of culture 
data, particularly when highlighting a chronic or unresponsive case, can provide information to 
assist with culling decisions.  Accordingly, benefits mentioned by dairies in either group during 
the follow-up questionnaire were the ability to make decisions quickly, particularly for cows that 
they would cull (not treat), or for those organisms they may elect to treat with additional 
supportive care.  Decreased treatment costs, and seamless data entry due to loop access between 
QMPS and the dairies were also mentioned as benefits.  Reductions in antimicrobial usage 
ranged from 6.8% to 92.5%.  Differences between farms occurred due to dissimilarities in 
pathogen profiles and in choice of treatment protocols.  For example, the combined effect of only 
treating gram-positive pathogens in addition to having only 7.5% of cultures positive for these 
organisms led to a decrease of 92.5% in antibiotic use on herd 6.  This compares with herd 5, 
which elected not to treat only negative cultures, of which they only had 27.1%, contributing to a 
27.1% reduction. 
Three dairies were intrigued by the recovery rates of untreated cases and believed they 
were more educated on the behavior of pathogens on their dairies.  Negative aspects of the 
program were the need to coordinate sampling with parlor workers, difficulty segregating cows 
once for sampling and again for treatment, and the frustration of experiencing negative culture 
results.  Suggested improvements were adding weekend pickup, more frequent training of 
sampling personnel, and establishing more interpretable codes for results within DC305.   
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Accounting for the cost of cultures, savings on antibiotics alone was between $2,200 and 
$4,600 ($3.00-$6.00 per cow) over the course of one year.  Several dairies indicated the 
difficulty of placing value on cows that they were able to cull sooner due to knowledge of 
etiology.  One of these dairies provided additional supportive care to E.coli-positive, nonsevere 
cases when results were returned; management declared that survivability of these cases 
increased.  One dairy owner in the 5 d pickup group noted that decreased labor costs should be 
factored into analysis as he had used OFC prior to the study.   
Despite the few negative comments on the follow-up survey, all 6 dairies currently pay 
for continued courier and culture services on a 5-day-per-week basis.  Though no changes in 
BTSCC were seen for the specific dairy, one herd relayed that mastitis detection has improved 
due to positive reception of the program by employees. The 2 OFC farms continue to culture 
their mastitis cases, though both now prefer the use of AccuMast plates (FERA Animal Health, 
Ithaca, NY) over Minnesota Tri-plates. 
 
CONCLUSIONS 
Implementation of culture systems or prompt reporting of culture results by nearby 
laboratories can effectively drive pathogen-based clinical mastitis treatment decisions on 
moderate sized dairies, resulting in decreased use of antimicrobials on all dairies involved.  
While the two on farm systems experienced moderate agreement with laboratory results, cultures 
from all eight farms provided data that was useful for decision making, whether for IMM 
treatments or culling decisions.  For most dairies, no negative outcomes were noted when 
evaluating chronicity, monthly mastitis incidence, BTSCC, or milk production. 
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ABSTRACT 
Culture-negative and Escherichia coli cases are uncommonly treated in pathogen-based 
protocols for nonsevere mastitis. High-throughput 16S rRNA sequencing might reveal the 
presence of other pathogens and can provide information on microbial diversity. The objective 
was to explore the milk microbiome and its association with survival in the herd, milk 
production, and postevent linear score (LS) for cows with clinical mastitis characterized as 
negative or E. coli by culture.  Fifty E. coli-positive and 35 culture-negative samples from 
mastitis cases were enrolled. No cases were treated with antimicrobials. Follow-up samples were 
taken 14 d post-mastitis for the E.coli-positive quarters to determine chronicity. On culture of the 
follow-up samples, none were positive for E. coli.  A difference in α-diversity (Shannon index) 
was present between enrollment and follow-up samples (3.8 versus 5.1). When α-diversity was 
explored for enrollment E. coli samples, there was no relationship between the Shannon indices 
of these samples and post-mastitis LS. Alpha-diversity of the enrollment samples was lower for 
E. coli-positive cows that subsequently had greater losses in milk production. This difference 
was explained by a greater relative abundance of the family Enterobacteriaceae (67.8% versus 
38.4%) for cows that dropped in production. Analysis of composition of the microbiome 
identified one phylum, Proteobacteria, that differed between E. coli-positive cows that dropped 
in production and those that did not. Evaluation of β-diversity found no statistical relationship 
between post-mastitis LS and microbiome. Nine culture-negative quarters had profiles 
dominated by taxonomic families containing common mastitis pathogens. When evaluating α- 
and β-diversities and composition of the microbiomes for culture-negative quarters, no 
associations were found for milk production changes and post-mastitis LS. Three cows did not 
remain in the herd, limiting the ability to analyze survival. The findings suggest that a 
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contributing factor to negative outcomes in E. coli-positive cows is relative abundance of this 
pathogen, and that no single or collective group of bacterial families is associated with milk 
production changes or post-mastitis LS in culture-negative quarters. While additional studies 
should be performed, the absence of associations between outcomes explored and microbial 
profiles in this study suggests that we are not missing opportunities by not treating nonsevere 
E.coli or culture-negative mastitis. 
Key words: mastitis, Escherichia coli, milk microbiome, metagenomics 
 
INTRODUCTION 
As outlined in Journal of Dairy Science’s 100-year review, mastitis, the inflammation or 
infection of the mammary gland, remains the most common bacterial disease on the majority of 
dairies and its treatment or prevention accounts for the majority of antimicrobials administered to 
adult dairy cattle (Pol and Ruegg, 2007; Stevens et al., 2016; Ruegg, 2017). Pathogen-based 
treatment strategies for clinical mastitis (CM) have been useful in decreasing antibiotic use 
without consequential negative outcomes (Lago et al., 2011b; a; Vasquez et al., 2017). These 
strategies use aerobic culture results to guide therapy, often resulting in treatment of only gram-
positive organisms. Pathogen-based protocols were developed in response to research that 
suggested a lack of efficacy of intramammary (IMM) antimicrobials for gram-negative mastitis 
pathogens (Pyörälä et al., 1994; Suojala et al., 2013). Additionally, the use of antimicrobials on 
culture-negative quarters can be difficult to justify; provided that 25-35% of cases produce 
negative results, accurate diagnostic tools should replace the routine use of treating all cases 
prior to etiologic diagnosis (Hogeveen et al., 2011; Oliveira and Ruegg, 2014). Though aerobic 
culture remains the gold standard for diagnosis, it is inherently biased toward bacteria that can 
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grow in specific conditions, and for organisms that are present in high numbers in the commonly 
aliquoted inoculum of 10µL.  
 Alternatively, sequencing and analysis of hypervariable regions in the 16S rRNA gene 
can assess bacterial diversity in milk from affected cows and might elucidate what organisms are 
contributing to culture-negative and other etiologic disease (Kuehn et al., 2013; Oikonomou et 
al., 2014; Oultram et al., 2017). Profiles generated from mastitic human and bovine milk suggest 
that CM is associated with dysbacteriosis and a robust microbial community in the mammary 
gland might aid in the prevention of an intramammary infection (IMI) (Fernández et al., 2013; 
Oikonomou et al., 2014). A dysbacteriosis detected using sequencing methods might provide 
information for treatment or culling decisions, however, analyses of the relationships of bacterial 
composition and cow-level outcomes should also be assessed. Although relationships to 
production and health outcomes were not investigated, Kuehn et al. (2013) identified bacterial 
genera that might be responsible for the microbial differences between mastitic and healthy 
quarters. The presence of some of genera suggested that well-known mastitis pathogens were 
present below culture detection thresholds. Alternatively, if a dominant pathogen such as E.coli 
is present, its disruption to the diversity of the microbiome might contribute to the development 
of clinical disease. As such, one could speculate that the non-treatment of these profiles in a 
selective treatment protocol represents a missed opportunity. Independent of treatment, the 
impact of microbial profiles at diagnosis on health and production outcomes must be assessed. In 
this study, we chose to focus on E.coli and culture-negative mastitic quarters, as in a selective 
treatment protocol, these animals do not receive IMM treatment.  
Our first objective was to determine if non-treatment of nonsevere E. coli cases would 
result in chronicity. Our second objective was to explore the microbiome of cows with nonsevere 
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E. coli CM to determine if microbial profiles differ between cows that had positive (survival in 
the herd, no drop in milk production, or a next-test linear score [LS] of <4.0) or negative (culling 
from the herd, a drop in milk production, or a next test LS of ≥4.0) outcomes when not treated. 
Our last objective was to explore the microbiome of cows with non-treated culture-negative CM 
to determine if microbial profiles differ between cows that had positive or negative outcomes as 
defined above. Characterizing these associations will improve our understanding of CM, 
allowing for more effective treatment strategies.  
 
MATERIALS AND METHODS 
Study Animals 
Mild to moderate CM cases that were positive for E. coli or negative for growth on 
aerobic culture were assessed for inclusion at a 3500 Holstein-cow commercial dairy in central 
New York between December 2014 and April 2015 under Institutional Animal Care and Use 
Committee approval. The resulting cases were a subset from a larger group (n = 725) of clinical 
cases that were used to investigate a pathogen-based treatment protocol. Herd characteristics 
including distribution of mastitis pathogens are described elsewhere (Vasquez et al., 2017). The 
J-vac coliform vaccine (Merial Limited, Duluth, GA) was given at dry off, 3-4 weeks pre-
calving, and 3-4 weeks post-freshening according to the labeled directions. The farm used Dairy 
Herd Information Association (DHIA) services, which included monthly somatic cell counts 
(SCC) and milk weights. Health records were recorded using Dairy Comp 305 (DC305; Valley 
Ag. Software, Tulare, CA, USA). 
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Case Definition 
Each mastitis case was detected by trained on-farm employees by observing 
abnormalities in milk such as changes in consistency and color or “udder” signs including hard, 
swollen, or red quarters. Cows exhibiting severe symptoms such as depression, anorexia, 
dehydration, or fever received systemic antimicrobials and anti-inflammatories and were 
excluded from the study. Other exclusion criteria were treatment with antimicrobials or anti-
inflammatories in the previous 15 d or impending sale of the animal.  
 
Sample Collection and Treatment Assignment 
Using aseptic technique, a milk sample was collected from each affected quarter into a 
milk culture tube. These samples were defined as “enrollment” samples. The tube was labeled 
and promptly placed in a 5°C refrigerator. Culture results within 24 h of sample collection were 
achieved through the use of daily sample pick-up via the Quality Milk Production Services 
(QMPS) program at the Animal Health and Diagnostic Center in Ithaca, NY. This study focused 
on non-treated clinical quarters; only culture-negative and quarters positive for E. coli were 
included in the analysis. To assess for chronicity of E.coli-positive quarters, post-enrollment 
samples were targeted to be retrieved from the same quarter 14 ± 3 d after each mastitis event. 
These samples were defined as “follow-up” samples. 
 
Microbiological Methods 
Standard culture technique was performed on all samples by QMPS employees according 
to National Mastitis Council guidelines for identification of aerobic organisms and Mycoplasma 
spp. (National Mastitis Council, 2017). Briefly, 0.01 mL of milk was streaked on trypticase soy 
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agar containing 5% sheep blood and 1% esculin (PML Microbiologicals; Mississauga, ON, 
Canada) and MacConkey’s agar (Hardy Diagnostics; Santa Maria, CA), and plates were 
incubated aerobically at 37°C for 18 to 24 h. Colonies from pure cultures were subjected to 
matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) using a Bruker 
MALDI-TOF Biotyper version 3.1.66 (Bruker Corp., Billerica, MA). Confidence levels were 
assigned by the machine software by referencing the Bruker 5989 RUO bacterial library. Levels 
accepted for species identification were ≥2.0 and for genus identification between 1.8 and 2.0. 
Diagnosis and confirmation of an IMI by culture of a single quarter milk sample was based on 
standard published definitions (Dohoo et al., 2011). Confirmation of E. coli as the etiologic cause 
was defined as the isolation of one or more colonies from ten microliters of milk.  
Any cow not following treatment protocol was excluded from all analyses; the 
distribution of cows in each group not following protocol was described in Vasquez et al. (2017). 
Cows in the study were followed up for post-mastitis milk production, post-mastitis LS, and 
survival in the herd. All values and dates were retrieved from farm management, DHIA test-day 
records, or DC305. Each cow was followed until the end of its current lactation, the date it was 
culled, or 60 d post-enrollment, whichever arrived first. All cows remained in the treatment pen 
until milk returned to normal visual appearance.  
 
Metagenomic Analysis 
DNA Extraction, Isolation, and Purification. Milk samples were thawed, vortexed, and 
a 2 mL aliquot was removed for isolation and purification. The samples were centrifuged at 4°C 
and 16,000 x g for 3 min. The supernatant and fat were discarded and DNA was extracted from 
the pellet using the Powerfood DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) 
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according the manufacturer’s protocol. Concentration of DNA was first evaluated using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE) with the 
following wavelengths: 230, 260, 280 nm.  
Amplification of the Hypervariable Region of the 16S rRNA gene. Amplification of the 
V4 hypervariable region of the bacterial 16S rRNA gene was performed via PCR using the 
primers 515F and 806R optimized for the Illumina MiSeq platform and 140 different 12 base-
pair error-correcting Golay barcodes (Illumina Inc., San Diego, CA) as previously described 
(Gilbert et al., 2010; Caporaso et al., 2012). Positive and negative controls were included in each 
plate and consisted of the following, respectively: DNA extracted from a pure colony of 
Streptococcus uberis (ATCC 700407) and DNA-free water. Amplicons were generated in 
triplicate using 3µL of DNA template, 1 X EconoTaq® Plus Green Master Mix (Lucigen®, 
Middleton, WI, USA), and 5 µM of each primer. Amplification of the 16S rRNA gene consisted 
of the following: an initial denaturing step of 94°C for 3 min followed by 35 cycles of 94°C for 
45 s, 50°C for 1 min, 72°C for 90 s, and an elongation step of 72°C for 10 min. Amplicons from 
the triplicate wells were pooled and subsequently purified with a Gel/PCR DNA Fragment 
Extraction kit (IBI Scientific, Peosta, IA) according to the manufacturer’s guidelines. Amplicons 
and controls were visualized by electrophoresis using 1.2% (wt/vol) agarose gels stained with 0.5 
mg/mL ethidium bromide. Quantification of amplicon DNA was performed using the Qubit 
Fluorimeter (Life Technologies Corporation, Carlsbad, CA). 
Library preparation and sequence analysis. Amplicons from individual samples were 
standardized to the same concentration and pooled. Equimolar libraries were sequenced on the 
Illumina MiSeq platform in 2 runs using the MiSeq reagent kit V2 for 300 cycles. Each run 
included 279 samples from multiple bovine projects and one sequencing control (purified 
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barcoded PCR product of DNA extracted from Streptococcus uberis). The raw single-end 
sequences generated were processed through the Quantitative Insights Into Microbial Ecology 2 
(QIIME2; version 2017.9) open source software pipeline (Caporaso et al., 2010a). Quality 
control was performed on demultiplexed sequences using the DADA2 pipeline, which removed 
phiX artifacts and chimeric sequences, and a truncation at 180 bases was chosen (Callahan et al., 
2016). Open-reference taxonomic assignment into operational taxonomic units (OTUs) with 
97% identity was performed using UCLUST, RDP classifier, PyNAST, and Greengenes 
databases (DeSantis et al., 2006; Caporaso et al., 2010b; Edgar, 2010; McDonald et al., 2012). 
Within-sample diversity, alpha-diversity (α-diversity) was assessed using the Shannon index 
calculated in a randomly selected subset of the OTU database obtained through the script 
“diversity α-group-significance” after creation of rooted and unrooted phylogenetic trees using 
the mafft and FastTree programs in QIIME2 at a rarefication level of 1500 reads per sample. 
Shannon index evaluates richness and abundance of OTU. Between-sample diversity, beta-
diversity (β-diversity) was assessed through phylogenetic-based weighted and unweighted 
Unifrac distances, calculated in QIIME2 through the script “diversity beta-group-significance” 
and the distance matrix produced was used for comparisons between outcome groups (Lozupone 
and Knight, 2005).  
 
Statistical comparisons 
The UNIVARIATE procedure in SAS version 9.4 (SAS Institute Inc., Cary, NC) was 
used for descriptive analysis. Tabulation of relative abundances for the 24 most abundant 
bacterial families was performed using the tabulate function of JMP Pro 12 (SAS Institute Inc., 
Cary, NC). The remaining families were compiled into a single category defined as “Other.” As 
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relative abundances and measures of diversity were not normally distributed, outcomes of 
interest were evaluated using nonparametric statistics. The outcomes investigated were culling or 
sale prior to 60 d post-mastitis, drop in milk production between the test days before and after the 
CM event, and LS at the test day after the mastitis event. Linear score and loss in milk 
production outcomes were also explored as dichotomous outcomes: loss in production was 
dichotomized into a reduction of >2.2 kg or not, and LS was dichotomized into ≥4.0 or <4.0. A 
milk production drop of 2.2 kg was chosen (approximately 5lbs) for several reasons. First, it 
accounts for more than the milk production declines of a normal-mid lactation curve between test 
days, and it is an economically meaningful loss for dairy herds. Additionally, the distribution of 
cattle for each outcome was similar. A linear score cutoff of 4.0 (SCC of 200,000 cells/mL) was 
chosen as it is commonly used as an indicator of IMI (Dohoo and Leslie, 1991; Schepers et al., 
1997). PROC CORR procedures of SAS were used to determine Spearman’s rank correlation to 
test whether α-diversity of the samples was associated with the outcomes. This test was also used 
to determine whether α-diversity of the samples was associated with the relative abundance of 
Enterobacteriaceae or Ruminococcaceae in the enrollment samples or associated with the 
change in relative abundance of Enterobacteriaceae between the enrollment and follow-up 
samples in the E. coli group. When α-diversity comparisons were made between enrollment and 
follow-up samples, the Wilcoxon test was used to account for repeated measures. The 
NPAR1WAY (Kruskal-Wallis or Wilcoxon test) procedure in SAS was used to determine the 
association between the relative abundance of Enterobacteriaceae or Ruminococcaceae and 
dichotomous outcomes. Changes in relative abundance of Enterobacteriaceae and the 
relationships to dichotomous outcomes were also explored. PROC REG in SAS was used to 
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explore the relationship between three continuous variables: change in milk production, Shannon 
index, and relative abundance of Enterobacteriaceae in the enrollment samples. 
 Multivariate analysis of the milk microbial profile was performed in QIIME2 and R (R 
Core Team, Vienna, Australia). Unifrac distances are quantitative measures of community 
dissimilarity that incorporate phylogenetic relationships between the samples. Unweighted 
UniFrac distances (most efficient for detecting abundance changes in rare lineages) and weighted 
UniFrac distances (most sensitive to detect changes in abundant lineages) were both investigated. 
Initially, the non-parametric test, Permutational Analysis of Variance (PERMANOVA), was 
used on Unifrac distance matrices in QIIME2 to determine relationships to the outcomes 
(Anderson, 2001). Analysis of similarities (ANOSIM) was performed on non-rarefied data using 
the vegan package in R. Groups that had statistical differences using ANOSIM underwent 
Analysis of Composition of Microbiomes (ANCOM) in QIIME2 to identify which OTUs were 
driving these differences. Visualization of the differences were permitted by performing 
principal coordinate analysis of weighted Unifrac distances in EMPeror (Vázquez-Baeza, et al., 
2013). To test whether β-diversity of the samples in each dataset (culture-negative samples and 
E. coli enrollment samples) was associated with the dichotomized production outcomes, the 
“diversity beta-group-significance” command was used in QIIME2 to compare the Unifrac 
distance matrices between the categorical descriptors. Descriptive analyses of results are 
presented as medians, means, and standard errors. 
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RESULTS 
Chronicity of Escherichia coli: Aerobic Culture Results 
Of the 489 qualifying mild and moderate quarter-level mastitis events outlined in 
Vasquez et al. (2017), 113 were culture-positive for E.coli (23%). A total of 56 cases were 
assigned to the non-treated group (49.6% of E. coli cases). Of these, 6 were omitted from the 
analysis of chronicity for the following reasons: cow was dried early (n = 4), cow died (n = 1), 
and quarter became agalactic (n = 1). The remaining 50 cases were each contributed by an 
individual cow. The mean and median number of DIM at the culture event was 127 d (S.E. 12 d) 
and 115 d. The majority of cows (n = 37; 74%) were experiencing their first case of mastitis in 
the current lactation. Mastitis events were distributed across each lactation category as follows: 
28% first parity (n = 14), 34% second parity (n = 17), and 38% third and greater parities (n = 19). 
The mean number of days between mastitis event and follow-up culture was 16 ± 3. At the time 
of the follow-up sample, no cows were experiencing clinical signs. The most commonly reported 
follow-up culture result was “negative” (n = 44, 88%). The remaining 6 cases were characterized 
as Streptococcus spp., CNS, yeast, gram-positive bacillus, Streptococcus dysgalactiae, or 
Trueperella pyogenes. No follow-up cultures were characterized as E. coli.  
 
Descriptive Data: All Samples 
 Mean DIM and distribution of parity at mastitis event for each outcome can be seen in 
Table 5.1. These variables were not different between outcome groups for E. coli positive 
quarters. Days in milk at mastitis event were also similar for all outcome groups for culture-
negative quarters. Statistically, a greater number of higher parity cows experienced negative 
outcomes (LS ≥4, milk drop) as compared with the number of higher parity cows that 
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experienced positive outcomes (P = 0.03, P = 0.007, respectively). As milk drop was calculated 
as the difference in milk production between the test days before and after the mastitis event, the 
distribution of days surrounding the event and each test day was evaluated. There was no 
statistical association between the number of days between the prior test date and the mastitis 
date and the milk drop outcome. However, when the same was evaluated for the postevent test 
date, a fewer number of days between the mastitis date and postevent test day was associated 
with the higher LS category (P = 0.03). The number of days between the mastitis event and the 
postevent test day was not associated with the other outcomes evaluated. 
 
Sequencing Results and Taxonomic Classification 
On average across all samples, 15.4% of all reads were not classified on the family level 
(SE = 0.9%); the number of unclassified reads at the genus level was 37.7% (SE = 1.4%). A total 
of 3,193,730 sequences were used for downstream analysis of the E.coli positive samples (n = 
100 samples; 50 enrollment samples and 50 follow-up samples). The mean number of reads was 
31,937 reads/sample (SE = 1,654). A total of 981,958 sequences were used for downstream 
analysis of the negative samples (n = 35). The mean number of reads was 28,056 reads/sample 
(SE = 2,886).  
For E.coli samples, the prior test day occurred at 22 d before the mastitis event (SE = 1.5 
d; range 8-41 d), while the post-mastitis test day occurred 24.5 d after the event (SE = 1.4 d; 
range 8-45 d). The mean number of days between retrieval of the enrollment and follow-up 
samples was 15.2 d (SE = 0.3 d; range, 12-21 d). For culture negative samples, the prior test day 
occurred at 26.0 d before the mastitis event (SE = 1.4 d; range, 9-41 d), while the post-mastitis 
test day occurred 22.6 d after the event (SE = 2.0 d; range, 8-41 d). 
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The most abundant families in the enrollment samples that were culture positive for E. 
coli were Enterobacteriaceae (mean = 55.7%, SE = 5.6%), Ruminococcaceae (mean = 11.9%, 
SE = 2.3%,), Lachnospiraceae (mean = 4.7%, SE = 0.6%), Corynebacteriaceae (mean = 2.5%, 
SE 0.7%), Bacteroidaceae (mean = 2.2%, SE = 0.4%), Aerococcaceae (mean = 1.8%, SE = 
0.4%), Paraprevotellaceae (mean = 1.6%, SE = 0.3%), Peptostreptococcaceae (mean = 1.5% SE 
= 0.3%), Succinivibrionaceae (mean = 1.3%, SE = 0.3%), and Dermabacteraceae (mean = 1.1%, 
SE = 0.4%). The average reduction in relative abundance of Enterobacteriaceae between the 
enrollment and follow-up sample was 40.4% (SE = 7.8%). Detailed information on bacterial 
profile per study animal is shown in Figures 5.1 and 5.2. 
The most abundant families in the enrollment samples that were culture-negative were 
Ruminococcaceae (mean = 31.4%, SE = 4.5%), Streptococcaceae (mean = 11.7%; SE = 4.5%), 
Lachnospiraceae (6.9%, SE = 0.8%), Corynebacteriaceae (mean = 6.6%; SE = 2.6%), 
Bacteroidaceae (mean = 3.6%, SE = 0.4%), Moraxellaceae (mean = 1.4%, SE = 0.6%), 
Enterobacteriaceae (mean = 2.9%, SE = 2.0%), Bacillaceae (mean = 2.2%; SE = 1.0%), 
Planococcaceae (mean = 2.4%, SE = 2.1%), and Paraprevotellaceae (mean = 2.7%, SE = 0.3%). 
Nine quarters had >25% abundance of a taxonomic family that includes species associated with 
major or minor mastitis-causing pathogens. These animals had profiles dominated by 
Streptococcaceae (n = 4: 84.0%; 71.6%, 86.9%, 99.9%), Enterobacteriaceae (n = 1: 72.5%), 
Corynebacteriaceae (n = 2: 42.8%, 86.7%), Staphylococcaceae (n = 1: 38.3%), and 
Clostridiaceae (n = 1: 86.0%). Two quarters had >25% abundance of a taxonomic family not 
currently documented to include mastitis-causing pathogens: Planococcaceae (75.6%) and 
Methylobacteriaceae (72.4%). Detailed information on bacterial profile per study animal is 
shown in Figures 5.3 and 5.4. 
 174 
 
 
Alpha-Diversity: Associations with Outcomes for E. coli Positive Quarters 
Survival data was dichotomized into cows surviving in the herd 60 d post-mastitis event, 
and those that did not. Only one cow (2.0%) did not remain in the herd. As this sample number 
was not ideal for statistical comparisons of microbiome data, analysis was not performed for 
survival in the herd, however, the profile of this quarter is indicated with a symbol in Figures 5.1 
and 5.2.  
Milk production change was normally distributed with a mean drop in milk production 
for culture-positive E.coli samples (n = 43 with full data) of 3.6 kg (SE = 1.2 kg). There was a 
relationship between the measure of α-diversity and changes in milk production. As Shannon 
index increased (Spearman r = 0.36, P = 0.02), production loss decreased (Figure 5.1A). When 
the outcome was dichotomized into cows that dropped in milk production by more than 2.2 kg 
and those that did not, the difference in Shannon index was 1.7. Cows that dropped in milk 
production had a mean loss of 3.1 kg (SE = 0.5); those that did not had a mean loss of 4.8 kg (SE 
= 0.5; P = 0.02) (Figure 5.5A). Likely associated with these differences is the relative abundance 
of Enterobacteriaceae in the enrollment samples, which was 38.4% (SE = 9.0%) for cows that 
did not experience a drop in milk production and 67.8% (SE = 7.0%) for cows that did (P = 0.01; 
Figures 5.1B and 5.6A). When both the initial relative abundance of Enterobacteriaceae and 
change in milk production are used as parameters in linear regression to predict Shannon index, 
only Enterobacteriaceae (P < 0.001) remained important in the model. Despite these 
relationships, there was no statistical difference between the cows that experienced a milk drop 
and those that did not when assessing the change in relative abundance of Enterobacteriaceae 
between the enrollment and follow-up samples (P = 0.17; Figures 5.1B and 5.6C). 
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Linear score at next test was normally distributed with a mean of 3.4 and a SE of 0.3 (n = 
47). The relationship between the measure of α-diversity and post-mastitis linear score was not 
statistically important (Spearman r = -0.18, P = 0.23) (Figure 5.2A). When the outcome was 
dichotomized into cows that had a LS ≥4.0 (SCC ≥200,000 cells/mL) or LS <4.0 (SCC <200,000 
cells/mL), the difference in Shannon index was 0.6; cows in the lower LS group had a mean 
Shannon index of 4.0 (SE = 0.5), those in the higher group had a mean of 3.4 (SE = 0.6; P = 
0.31) (Figure 5.5B). Unlike the milk production outcome, the relative abundance of 
Enterobacteriaceae in the enrollment samples was not associated with the LS outcome (P = 
0.32; Figures 5.2B and 5.6B). There was no statistical difference between the cows that 
experienced a LS <4.0 and those that did not when assessing the change in relative abundance of 
Enterobacteriaceae between the enrollment and follow-up samples (P = 0.32; Figures 5.2B and 
5.6D). 
Also associated with α-diversity and independent of outcome was the relative abundance 
of Enterobacteriaceae in the enrollment sample (n = 50). As relative abundance increased, the 
Shannon index decreased (Spearman r = -0.91, P < 0.0001). This relationship was also present 
when comparing the linear correlation between change in relative abundance of 
Enterobacteriaceae between enrollment and follow-up samples and the Shannon index of the 
enrollment samples (Spearman r = 0.79, P < 0.0001).   
The difference in α-diversity between enrollment and follow-up samples for E. coli-
positive cows (n = 50) was also investigated. Shannon diversity was statistically different 
between the sample types (enrollment = 3.8, SE = 0.3; follow up = 5.1, SE = 0.3, P = 0.01) 
(Figure 5.5C). 
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Beta-Diversity: Associations with Outcomes for E. coli Positive Quarters 
 Test statistics and P-values for β-diversity comparisons can be found in Table 5.2. The 
relative abundance of the family Enterobacteriaceae, as also noted in the α-diversity 
comparisons, was the main driver of the variation in UniFrac distances (Figure 5.7A) in samples 
from E. coli-positive cows. A difference in the milk microbiome was detected between cows that 
did and did not experience a drop in milk production of >2.2 kg (PERMANOVA unweighted P = 
0.03, weighted P = 0.01). This is corroborated by the ANOSIM test (P = 0.05; Figure 5.7B), and 
by visualization of PCoA biplots in which the outcomes are somewhat clustered. Several highly 
influential samples from cows that experienced a drop in milk production (n = 5) might be 
driving this difference. These samples each had >99% abundance of Enterobacteriaceae and 
accounted for 5 out of 6 of the samples with >99% abundance; 1 sample with high abundance of 
Enterobacteriaceae was contributed by a cow that did not experience a drop in milk production. 
Analysis of composition of the microbiome (ANCOM) identified one OTU that differed 
statistically between groups, assigned to the phyla Proteobacteria. No differences were found at 
the family level. 
 
Enrollment Samples: Culture-Negative Quarters  
The subset of cows chosen from the larger study for metagenomic analysis of negative 
culture results (n = 35) had no previous cases of mastitis in the current lactation, nor were they 
treated with IMM antimicrobials. The mean and median number of DIM at the time of the 
mastitis event were both 108 d (SE = 11.7). Mastitis events were distributed across each lactation 
category as follows: 25.7% first parity (n = 9), 20.0% second parity (n = 7), and 54.3% third and 
greater parities (n = 19).  
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Alpha-Diversity: Associations with Outcomes for Culture-Negative Quarters 
Survival data was dichotomized into cows surviving in the herd 60 d post-mastitis event, 
and those that did not. Only 2 cows (5.7%) did not remain in the herd. As sample number was 
not ideal for statistical comparisons of microbiome data, analysis was not performed for survival 
in the herd.  
Milk production change was normally distributed with a mean drop in milk production 
for culture-negative samples of 2.4 kg (SE = 2.3 kg). There was no statistical relationship 
between the measures of α-diversity and changes in milk production (Spearman r = -0.18, P = 
0.32) (Figure 5.3B). Results were similar when the outcome was dichotomized into cows that 
dropped in milk production by more than 2.2 kg and those that did not; the difference in Shannon 
index was 0.1 (cows that dropped in production = 4.3 SE = 0.5; those that did not = 4.4, SE = 
0.4; P = 0.95) (Figure 5.8A).  
Linear score at next test was normally distributed with a mean of 3.3 and SE of 0.4. The 
relationship between the measures of α-diversity and post-mastitis linear scores was not 
statistically significant (Spearman r = 0.04, P = 0.84) (Figure 5.4). When the outcome was 
dichotomized into cows that had a LS ≥4.0 or LS <4.0, the difference in Shannon index was 0.1; 
cows in the lower LS group had a mean Shannon index of 4.4 (SE = 0.6) and those in the higher 
group had a mean of 4.5 (SE = 0.4; P =0.90) (Figure 5.8B).  
Also explored was the relative abundance of Ruminococcaceae and Shannon index, as 
milk from healthy cows has been documented to have comparatively larger relative abundances 
of this family. However, a relationship between the two parameters was not statistically 
significant (Spearman r = 0.24, P = 0.17). The relative abundance of Ruminococcaceae was also 
not associated with a linear milk production change or the dichotomous milk drop outcome 
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(linear: r = 0.27, P = 0.26; dichotomous: cows that dropped in production = 24%, SE = 0.06, 
those that did not = 39%, SE = 0.07, P = 0.13).  Linear score analysis produced similar findings, 
though abundances of Ruminococcaceae were numerically higher for those cows that did not 
experience negative outcomes (linear: r = -0.19, P = 0.26; dichotomous: LS ≥4.0 mean = 25.2%, 
LS <4.0 mean = 34.2%, P = 0.37). 
 
Beta-Diversity: Associations with Outcomes for Culture-Negative Quarters 
 Test statistics and P-values for β-diversity comparisons can be found in Table 5.2. No 
statistical differences were found for comparisons made between cows experiencing positive and 
negative outcomes within the dataset of culture-negative cows. Analysis of composition of 
microbiomes was explored but no differential OTUs were present at any taxonomic level when 
comparing outcomes. 
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Table 5.1. Cow and data retrieval descriptors for each clinical mastitis outcome analyzed. 
Mastitis cases were characterized and analyzed separately for E. coli-positive or culture-negative 
quarters 
1Linear Score at next test (8 to 43 d) after the mastitis event, dichotomized. 
2Student’s t-test for continuous data, Pearson’s chi-squared for parity comparison.  
3Milk production drop between test day previous to mastitis event (8 to 43 d) and test day after 
the mastitis event (8 to 43 d), dichotomized into ≤2.2 kg or >2.2 kg. 
4Days in milk at the mastitis event. 
5Mean number of days prior to the mastitis event that data was retrieved to analyze milk 
production drop, not applicable to LS outcome. 
6Mean number of days post-mastitis event that data was retrieved for analysis of LS and MD. 
 
E. coli Positive 
 LS1 <4 LS1 ≥4 P-value2 No MD3 MD3 P-value2 
DIM4 130 122 0.73 128 146 0.46 
Parity, no. (%) 
  
0.16 
  
0.76 
1st 11 (37.9) 3 (16.7)   7 (35.0) 6 (26.1)   
2nd 11 (37.9) 5 (27.8)   6 (30.0) 10 (43.5)   
3rd 4 (13.8) 5 (27.8)   5 (25.0) 4 (17.4)   
>3rd 3 (10.3) 5 (27.8)   2 (10.0) 3 (13.0)   
Test before5 N/A N/A   20 23 0.45 
Test after6 26 25 0.76 28 25 0.45 
 
Culture-Negative 
 
LS1 <4 LS1 ≥4 P-value2 No MD3 MD3 P-value2 
DIM4 110 104 0.82 110 114 0.57 
Parity, no. (%) 
  
0.03 
  
0.007 
1st 7 (29.2) 2 (18.2)   8 (44.4) 
 
  
2nd 7 (29.2) 
 
  3 (16.7) 3 (21.4)   
3rd 6 (25.0) 2 (18.2)   2 (11.1) 5 (35.7)   
>3rd 4 (16.7) 7 (63.6)   5 (35.7) 6 (42.9)   
Test before5 N/A N/A   27 24 0.26 
Test after6 26 16 0.03 25 20 0.29 
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Figure 5.1. Investigating the relationship between metagenomic profile and milk production outcomes. 
The top 25 most abundant families in individual cows (n = 43) experiencing mild to moderate clinical 
mastitis characterized on aerobic culture as E. coli (final column is mean of all cows). A. The relationship 
of the microbial profile to the Shannon index (yellow squares), plotted by the change in milk production 
(kg) between the test day before and after the mastitis event (x-axis) B. The relationship of the microbial 
profile to the Shannon index (yellow squares), change in milk production (white triangles) plotted by the 
change in relative abundance of Enterobacteriaceae between enrollment and follow-up samples (x-axis; 
14 days after mastitis event), ‡ = cow did not survive in the herd > 60 d 
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Figure 5.2. Investigating the relationship between metagenomic profile and linear score outcomes. The 
top 25 most abundant families in individual cows (n = 47) experiencing mild to moderate clinical mastitis 
characterized on aerobic culture as E. coli (final column is mean of all cows). A. The relationship of the 
microbial profile to the Shannon index (yellow squares), plotted by the linear score on the DHIA test day 
8-43 d after the mastitis event (x-axis) B. The relationship of the microbial profile to the Shannon index 
(yellow squares), linear score (red diamonds) plotted by the change in relative abundance of 
Enterobacteriaceae between enrollment and follow-up samples (x-axis; 14 days after mastitis event), ‡ = 
cow did not survive in the herd > 60 d 
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Figure 5.3. Investigating the relationship between metagenomic profile and milk production 
outcomes for individual cows experiencing mild to moderate clinical mastitis and negative 
aerobic culture results. Final column is mean of all cows.  A. Relationships of the microbial 
profile to linear score at next test (red triangles), the Shannon index (yellow squares), and change 
in milk production (x-axis) between the test dates before and after the mastitis event, plotted by 
the relative abundance of Ruminococcaceae for all cows (n = 35) in the dataset. B. Relationships 
of the microbial profile to the Shannon index and increasing positive milk production changes (n 
= 32), ‡ = cows that did not survive in the herd > 60 d 
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Figure 5.4. Investigating the relationship between metagenomic profile, Shannon index, and 
linear score outcomes for individual cows experiencing mild to moderate clinical mastitis and 
negative aerobic culture results. Final column is mean of all cows (n = 35), ‡ = cows that did not 
survive in the herd > 60 d 
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Figure 5.5. Scatterplots investigating the relationship between alpha-diversity (Shannon index) 
of milk samples and outcomes for cows experiencing mild to moderate clinical mastitis 
characterized on aerobic culture as E. coli. A. Shannon index comparison of enrollment samples 
when milk production has been dichotomized into cows that have decreased in production by 2.2 
kg (Drop) or did not (No Drop) between the test day prior to mastitis and the test day after (n = 
43). B. Shannon index comparison of enrollment samples when linear score is dichotomized into 
cows that have a post-mastitis test-day linear score of ≥4.0 and those <4.0 (n = 47). C. Shannon 
index comparison of enrollment samples versus follow-up samples (n = 50). Medians and 
quartiles represented, dotted line represents grand mean. Statistical testing with Kruskal-Wallis 
(A and B) and Wilcoxon (C). 
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Figure 5.6. Scatterplots investigating the relationship between relative abundance of 
Enterobacteriaceae (A, B) and change in relative abundance of Enterobacteriaceae between 
enrollment and follow-up samples (C, D) for the following outcomes: drop in milk production (n 
= 43) (A, C) or post-mastitis linear score <4.0 or ≥4.0 (n = 47) (B, D). Medians and quartiles 
represented, dotted line represents grand mean. Statistical testing with Kruskal-Wallis (A and B) 
and Wilcoxon (C and D)  
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Table 5.2. Beta-diversity statistical comparisons between metagenomic profiles of cows with 
negative versus positive outcomes for cows experiencing mild to moderate clinical mastitis 
characterized as E. coli or negative on aerobic culture 
1Drop in milk production dichotomized into ≤2.2 kg or >2.2 kg. 
  
  
Unweighted Unifrac Weighted Unifrac 
Outcome no. Test Statistic P-value Test Statistic P-value 
Milk production drop vs. no drop1 
   
  
 E. coli on culture 43 1.97 0.03 4.11 0.01 
Negative on culture 32 0.85 0.70 0.97 0.38 
Linear Score <4.0 vs. ≥4.0 
   
  
 E. coli on culture 47 0.92 0.50 0.44 0.76 
Negative on culture 35 0.84 0.73 0.45 0.75 
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Figure 5.7. Biplots depicting use of weighted UniFrac distances for principal coordinate analysis 
(PCoA) of E. coli culture-positive samples (n = 43) and (A) the coordinates of the five most 
abundant family-level taxa (red spheres) in the context of relative abundance of 
Enterobacteriaceae. (B) Relationship of the same samples comparing samples of cows that 
dropped in milk production , “Drop” (>2.2 kg) and those that did not, “No Drop” in analysis of 
similarity (ANOSIM)  
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Figure 5.8. Scatterplots investigating the relationship between alpha diversity (Shannon index) 
and outcomes for cows experiencing mild to moderate clinical mastitis characterized on aerobic 
culture as negative. A. Shannon index comparison when milk production has been dichotomized 
into cows that had a decrease in production by 2.2 kg (Drop) or did not (No Drop) between the 
test day prior to mastitis and the test day after (n = 32). B. Shannon index comparison when 
linear score is dichotomized into cows that have a post-mastitis test-day linear score of ≥4.0 and 
those <4.0 (n = 35). Median and Quartiles represented, dotted line represents grand mean. 
Statistical testing with Kruskal-Wallis  
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DISCUSSION 
Reduced microbial diversity has been associated with several human diseases such as 
inflammatory bowel disease and obesity (Ley et al., 2006; Turnbaugh et al., 2009). Additionally, 
primiparous cows that would go on to experience mastitis within the first 30 d postpartum had 
colostrum with a lower diversity index than those that did not (Lima et al., 2017). Using these 
concepts we wished to determine if there is a characteristic “mastitis microbiome” associated 
with LS or changes in milk production, in the absence of treatment. This study applied 16S 
metagenomic characterization of culture-negative and E. coli-positive nonsevere mastitis cases 
for this purpose. When milk production changes and post-mastitis LS were investigated for E. 
coli-positive cows, associations between α- and β-diversity measurements, milk production 
changes, and initial abundance of Enterobacteriaceae were present. No associations were found 
for α- and β-diversity measurements and outcomes for culture-negative cows. There was no set 
of microorganisms in E. coli-positive or culture-negative samples that was associated with the 
outcomes explored.  
Alpha- and β-diversities of the E.coli-positive samples were associated with relative 
abundance of Enterobacteriaceae and milk production changes. The larger relative abundance of 
Enterobacteriaceae in samples from cows that experienced larger drops in milk production is 
perhaps reflective of a higher relative abundance of E. coli, though the current taxonomic 
analysis did not classify organisms to the species level.  If relative abundance is used as a proxy 
for bacterial numbers, which is often true when the pathogen identified is the etiologic cause, the 
association between diversity measurements and milk production changes found is likely due a 
greater concentration of lipopolysaccharide (LPS) in the mammary gland.  This ascribes to the 
knowledge that the outcome and severity of E.coli mastitis is mainly attributed to environmental 
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and immune factors in response to LPS, rather than virulence of the E. coli strain (Burvenich et 
al., 2003; Mehrzad et al., 2008). Likewise, increased cytokine synthesis is associated with an 
increased concentration of E. coli particles (Günther et al., 2011). The authors speculate that 
associations were found for changes in milk production, but not for post-mastitis LS, due to the 
transient nature of the organism. Initial growth of E.coli is decelerated by a quick spike in 
somatic cells in the milk (Hill, 1981), and while LS recovers, perhaps secretory epithelial 
damage in the gland undergoes a more delayed resolution, if any. Further investigation using 
quantitative PCR, LPS bioassays, or biopsy would provide answers to these hypotheses. 
Upon analysis of composition of microbiomes (ANCOM), the phylum Proteobacteria 
was differentially abundant between the E.coli samples from cows that experienced a drop in 
production and from those that did not. Proteobacteria was also higher in abundance in E.coli-
positive quarters compared with healthy quarters in Ganda et al. (2016), and was driven by 
greater abundances of Enterobacteriaceae, as observed in the current study. Other investigators 
have observed that drops in milk production were highest and most persistent for cows with 
E.coli infections (Gröhn et al., 2004; Schukken et al., 2009), which agree with our findings for 
these quarters. Also, clinical cure was statistically different between cows having higher versus 
lower abundances of Enterobacteriaceae in Ganda et al. (2016), indicating that clinical outcomes 
are affected by this measure.  
Despite the presence of only E. coli on aerobic culture or the absence of pathogens for the 
culture-negative samples, metagenomic analysis of milk from these quarters revealed the 
presence of a large diversity of taxonomic families.  This is consistent with previous 
characterization of mastitic and healthy human and bovine milk microbiomes and also supports 
the idea of an endogenous entero-mammary pathway, as many families present in the 
 191 
 
 
gastrointestinal tract such as Ruminococcaceae, Clostridiaceae, and Lachnospiraceae were 
present in the milk samples (Kuehn et al., 2013; Oikonomou et al., 2014; Addis et al., 2016; 
Ganda et al., 2016).  Using quantitative methods, groups have shown that despite the vast 
representation of different microbial species in both healthy and mastitic milk samples, mastitic 
samples contain statistically larger bacterial loads or higher overall DNA concentrations than 
their healthy counterparts (Kuehn et al., 2013; Ganda et al., 2016). Additionally, negative 
correlations between the Shannon index and bacterial load have been described, indicating that 
when overall microbial concentration increases, there is a reduction in microbial diversity 
(Bonsaglia et al., 2017). This can be observed for the Shannon indices of the mastitic quarters in 
the current study, which were 3.5 for E.coli-positive quarters and 4.5 for culture-negative 
quarters.  Values are similar to those documented for mastitic quarters and much lower than 
values observed in healthy quarters, which range from 7.0 to 9.0 (Oikonomou et al., 2014; Ganda 
et al., 2016; Rodrigues et al., 2017). In the 14 d follow-up samples, quarters in the current study 
reached a mean value of 5.1; in the Ganda et al. study, mean values for E.coli and culture-
negative mastitic quarters at 14 d were approximately 6.5. This could be due to a greater 
decrease in relative abundance of Enterobacteriaceae from days 1 to 14 (reduction from 62.6% 
to 9.7%) in Ganda et al. as compared to our findings (reduction from 55.7% to 15.2%).  
Although a relative abundance of 9.7% Enterobacteriaceae on 16S analysis of post-
mastitis samples was observed, all cows with cultures positive for E. coli experienced 
bacteriological cure by day 14.  Unfortunately, as the risk for cure was 100%, the differences 
between the microbiomes of quarters that did and did not cure could not be evaluated. Our high 
spontaneous cure rate agrees with Ganda et al. (2016) who found that 80% of non-treated and 
85% of treated E. coli-positive quarters experienced bacteriological cure. Roberson et al. (2004) 
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also found that 85% of E. coli cases (17/20) were cured bacteriologically by 7 d, regardless of 
treatment. Collectively, these findings agree with conclusions made by Döpfer et al. (1999): less 
than 5% of “chronic” or recurrent E.coli mastitis cases are genotypically identical.  Regardless, if 
we had identified chronic strains of E.coli in the current study, that would not necessarily 
indicate the need for IMM antimicrobial treatment as research shows that persistency of E. coli is 
associated with higher odds of resistance to ampicillin  and ceftiofur, common drugs labeled for 
the treatment of CM (Fairbrother et al., 2015). 
Bacteriological cure was not assessed for culture-negative quarters as no pathogen was 
isolated on aerobic culture.  Indeed, a major finding in this study was the inability to identify a 
potentially causative taxonomic family in the microbial profiles of 24 of the 35 samples. This is 
similar to results outlined in Ganda et al. (2016) and Oikonomou (2014): none of the culture-
negative clinical quarters contained a taxonomic family representing over 25% relative 
abundance. Our findings are also similar to those described in Kuehn et al. (2013), where no 
genus represented greater than 25% of the microbiome in 9 out of 10 culture-negative clinical 
mastitis samples.  The largest mean relative abundance, 20.4%, in Kuehn et al. (2013) was for 
the genus Sphingomonas. Culture-negative quarters in Oikonomou et al. (2014) had a mean 
relative abundance of 20.6% Caulobacter leidyi, a poorly-characterized species also associated 
with the Sphingomonas genus.  Conflicting with this idea is the finding by Hunt et al. (2011), 
who listed Sphingomonas among the 15 most abundant genera found in healthy human milk.  
However, given that its relative abundance in healthy human milk is 2.4% (Hunt et al., 2011), 
establishment of a dysbacteriosis during the clinical mastitis event should not be ruled out.  The 
family Sphingomonadaceae, while present in the current study, was found in very low 
abundances (<1%) across all culture-negative samples. A longitudinal or challenge study needs 
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to be performed to provide proof of pathogenicity for these organisms as a primary cause of 
bovine CM. This argument can also be made for the families Planococcaceae and 
Methylobacteriaceae which are present in high abundance in two culture-negative samples from 
the current study; neither of which is reported in the samples from Hunt et al. (2011), Kuehn et 
al. (2013), or Oikonomou et al. (2014).   
Nine culture-negative quarters were dominated by one taxonomic family that includes 
species associated with major or minor mastitis-causing pathogens. If these pathogens were the 
primary cause of mastitis, they would likely have been apparent by culture if the bacteria were at 
higher concentrations, or more importantly, if the bacteria were still viable—a characteristic that 
cannot be assessed through sequencing methods. Therefore, the presence of a dominant family 
on 16S analysis of culture-negative samples may be indicative of a primary infection that has 
spontaneously resolved.  The dominant families identified in 7 of the samples (Streptococcaceae, 
Corynebacteriaceae,  and Staphylococcaceae) have also been identified in healthy human and 
bovine milk, suggesting that they are a normal part of the milk microbiota (Hunt et al., 2011; 
Ward et al., 2013; Ganda et al., 2016; Bonsaglia et al., 2017). Therefore, again, we cannot rule 
out a dysbacteriosis or disruption of the normal microbiota as an alternative to, or an addition to, 
a primary infection. Alternatively, members of the Staphylococcaceae and Corynebacteriaceae 
families can be commensals habituating teat skin, which, taking into account our procedure for 
collecting milk, might be contaminants or might support the overlap of the microbiota of the 
environments (Verdier-Metz et al., 2012; Kuehn et al., 2013). The finding of several anaerobic 
families such as Lachnospiraceae, Paraprevotellaceae, Clostridiaceae, and Ruminococcaceae 
indicate an accurate description of the microbiomes and not simply contamination. This agrees 
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with findings from bovine colostrum (Lima et al., 2017), bovine milk (Bonsaglia et al., 2017; 
Rodrigues et al., 2017), and human milk (Fernández et al., 2013; Jiménez et al., 2015).  
Characterization of the microbiomes of culture-negative samples infrequently identified a 
dominant pathogen.  Likewise, no differential taxa or group of pathogens was associated with LS 
or milk production outcomes.  Additionally, α- and β-diversity measures within and between 
outcome groups were similar. The inability to detect a “pathogenic profile” sheds light on 
previous findings from culture-based selective treatment protocols where authors showed no 
differences in several health and production outcomes between cows assigned to blanket IMM 
therapy and cows assigned to selective treatment (Lago et al., 2011b; a; Vasquez et al., 2017; 
McDougall et al., 2018). For example, in Lago et al. (2011), linear SCC, days to clinical cure, 
bacteriologic cure risk, new infection risk, treatment failure risk, and milk production were 
similar between untreated culture-negative cases and treated culture-negative cases as well as 
between untreated gram-negative cases and treated gram-negative cases (Lago et al., 2011b).  
Not all outcomes investigated in Lago et al. were explored for their relationship to the 
microbiome in the current study. Few cows with no-growth or E. coli-positive cultures 
experienced negative outcomes related to culling, clinical cure, or treatment failure; low sample 
numbers prevented the ability to assess these outcomes in the current study.  While inherently 
bacteriological cure risk cannot be evaluated for culture-negative cases, follow-up cultures would 
have allowed for exploration of new infection risk and the relationship to aspects of the mastitis 
microbiome, something that was not performed in the current study.   
  Perhaps no associations were present at the family level between culture-negative cows 
that experienced negative outcomes and those that experienced positive outcomes because the 
samples were similar to profiles of healthy quarters. The resilient nature of the milk microbiome 
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was described by Ganda et al. (2016). In that study, differences were found between profiles of 
culture-negative mastitis samples versus healthy samples on day 0 when evaluating analysis of 
similarities (ANOSIM), but a clear separation in principal coordinate analysis (β-diversity) was 
not observed. When comparing healthy to culture-negative mastitic quarters, shifts in the milk 
microbiome for several different phyla (Firmicutes, Bacteroidetes, Tenericutes, and 
Spirochaetes) were found in Ganda et al. (2016). At day 14, however, the profiles were 
indistinguishable. Evaluation on the phyla level was evaluated for culture-negative samples in 
the current study, but no differential phyla were found. The addition of more cows to the current 
study might have allowed us to detect differences in microbial profiles. In the advent of big data, 
there are no guidelines dictating or suggesting an appropriate sample size to ensure the ability to 
detect differences in microbiomes between multiple groups, given a specified level of Type I 
error.  
A limitation of our study design is the absence of healthy quarter samples or follow-up 
cultures from each affected quarter.  Benefits exist for having a healthy quarter comparison as 
individuals can have diverse microbial profiles dependent on parity, stage of lactation, 
environment, or bodyweight (Hunt et al., 2011; Cabrera-Rubio et al., 2016; Lima et al., 2017). In 
the current study, we were therefore unable to determine if the samples could be discriminated, 
in profile, from healthy milk from the same animal.  Characterization of a healthy contralateral 
quarter or a post-resolution sample would allow us to discriminate between a primary infection 
or a dysbacteriosis. From a healthy quarter comparison, Oultram et al. (2017) used a 2-fold 
increase in bacterial relative abundance to diagnose 80% of the potentially causative pathogens. 
As noted above, Kuehn et al. (2013) also used a healthy quarter comparison to identify 7 
differentially present genera in culture-negative mastitis samples versus healthy samples. If 
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follow up samples were available, similar techniques could have been used in the current study 
to determine whether certain bacteria in the culture-negative quarters were causative; healthy 
versus mastitic analysis would allow us to rule out the contribution of specific taxonomic 
families to negative outcomes.  
There were a statistically higher number of later lactation cows in the LS ≥4.0 and milk 
drop groups versus the respective positive outcome groups for culture-negative quarters. This 
finding is well supported by research that shows that higher-parity cows experience greater 
impacts on milk production during mastitis events, and are overall more susceptible to repeat 
mastitis events (Gröhn et al., 2004; Pinzón-Sánchez et al., 2011; Hiitiö et al., 2017). As 
microbiota can be more diverse for higher parity animals, a selection of cows from the same 
lactation may have provided a better comparison (Lima et al., 2017). Similarly, a shorter time 
period between the mastitis event and the next-test day was associated with the higher LS 
category. Therefore, cows in the dataset that were allowed more time to recover from the mastitis 
event prior to data retrieval appeared to experience more positive outcomes. Collection of a milk 
sample from the affected quarter at a standard number of days after the event would eliminate 
this bias. Ideally, to minimize bias associated with time between the mastitis event and test day 
data, and to best characterize the effects of microbiota on milk production and linear score, daily 
milk weights and LS could be recorded, though statistical comparisons in a multivariate model 
could prove difficult. Despite discrepancies between demographics of the outcome groups, the 
results for comparisons of diversity measurements of pathogen profiles do not support the need 
to treat E. coli and culture-negative cases with currently available antibiotics. However, cow 
characteristics and historical LS should also be considered when making treatment decisions.  
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CONCLUSIONS 
 The current study presented an analysis of the milk microbiome of culture-negative and 
E.coli-positive CM quarters. Irrespective of metagenomic characteristics, many of the cases 
experience positive outcomes without treatment. There was no pathogen profile in culture-
negative cases that was associated with linear score or milk production outcomes. Relative 
abundance of Enterobacteriaceae was associated with greater losses in milk production between 
test days for cows that were experiencing nonsevere E.coli mastitis. However, no E.coli-positive 
cow cultured positive for this organism 14 d after the mastitis event. As dairies are more 
commonly using diagnostic tools to aid in treatment decisions, more research is needed for those 
cases that will not be treated, specifically for characterizing or confirming a dysbacteriosis and 
for exploring associations between the microbiome and additional outcomes.  
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ABSTRACT 
 
An algorithm using only computer-based records to guide selective dry cow therapy was 
evaluated at a New York dairy farm via a randomized field trial. Dairy Comp 305 and Dairy 
Herd Information Association test-day data were used to identify cows as low risk (cows that 
might not benefit from dry cow antibiotics) or high risk (cows that will likely benefit). Low-risk 
cows were those that had all of: somatic cell count (SCC) ≤200,000 cells/mL at last test, an 
average SCC ≤200,000 over the last 3 tests, no signs of clinical mastitis at dry-off, and have not 
had greater than one clinical mastitis event in the current lactation. Low-risk cows were 
randomly assigned to receive intramammary antibiotics and external teat sealant (ABXTS) or 
external teat sealant only (TS) at dry-off. Using pre-dry-off and post-calving quarter-level culture 
results, low-risk quarters were assessed for microbiological cure risk and new infection risk. 
Groups were also assessed for differences in first-test milk yield and linear scores (LS), 
individual milk weights for the first 30 days, and culling and mastitis events before 30 days in 
milk. A total of 304 cows and 1,040 quarters in the ABXTS group and 307 cows and 1,058 
quarters in the TS group were enrolled. Among cows to be dried, the proportion of cows that met 
low-risk criteria was 64% (n = 611/953). Of cultures eligible for bacteriological cure analysis (n 
= 171), 93% of ABXTS cured, while 88% of TS experienced cure. Of the non-cures, 95% were 
contributed by the minor pathogens coagulase-negative staphylococci (CNS; n = 19/20). These 
organisms also accounted for 57.5% of new infections (n = 77/134). There were no statistical 
differences between treatment groups for new infection risk (TS = 7.3% quarters experiencing 
new infections; ABXTS = 5.5%), milk production (ABXTS = 40.5 kg; TS = 41.2 kg), LS 
(ABXTS = 2.5; TS = 2.7), culling events (ABXTS n = 18; TS n = 15), or clinical mastitis events 
(ABXTS n = 9; TS n = 5). Results suggest that the employed algorithm decreased dry-cow 
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antibiotic use by approximately 60% without adversely impacting production or health 
outcomes. 
Key words: selective dry cow therapy, mastitis 
 
INTRODUCTION 
The rate of clinical mastitis for cows is highest within the 2 wks post-calving as 
compared with any other time during lactation and is associated with intramammary infections 
(IMI) with major pathogens during the dry period (Green et al., 2002). Using serial culture 
throughout this period, groups have confirmed that a majority of clinical mastitis cases are 
contributed by chronic subclinical or newly acquired cases from dry-off to calving (Todhunter et 
al., 1991; Bradley and Green, 2000; Green et al., 2002).  
Dry cow antimicrobial administration was developed and implemented in the 1960s as 
part of a series of management strategies to mitigate the high incidence of IMI in early lactation 
(Neave et al., 1966; Smith et al., 1966). A survey by the National Animal Health Monitoring 
System in 2014 indicated that over 90% of cows are treated and 90% of operations use 
antimicrobial products at dry-off (USDA, 2016a). This suggests that blanket dry cow therapy 
(BDCT) is widely employed; all quarters are treated with a long-acting antimicrobial 
immediately after the last milking. Success of mastitis control programs is indicated by the 
increase in negative quarter-level culture results at dry-off from 44% in 1985 to between 73 and 
95% of quarters within the last decade (du Preez and Greeff, 1985; Pantoja et al., 2009; Rajala-
Schultz et al., 2011).  The decreased prevalence of contagious mastitis pathogens and reduction 
of bulk tank somatic cell counts (BTSCC) also suggests that BDCT is not currently a necessity in 
all herds (Ekman and Osteras, 2003; Robert et al., 2006b). Finally, concerns exist for non-
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prudent use of antimicrobials in regards to public health consequences. For these reasons, Nordic 
countries have adopted restrictions that permit only selective use of antimicrobials, leading to 
reductions of approximately 80% and 40% for dry cow and clinical mastitis treatments, 
respectively (Ekman and Osteras, 2003). External or internal teat sealants are additional 
technologies that can offer further protection against new intramammary infections and are 
readily available in the US (Crispie et al., 2004; Timms et al., 2004; Krömer et al., 2014). 
Selective treatment of cows at dry-off might produce economic returns via decreased labor and 
dry-tube costs, even when increases in incidence of mastitis are accounted for (Huijps and 
Hogeveen, 2007; Scherpenzeel et al., 2016).  
Selective dry cow therapy (SDCT) identifies and treats cows currently infected or at 
higher risk for infection during the dry period and is an alternative to BDCT. There are several 
approaches to SDCT that have been investigated including culture-based diagnostics (Cameron 
et al., 2014; Patel et al., 2017). While culture remains the gold standard for diagnosing an IMI, 
there are disadvantages to its use including costs and time associated with materials, sampling, 
and labor. Culture-independent cow-side tools such as the California Mastitis Test and milk 
leukocyte differential tests are available and have been used in SDCT protocols (Poutrel and 
Rainard, 1981; Hockett et al., 2014). Fair to good sensitivities and specificities have been 
reported for diagnosing IMIs from late lactation milk samples using these tests, dependent upon 
cut-point and interpretation (Godden et al., 2017). Use of a single composite somatic cell count 
(SCC) before dry-off to serve as a proxy for inflammation and infection has also been used to 
identify cows to be treated (Schukken et al., 1993; Scherpenzeel et al., 2014). However, 
identification and treatment of high SCC cows or quarters at dry-off based upon one time-point 
was shown to have negative consequences on udder health in several studies (Schukken et al., 
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1993; Scherpenzeel et al., 2014). Lastly, combination screening using SCC, mastitis history, plus 
or minus bacteriologic culture has produced beneficial effects for several outcomes, but 
successful implementation can be farm-dependent (Rajala-Schultz et al., 2011; Cameron et al., 
2014; Cameron et al., 2015).  
Our group tested a culture-independent method using only on-farm data in the form of a 
computer-driven algorithm to guide SDCT. Ninety-eight percent of large dairies (>500 cows) use 
an on-farm computer record-keeping system and 82.7% of cows in the United States are housed 
on operations that use these systems (USDA, 2016b). Our approach was to use DHIA and Dairy 
Comp 305 records employed by 72.4% and 68% of large US dairies, respectively (USDA, 
2016b), to determine whether a cow was at low or high risk for having or acquiring an infection 
during the dry period. Our objective was to use an algorithm to identify low-risk cows and then 
compare outcomes (bacteriological cure, new infection risk, milk production, linear scores, 
mastitis cases, and culling) between those receiving IMM antibiotics and external teat sealant at 
dry-off and those receiving external teat sealant only. 
 
MATERIALS AND METHODS 
 This randomized field trial was performed at a New York commercial dairy, milking 
1,800 cows, between June 2016 and March 2017. The rolling herd average milk production, 
BTSCC, culling rate, monthly clinical mastitis incidence, and 21-day pregnancy rate were 13,388 
kg, 201,000 cells/mL, 36.2%, 2%, and 20%, respectively. Cows were housed in freestalls with 
reclaimed sand and calved in a pen bedded with straw. The trial herd milked most cows three 
times per day while late lactation animals were milked twice per day. All cows eligible for dry-
off according to guidelines defined by the dairy (pregnant >220 d or pregnant >180 d and 
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producing <11.4 kg of milk) were considered for inclusion. This farm used DHIA services, 
which included monthly SCC and milk weights and Dairy Comp 305 (DC305; Valley Ag. 
Software, Tulare, CA) for recording mastitis and culling events. 
 
Sample Size Calculation 
The primary outcome was new IMI at freshening, which has a documented prevalence of 
6.4% to 25% at the quarter level (Godden et al., 2003; Pantoja et al., 2009; Arruda et al., 2013). 
Using a prevalence of 15%, an alpha of 0.05, a power of 80%, and the ability to detect a change 
in risk of 5%, a sample size of 1,884 (942 quarters per group; 236 cows) would be required.  
After accounting for a 20% loss to follow-up, the sample size amounts to 2,261 quarters, or a 
total of 565 cows (approximately 300 cows per group).  
 
Algorithm Details, Treatment Allocation, and Sampling Procedures 
 This study was approved by Cornell University Institutional Animal Care and Use 
Committee, approval #2013-064. Each cow eligible for dry-off was classified into low- or high-
risk groups based on the following algorithm: a low-risk cow was defined as having an average 
SCC over the last 3 tests before dry-off of ≤200,000 cells/mL, a SCC ≤200,000 cells/mL on the 
last test, and having no more than one case of clinical mastitis in the current lactation.  The 
expected dry period had to be <100 d and each low-risk cow could not have been treated with 
antibiotics in the last 30 d. All other cows were categorized as high-risk by the algorithm. The 
computer-based algorithm was automated within DC305. All previous mastitis events were 
detected by farm personnel and all events were recorded in DC305 regardless of treatment 
protocol. Aside from computer-based assignment, if a cow had clinical mastitis on dry-off day or 
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had <3 functional quarters, she was considered a high-risk cow. All high-risk cows received dry 
cow intramammary antibiotics and external teat sealant. Eligible low-risk cows were randomized 
to either the external teat sealant only (TS) group or the antibiotic and external teat sealant 
(ABXTS) group using a random number generator in Microsoft Excel (Microsoft Corp.; 
Redmond, WA). Low-risk cows were blocked within dry-off day, aiming to enroll an equivalent 
number of cows into each treatment group that day. 
The trial farm had a designated weekly dry-off day. Procedures, including dry tube 
antibiotic selection and use of external teat sealant, were not altered from the farm’s normal 
routine. Subsequent to the afternoon milking, dry cows were held in a pen to await dry-off 
procedures. They were individually placed into a tilt-table chute, teats were cleaned thoroughly 
with a dilute (1:128) chlorhexidine solution (2%; AgriLabs, St. Louis, MO) and teat ends were 
scrubbed with individual alcohol towelettes. Following initial fore stripping of milk, single 
quarter-level samples were collected into a culture tube by study personnel using sterile 
technique and promptly placed on ice. Immediately after sample collection, cows in the ABXTS 
group received one tube of cephapirin benzathine into each quarter according to label directions 
(Tomorrow; Boehringer Ingleheim, St. Joseph, MO). Subsequent to administration of the dry 
cow antibiotic, an external teat sealant (T-hexx Dry; Hydromer, Inc., Branchburg, NJ) was 
applied once to each barrel and teat end. For cows in the TS group, only external teat sealant was 
applied once to each barrel and teat end. Treatments were applied on a cow level; all quarters of 
cows in each group received antibiotics (ABXTS) or did not (TS). All cows were dried off 
abruptly and dry cow treatments and external teat sealants were administered by farm personnel.  
A red leg band was placed on every dry cow regardless of administration of antibiotics 
and management did not maintain records as to which cows received treatments though the study 
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investigators did. Each cow was also marked as treated with antibiotics in an effort to minimize 
bias when milkers or management detected cases of mastitis or made culling decisions as well as 
avoid residue issues. All trial cows remained in the dry cow pens or maternity pens until milk 
withdrawal times were met and milk production commenced. Any mastitis case defined during 
the trial was detected by on-farm employees, trained by Quality Milk Production Services 
(QMPS), by observing abnormalities in milk, inflammation of the quarter, or systemic signs in 
the cow. Milk samples from all mastitis cases were submitted to QMPS at the Animal Health and 
Diagnostic Center in Ithaca, NY for culture. Events (mastitis, sold, died) were recorded in 
DC305 by on-farm employees. 
Quarter-level samples were obtained from each low-risk cow after milking in the parlor 
at 1-7 DIM. Teat ends were scrubbed with individual alcohol towelettes and samples were taken 
following an initial forestrip procedure. If a cow received antimicrobial treatment before 
collection of the post-calving sample, its samples were removed from quarter-level analyses. 
Quarter-level samples were also retrieved on dry-off day and at 1-7 d fresh from a subset 
of high-risk cows to describe organism distribution and to calculate the positive and negative 
predictive values of the algorithm. Positive predictive value (PPV) is the probability that a cow 
assigned to the high-risk group has one or more positive quarters. Negative predictive value 
(NPV) is the probability that a cow assigned to the low-risk group had 4 negative quarters on 
culture.  
 
Microbiological Diagnosis 
Standard culture technique was performed on all milk samples by QMPS following 
procedures recommended in the Laboratory Handbook on Bovine Mastitis (National Mastitis 
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Council, 2017). Briefly, 0.01 mL of milk was streaked on trypticase soy agar containing 5% 
sheep blood and 1% esculin (PML Microbiologicals, Mississauga, ON, Canada), and plates were 
incubated aerobically at 37°C for 18-24 h. Colonies from pure cultures were subjected to matrix 
assisted laser desorption/ionization (MALDI-TOF) using a Bruker MALDI-TOF Biotyper 
version 3.1.66 (Bruker Corp., Billerica, MA). Confidence levels were assigned by the machine 
software by referencing the Bruker 5989 RUO bacterial library. Levels accepted for species 
identification were ≥2.0 and for genus identification between 1.8 and 2.0. A composite sample 
was created by combining 300µL of milk from each quarter for each cow for mycoplasma 
testing. Pools of milk from 5 cows were subjected for Mycoplasma screening using a dissection 
microscope after anaerobic incubation at 37°C for 7 d on Mycoplasma agar (Sigma-Aldrich 
LLC, St. Louis, MO). 
 
Treatment Outcomes 
 Quarters were assessed for bacteriological cure and new infection risk. Only quarters 
with pure, non-contaminated cultures were considered. Exclusions for these reasons were not 
different between groups (Tables 6.2 and 6.4). An infection was defined as the isolation of one or 
more colonies from 10µL of milk for all pathogens except for CNS. For CNS 2 or more colonies 
isolated from the sample were needed to establish the presence of an infection (Dohoo et al., 
2011). If one nonpathogenic or ≥2 dissimilar nonpathogenic colony types were present in low 
levels, the culture was defined as negative. Contamination was defined as the isolation of ≥3 
different colony types from the milk sample.  A quarter was defined as a bacteriological cure 
when the initial pathogen present at enrollment was not present in the fresh quarter sample. 
Negative quarters at dry-off were not included in analysis for bacteriological cure. A quarter was 
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defined as a new infection when the organisms cultured at dry-off and at fresh were different. If a 
cow left the trial due to culling during the dry period, or was missed for any reason at fresh, it 
was lost to follow-up for both bacteriological cure and new infection risk. Cows in the study 
were also followed up for first-test (1-41 d) milk production and linear scores, longitudinal milk 
production up to 30 DIM, mastitis events before 30 DIM, and survival/removal from the herd 
before 30 DIM. These values and dates were retrieved from DHIA monthly reports or DC305. 
Linear score (LS) is a transformation of SCC, calculated as [ln(SCC/100)/ln(2)] + 3 (Ali and 
Shook, 1980). 
 
Statistical Analysis 
 The effects of treatment on outcomes were analyzed using generalized linear mixed 
models for continuous variables and binomial logistic regression for dichotomous outcomes. 
Analysis of outcomes accounted for important covariates such as parity at fresh (2nd, 3rd, 4th, or 
>4th), DIM at sample collection, length of the dry period, previous milk yield and LS, mastitis 
events before and after the dry period (up to 30 DIM), and pathogen present at dry-off and at 
fresh. The primary explanatory variable of interest was the treatment group and all interactions 
with this variable were tested. All analyses were performed in SAS version 9.4 (SAS Institute 
Inc., Cary NC) using the PROC LOGISTIC command for binary outcomes: bacteriological cure, 
new infection risk, mastitis before 30 DIM, and culling before 30 DIM. The PROC MIXED 
command was used for milk production (longitudinal and at first test) and LS at first test. Each 
quarter was treated as an independent observation in the analysis of bacteriological cure and new 
infection risk. To select the best model, all possible confounding variables were subjected to 
bivariate analysis by means of Chi-squared, t-tests, or ANOVA tests using PROC FREQ, PROC 
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TTEST, PROC REG, or PROC ANOVA. Any terms with a P < 0.2 were offered into the 
models. Each variable was then examined by backwards stepwise removal from the regression 
until all covariates with P < 0.1 were identified and included. In many of the models, the 
treatment variable was forced. Quarter nested in cow was tested as a random effect to determine 
the contribution of interdependence of quarters. Basic graphing techniques were used to assess 
normality, homoscedasticity, and linearity of variables. Data transformations were performed 
and reported as necessary. Seven final models were established describing (1) the odds of 
bacteriological cure (2) the odds of new infection (3) first-test milk production, (4) longitudinal 
milk production, (5) first-test linear score, (6) the odds of culling before 30 DIM, and (7) the 
odds of mastitis before 30 DIM. An animal was not included in a model if it was missing a data 
point for a parameter included in the model; the number of animals with complete data for each 
analysis is indicated in each table. 
 
RESULTS 
Descriptive Statistics for Low- and High-Risk Cows and Quarters 
A total of 953 cows were dried between June 2016 and January 2017. Cows were 
allocated into the high-risk group (n = 321) by the algorithm for combinations of the following 
criteria: high average SCC, high last-test SCC, an anticipated dry period >100 d and >1 mastitis 
event in the current lactation. More than half of the excluded cows experienced more than one 
reason for assignment into the high-risk group (n =169). High last-test SCC is commonly used in 
SDCT protocols as criteria for administration of an IMM antimicrobial. The addition of criteria 
other than last-test SCC, for which 244 cows would have been excluded, resulted in an additional 
77 cows assigned to the high-risk group. The 2 most common reasons for placement into the 
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high-risk group were high SCC at last test and high average SCC over the last 3 tests (n = 268 
cows equaling 28% of cows eligible for dry-off and 83% of exclusions). Cows added last minute 
to the dry-off list (not due to dry-off by the farm’s criteria, but elected to dry-off by the 
management) were not sampled nor included in the either risk group (n = 21). Details of cow and 
quarter enrollment can be found in Figure 6.1. A total of 611 low-risk cows and 2,386 quarters 
were enrolled in the study. Fifty-eight cows were 3-quartered. Allocation to the low-risk group 
was 64%. Distribution between groups was similar with 50% of cows/quarters assigned to the TS 
group (n = 307/611; 1,202/2,386) and 50% assigned to the ABXTS group (n = 304/611; 
1,184/2,386).  Post-enrollment exclusions of low-risk cows resulted in 37 cows lost for analysis 
of milk production and LS due to death or culling during the trial period (n = 33) or no recorded 
LS (n = 4). The number of quarters lost to follow up for both bacteriological cure and new 
infection risk analyses was 288. Quarters were lost for the following reasons: no post-calving 
sample was collected (n = 34), sample was retrieved >7 DIM (n = 2), death or culling during 
early fresh or during the dry period (n = 75 quarters, 19 cows), and antimicrobial treatment 
before post-calving milk samples were retrieved (n = 52 quarters). An additional 125 quarters 
were excluded from bacteriological cure and new infection risk analyses due to contamination or 
mixed culture results. No statistical differences were observed between study groups with respect 
to post-enrollment exclusions. Cows experiencing culling or missing milk samples over the dry 
or early fresh period were still considered for culling and mastitis outcomes and for longitudinal 
milk production for as long as they remained in the herd. Overall, 1,058 TS quarters and 1,040 
ABXTS quarters were considered for analysis of bacteriological cure and new infection risk. 
Cow inclusion numbers for analyses of culling and mastitis risk was 307 TS cows and 304 
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ABXTS cows. Analyses of milk production and LS included 291 TS and 283 ABXTS cows 
(Figure 6.1.).   
Descriptors for each treatment group are found in Table 6.1. The distribution of cows 
experiencing one case of clinical mastitis in the lactation of enrollment was different between 
groups, with cows in the TS group experiencing more cases (17 versus 6). Mean last-test-day 
milk production and LS were 23.6 kg and 2.3, respectively. The mean and median number of 
DIM when the fresh quarter milk sample was retrieved was 2 and 3 d. The mean and median 
number of DIM that milk production and LS data were retrieved were each 16 d. Distribution of 
these variables were not statistically different between treatment groups. 
 
Infection Status at Dry-Off and Freshening 
A total of 142 high-risk cows (n = 553 quarters) were sampled to determine the ability of 
the algorithm to correctly classify cows as high or low risk. The cow-level IMI prevalence at 
dry-off for high-risk and low-risk cows was 70.7% (n = 99/140) and 29.4% (n = 178/605), 
respectively. The PPV and NPV for the algorithm were 70.7% (95% CI: 65.4-76.0) and 70.6% 
(95% CI: 66.4-74.7) at the observed apparent prevalence of infection (37.2%). Including mixed 
culture results and excluding contaminated quarters, the quarter-level prevalence for IMI was 
9.6% (n = 229/2,379) and 29.8% (n = 165/553), for low and high-risk quarters, respectively 
(13.4% overall).  Distribution of dry-off culture results for low and high-risk quarters are 
described in Tables 6.2 and 6.3. Randomization created a similar distribution of organisms 
between treatment groups (P > 0.05). The most commonly isolated organisms for both low and 
high-risk cows were coagulase-negative staphylococci (CNS), contributing to 4.9% and 13.9% of 
overall quarters and 59.8% and 46.6% of infections, respectively. Infection proportion with 
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Corynebacterium spp. was similar between high- and low-risk quarters, but Lactococcus spp. 
were more prevalent in high-risk quarters.  
Following calving, 7.3% of quarters in the high-risk group were culture positive (n = 
36/495), while 8.2% of low-risk quarters were (n = 182/2,225). The most common positive 
culture result was CNS, with 4.6% of the low-risk quarters and 3.0% of the high-risk quarters 
infected. The infection status of quarters in low-risk groups is seen in Table 6.4.  
 
Treatment Effects 
Bacteriologic Cure Risk. A quarter was not eligible for bacteriological cure if the dry-off 
sample had no growth (n = 1,927), the dry-off or fresh sample was contaminated (n = 69), or if 
the dry-off or fresh sample had mixed growth (n = 56). The number of quarters meeting 
inclusion criteria for analysis was 171. Bacteriological cure was seen in 151 of the quarters 
(88.3%): 72 (83.7%) of the TS quarters and 79 (92.9%) of the ABXTS quarters (Fisher’s exact P 
= 0.09).  This compares with high-risk cows that experienced a cure in 94.9% (n = 112/118) of 
quarters. Of the non-cures, 95.0% were contributed by the minor pathogens CNS in low-risk 
cows (n = 19/20) and 100% in high-risk cows (n = 6). Mixed model logistic regression of 
bacteriological cure produced a model that included etiology of infection and DIM at retrieval of 
fresh quarter sample (Table 6.5). While controlling for these variables, the odds ratio (OR) for 
bacteriological cure between TS and ABXTS was 0.32; bacteriological cure was approximately 
3.1 times higher for ABXTS quarters than for TS quarters (P = 0.04).  Extrapolation of least 
squares means (LSM) for bacteriological cure for this model indicated a cure of 93.2% of TS 
quarters and 97.7% of ABXTS quarters. To permit for the inclusion of etiology of IMIs in a 
regression model, the variable was condensed so that an acceptable number of quarters within 
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each category was established. Etiology was therefore dichotomized into “CNS” and “other.” 
When controlling for treatment group, odds of bacteriological cure for CNS-infected quarters at 
dry-off were lower than the grouping of other organisms (P = 0.03).  
New Infection Risk. A new infection was defined as the presence of new or different 
growth on the dry-off quarter sample from the fresh quarter sample. Contaminated and mixed 
growth quarters were not included in the analysis. Chronic quarters, or growth of the same 
organism for both samples, were included but not defined as new infections. New infections 
totalled 6.4% with 57.5% (n = 77/134) of new infections described as CNS. Quarters in the TS 
group experienced a numerically higher number of new infections (n = 77/1,058; 7.3%) than the 
ABXTS group (n = 57/1,040; 5.5%). Chi-squared analysis indicates a P-value for this difference 
of 0.09.  A logistic regression model includes parity and dry-off quarter growth (categorized into 
“CNS”, “Other”, and “No Growth” ) (Table 6.6). When controlling for these variables, the odds 
of new infection for TS versus ABXTS is 1.29 (95% CI: 0.9-1.85; P = 0.17). New infections in 
the high-risk group amounted to 6.8% (n = 31/456).   
Milk Production and LS. All cows with milk yield and LS values for the first test day 
after calving were included in the analysis. The mean test-day milk for all low-risk cows was 
40.8 kg. A mixed linear regression model used 574 observations (TS = 290, ABXTS = 284) and 
included LS at first test day, milk production at last test day before dry-off, and DIM on the first 
test day. Treatment group was not important in the model, though numerically the TS cows 
produced 0.69 kg more milk (LSM TS = 41.2 kg, ABXTS = 40.5 kg; P = 0.35). As expected, as 
LS at first test day increased, milk production decreased (P < 0.001). As milk production at last 
test day or DIM at first test day increased, milk production increased (P < 0.001).  A repeated 
measures analysis performed on daily milk yields (n = 15,987) over the first 30 DIM by 
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treatment group is shown in Figure 6.2. Means for milk production were numerically greater in 
the TS group for each of the first 26 DIM, but the effect of treatment nor the treatment by time 
interaction was important in the model (P = 0.20, P = 0.40, respectively). The same cows as in 
the milk production outcome were included in a linear regression model for first-test-day LS (n = 
574; Table 6.7). The mean test-day LS for all cows was 2.6. When controlling for other 
independent variables included in a linear regression model, the LSM for LS was numerically 
higher for the TS group (P = 0.10). Important in the model were the type of growth on dry-off 
and fresh samples, parity, mastitis before 30 DIM (dichotomized into “yes” or “no”), DIM at first 
test, and milk production at first test. A negative culture result for all 4 quarters at dry-off or 
fresh sampling was associated with a lower LS than a result of “CNS” or “other” for at least one 
quarter. Cows entering their second lactation had a lower LS than any other category of parity (P 
< 0.05). A cow that experienced mastitis within the first 30 DIM had a higher linear score than 
one that had not (P < 0.05).  
Culling and Mastitis Events. All cows enrolled were included in logistic regression 
models for culling and mastitis events up to 30 DIM. Overall, 94.6% of enrolled cows remained 
in the herd until they reached 30 DIM. A total of 33 cows were culled or died, 18 in the ABXTS 
group and 15 in the TS group (Chi-squared P-value = 0.57). In a logistic regression model, cows 
in the TS group had lower odds of leaving the herd than cows in the ABXTS group, but we did 
not observe an important difference between treatment groups (P = 0.60). The model for this 
outcome included parity only, with cows in parity 2 or 3 experiencing lower odds than parity > 4 
(P < 0.05; Table 6.8). The total number of cases of clinical mastitis in the first 30 DIM was 14 
(2.3%) with TS cows contributing 5 cases and ABXTS contributing 9 cases (Chi-squared P-
value = 0.27). Each cow (n = 14) had a single case of mastitis. No cases of clinical mastitis were 
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recorded during the dry period for cows in either group. Treatment group was not important in a 
logistic regression model, although the odds of clinical mastitis in the ABXTS group was 2.3 
times higher than the TS group (P = 0.21, Table 6.9). Regression analysis included LS at first 
test and whether the cow had one mastitis event during the lactation of enrollment (“yes” or 
“no”). As expected, when controlling for important variables, the odds for mastitis were 
numerically higher for a cow that had experienced one case of mastitis during the lactation of 
enrollment than a cow that had not (P = 0.08).  Finally, as first-test-day LS increased, the odds of 
clinical mastitis increased (P = 0.003). 
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These numbers reflect quarters 
included in initial analysis for 
bacteriological cure and new 
infection risk 
 
These cow numbers reflect 
cows included in analysis 
for milk production and 
linear scores 
 
Included 
n = 611 cows 
n = 2,386 quarters 
 
ABXTS 
1,184 quarters 
 
TS 
1,202 quarters 
 
Post-enrollment quarter 
losses  
n= 144 quarters 
 
 
These cow numbers reflect 
cows included in analysis 
for culling and mastitis 
events 
 
Cow losses due to: 
Culling prior to first test date (33); 4 cows missing linear scores  
 
Quarter losses due to: 
Loss of individual quarter: mixed or contaminated culture results 
Loss of 4 quarters per cow: when antibiotic treatment used prior 
to fresh sample, cull prior to fresh 
 
 
Post-enrollment quarter 
losses  
n= 144 quarters 
 
Total included in 
quarter level analysis 
1,058 quarters 
 
Total included in 
quarter level analysis 
1,040 quarters 
 
Figure 6.1. Enrollment of cows and quarters in a randomized field trial to evaluate the use of an algorithm that identifies high- and 
low-risk cows to guide selective dry-cow therapy. ABXTS = low-risk cows that receive antibiotic therapy and external teat sealant 
at dry-off; TS = low-risk cows treated with external teat sealant only.  
ABXTS 
n = 304 cows 
TS 
n = 307 cows 
Post-enrollment losses  
n = 16 
 
Post-enrollment losses  
n = 21  
 
n = 283 cows 
 
n = 291 cows 
 
Dried between June 2016 
and January 2017  
 
n = 3,812 quarters 
n = 342 cows 
Reasons for exclusion: 
Designated “High-risk” by algorithm = 321 
Added to list by producer on day of dry-off, after algorithm was run=21 
 222 
 
 
 
 
 
 
 
Table 6.1. Descriptors for cows in a randomized field trial evaluating treatment of low-risk cows 
with external teat sealant (TS; n = 307) or antibiotics and external teat sealant (ABXTS; n = 304) 
at dry-off 
 Treatment Group   
Item TS ABXTS All cows P-value1 
Parity2 (no.)    0.65 
   First 136 140 276 0.68 
   Second 84 81 165 0.86 
   Third 52 42 94 0.31 
   >Third 35 41 76 0.46 
DIM2 (d)     
   Mean 338 343 340 0.27 
   Median 313 330 340  
Actual dry period (d)    0.06 
   Mean 56 54 55  
   Median 54 53 54  
Mastitis Event3 (no.)    0.02 
   Yes 17 6 23  
   No  290 298 588  
Milk yield4 (kg)     
   Mean 23.6 23.5 23.6 0.87 
   Median 24.5 23.6 24.0  
Linear Score4     
   Mean 2.2 2.3 2.3 0.18 
   Median 2.2 2.4 2.3  
1P-values based on bivariate analysis (t-test, Fisher’s exact) of each variable by treatment group. 
2At enrollment. 
3If the cow had 1 mastitis event in the lactation before enrollment. 
4At test day before enrollment. 
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Table 6.2. Quarter-level culture results at dry-off for low-risk cows randomly assigned to receive 
either external teat sealant (TS; n = 1,204) or antibiotics and external teat sealant (ABXTS; n = 
1,183) at dry-off 1 
1Etiological classification is based on aerobic culture results and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) performed by Quality Milk and Production 
Services (Ithaca, NY).  
2P-values based on bivariate analysis (Fisher’s exact) of each etiology by treatment group. 
3Includes Streptococcus spp. unclassified to the species level and Streptococcus dysgalactiae. 
4Includes contamination, Gram-negative and Gram-positive bacilli. 
5Excludes contamination. 
  
 TS ABXTS  
Culture result No. % No. % P-value2 
Negative  1,086 90.2 1,064 90.0 0.84 
CNS 59 4.9 78 6.6 0.08 
Mixed Growth 22 1.8 20 1.7 0.88 
Corynebacterium spp. 24 2.0 12 1.0 0.06 
Lactococcus spp. 5 0.4 4 0.3 > 0.99 
Streptococcus spp.3 2 0.2 1 0.1 > 0.99 
Other4 6 0.5 4 0.3 0.75 
Total IMI5 114 9.5 115 9.7 0.84 
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Table 6.3. Quarter-level culture results at dry-off for high-risk cows as designated by a computer 
algorithm in a selective dry-cow therapy program1 
 
 
 
 
 
 
 
 
 
 
 
1 Etiological classification is based on aerobic culture results and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) performed by Quality Milk and Production 
Services (Ithaca, NY).  
2 Includes Streptococcus spp. unclassified to the species level and Streptococcus dysgalactiae. 
3Includes contamination, Pseudomonas spp., Serratia spp., and Gram-positive bacilli. 
4Excludes contamination.  
Culture result No. (553) % IMI (%) 
Negative  384 69.4  
CNS 77 13.9 45.6 
Mixed Growth 27 4.9 16.0 
Corynebacterium spp. 14 2.5 8.3 
Lactococcus spp. 35 6.3 20.7 
Streptococcus spp.2 8 1.4 4.7 
Other3 8 1.4 4.7 
Total IMI4 165 29.8  
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Table 6.4. Quarter-level culture results at fresh for low-risk cows randomly assigned to receive 
either external teat sealant (TS; n = 1,128) or antibiotics and external teat sealant (ABXTS; n = 
1,097) at dry-off 1 
1Etiological classification is based on aerobic culture results and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) performed by Quality Milk and Production 
Services (Ithaca, NY) on samples 1 to 7 DIM. 
2P-values based on bivariate analysis (Fisher’s exact) of each etiology by treatment group. 
3Includes Streptococcus spp. unclassified to the species level, Streptococcus dysgalactiae, and 
Streptococcus uberis 
4Includes Gram-negative and Gram-positive bacilli, Escherichia coli, Klebsiella, Trueperella 
pyogenes, and Enterococcus spp. 
5 Excludes contamination.  
 TS ABXTS  
Culture result No. % No. % P-value2 
Negative  983 87.1 998 91.0 0.004 
CNS 68 6.0 34 3.1 0.001 
Contamination 35 3.1 27 2.5 0.37 
Mixed Growth 12 1.1 7 0.6 0.36 
Lactococcus spp. 13 1.2 7 0.6 0.26 
 Streptococcus spp.3 8 0.7 10 0.9 0.64 
Corynebacterium spp. 2 0.2 6 0.5 0.17 
Other4 7 0.6 8 0.7 0.8 
Total IMI5 110 9.8 72 6.7 0.007 
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Table 6.5. Logistic regression model for the risk of bacteriological cure at freshening in quarters 
receiving external teat sealant only (TS; n = 86) or antibiotic dry-cow therapy and teat sealant 
(ABXTS; n = 85).  
Parameter Estimate SE P-value Odds Ratio 95% CI 
Intercept 6.25 1.30 <0.0001   
Treatment group 
   TS 
   ABXTS 
 
-1.12 
Referent 
 
0.55 
 
0.04 
 
 
 
0.32 
 
0.11-0.96 
Organism cultured at dry-off 
   CNS 
   Other 
 
-2.33 
Referent 
 
1.05 
 
0.03 
 
 
 
0.10 
 
 
0.01-0.80 
Days in milk at fresh sample -0.52 0.16 0.002   
 
 
 
Table 6.6. Logistic regression model for the risk of new infection at fresh in quarters receiving 
external teat sealant only (TS; n = 1,058) or antibiotic dry-cow therapy and teat sealant (ABXTS; 
n = 1,040).  
Parameter Estimate SE P-value Odds Ratio 95% CI 
Intercept -2.75 0.27 <.0001   
Treatment group 
   TS 
   ABXTS 
0.25 0.18 0.17  
1.29 
 
0.90-1.85 
Parity at fresh 
   2 
   3 
   4 
   >4 
 
-0.45 
0.23 
-0.20 
Referent 
 
0.29 
0.29 
0.34 
 
0.02 
 
 
0.64a 
1.25b 
0.82ab 
Referentab 
 
0.36-1.14 
0.71-2.23 
0.42-1.60 
 
Growth on dry-off sample 
   CNS 
   Other 
   No Growth 
 
-0.10 
1.70 
Referent 
 
0.40 
0.36 
 
<.0001 
 
 
0.91a 
5.49b 
Referentb 
 
0.41-2.0 
2.7-11.0 
a,b Values within the same column and parameter with different superscripts are different ( P < 
0.05) 
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Treatment*Time Interaction 0.40 
Figure 6.2. Longitudinal milk production (kg) over the first 30 DIM for cows receiving 
external teat sealant only (TS) or antibiotic therapy and teat sealant (ABXTS) at dry-off. Error 
bars signify 95% CI 
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Table 6.7. Linear regression model for linear score at first test (average DIM = 16 d) for cows 
receiving external teat sealant only (TS; n = 291) or antibiotic therapy and teat sealant (ABXTS; 
n = 283) at dry-off  
Parameter Estimate SE P-value LSM 95% CI 
Intercept 5.8 0.53 <0.0001   
Treatment group 
   TS 
   ABXTS 
 
0.22 
Referent 
 
0.13 
 
0.10 
 
 
 
2.7 
2.5 
 
2.5-2.9 
2.3-2.6 
Growth on dry-off sample1 
   CNS 
   Other 
   No Growth 
 
0.36 
0.65 
Referent 
 
0.18 
0.19 
0.002  
2.8b 
3.1b 
2.4a 
 
2.5-3.1 
2.7-3.4 
2.3-2.6 
Growth on Fresh Sample1 
   CNS 
   Other 
   No Growth 
 
1.30 
0.72 
Referent 
 
0.21 
0.18 
<0.0001  
3.6b 
3.0b 
2.3a 
 
3.2-4.0 
2.7-3.3 
2.2-2.5 
Parity at fresh 
   2 
   3 
   4 
   >4 
 
-0.67 
-0.18 
0.09 
Referent 
 
0.22 
0.23 
0.26 
 
<0.0001 
 
 
2.2a 
2.7b 
3.0b 
2.9b 
 
2.1-2.4 
2.5-3.0 
2.7-3.3 
2.5-3.3 
Mastitis before 30 DIM 
   No 
   Yes 
 
-0.18 
Referent 
 
0.15 
 
0.0006 
 
 
 
2.5a 
4.2b 
 
2.4-2.7 
3.2-5.1 
DIM at 1st test -0.03 0.01 0.008   
Milk (kg) at first test -0.03 0.007 <0.0001   
a,b Values within the same column and parameter with different superscripts are different ( P < 
0.05). 
1A cow had to have no growth on culture of all 4 quarters to be characterized as “No Growth”; if 
one or more quarters contained CNS, but no additional organism, she was characterized as 
“CNS”; Any other growth was “Other”. 
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Table 6.8. Logistic regression model for the risk of culling before 30 DIM for cows receiving 
external teat sealant only (TS; n = 307) or antibiotic dry-cow therapy and teat sealant (ABXTS; n 
= 304).  
a,b Values within the same column and parameter parameter with different superscripts are 
different ( P < 0.05). 
  
Parameter Estimate SE P-value Odds 
Ratio 
95% CI 
Intercept -2.73 0.18 <0.0001   
Treatment group 
   TS 
   ABXTS 
 
-0.09 
Referent 
 
0.18 
 
0.60 
 
 
0.83 
 
0.40-1.69 
 
Parity at fresh 
   2 
   3 
   4 
   >4 
 
-0.78 
-0.38 
0.22 
Referent 
 
0.31 
0.33 
0.33 
 
0.002 
 
 
0.18a 
0.26a 
0.48ab 
Referentb 
 
0.07-0.46 
0.10-0.71 
0.18-1.32 
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Table 6.9. Logistic regression model for the risk of clinical mastitis before 30 DIM for cows 
receiving external teat sealant only (TS; n = 291) or antibiotic dry-cow therapy and teat sealant 
(ABXTS; n = 283) 
 
  
Parameter Estimate SE P-value Odds Ratio 95% CI 
Intercept -4.63 0.74 <.0001   
Treatment group 
   TS 
   ABXTS 
 
-0.42 
Referent 
 
0.33 
 
0.21 
 
 
 
0.44 
 
 
0.12-1.60 
 
Mastitis event in lactation before enrollment 
   Yes 
   No 
 
0.80 
Referent 
 
0.45 
 
0.08 
 
 
4.95 
 
0.83-29.4 
First Test Linear Score 0.39 0.13 0.003   
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DISCUSSION 
In this study, removal of an antibiotic dry treatment in cows determined to be low-risk by 
a computer-based algorithm did not have adverse effects on new infection risk, milk yield, first-
test linear score, clinical mastitis, or culling compared with low-risk cows that were treated. 
Bacteriological cure was statistically different between the groups, with antibiotic-treated 
quarters at higher odds for cure. Coagulase-negative staphylococci comprised 95% of the non-
cures on the trial dairy, yet these minor pathogens only contributed one case of clinical mastitis 
in low-risk cows over the trial period. Using the already incurred costs of computer and testing 
programs implemented on-farm, a culture-independent algorithm that selectively distinguishes 
between high- and low-risk cows could result in a reduction in dry cow antibiotic use of 
approximately 60% when low-risk cows are not treated. 
It is difficult to describe the representativeness of one or more dairies by referencing an 
expected prevalence of dry period infection; much variation exists for new and current IMI, both 
at cow and quarter levels. In the current study, the prevalence for quarter level dry-off IMI was 
29.8% and 9.6% for high- and low-risk quarters, respectively, which is lower than an average 
quarter-level prevalence (34.7%) in a Wisconsin study surveying 4 dairies (Johnson et al., 2016). 
However, 2 studies described a range of subclinical infection between 13 and 35% when 
collectively assessing 7 dairies in 4 states (Pantoja et al., 2009; Arruda et al., 2013). One 
common finding is a majority of infections are characterized as CNS: in the current trial, 60% of 
IMI in low-risk quarters at dry-off were CNS. This is similar to the 69% documented in the study 
by Johnson et al. (2016).  
Despite a greater number of CNS-positive quarters allocated to the ABXTS group, 
creating potential bias against these quarters, the odds for bacteriological cure was greater for 
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this group. Our higher odds of cure for antibiotic-treated quarters versus untreated quarters 
agreed with the conclusions of a meta-analysis of 4 SDCT trials and 13 BDCT trials, although 
our odds ratio of 3.1 was greater than the meta-analytic pooled relative risks of 1.76 and 1.78, 
respectively (Halasa et al., 2009b).  A recent trial by Cameron et al. (2014) found no statistical 
difference in bacteriological cure between BDCT quarters and SDCT quarters from 16 Canadian 
herds when treatment was performed at the cow level (n = 729 cows). A similar study on a dairy 
in Minnesota (n= 56 cows) implemented assignment on the cow level and treatment on the 
quarter level. Statistical differences were not found between BDCT and SDCT cows, though a 
cure risk difference of 5.7% was stated (Patel et al., 2017). This is comparable to our statistical 
cure risk difference of 4.5% with a larger sample size.  Culture screening was performed on all 
SDCT cows in the Cameron et al. (2014, 2015) and Patel et al. trials (2017) before treatment of 
positive cows/quarters; the study design dictated that comparisons be made between blanket-
treated cows and a group comprised of treated and untreated cows/quarters. This is one reason 
why differences in this outcome were observed in the current trial in which we made 
comparisons between treated and untreated low-risk quarters. We did not analyze differences 
between treated high-risk quarters and treated low-risk quarters, nor did we include a group of 
untreated high-risk quarters. We have structured the algorithm to determine, independently of 
culture and based on thresholds, which animals would likely benefit from antibiotic treatment. 
As high-risk quarters were projected to have a higher prevalence of pathogens, and given that 
commercial dry cow preparations must meet label and efficacy requirements for Food and Drug 
Administration approval, IMM antimicrobials were assumed likely to be beneficial and were not 
withheld from these animals. However, we are unable to conclude whether antibiotic therapy 
was appropriate in these cows. 
 233 
 
 
In the current trial, the majority of quarters included in analysis for bacteriological cure 
(171 quarters) were contributed by the minor pathogens CNS (n = 126) and Corynebacterium 
spp. (n = 31) with 77% and 91% of non-treated and treated CNS cases curing, respectively.  
Similarly, the meta-analysis by Halasa et al. (2009b) found that while antimicrobial dry cow 
therapy led to a 77% cure risk for CNS, spontaneous cure was on average 44%, suggesting that 
antimicrobial therapy is effective against these organisms. In a survey performed in Belgian 
herds of CNS present at parturition, 20% of all quarters of multiparous cows had IMIs 
characterized by 8 different CNS species and over 20 different species have been found in 
bovine milk (Vanderhaeghen et al., 2015; De Visscher et al., 2016).  When analyzed as 3 
different groupings of 8 different species, those quarters treated with antimicrobials at dry-off 
experienced statistically lower odds of having an IMI characterized by CNS at calving relative to 
those that were not treated (De Visscher et al., 2016). However, there might be an advantage to 
the presence of CNS in quarters: some groups have observed higher milk production in CNS-
infected animals relative to uninfected animals (Schukken et al., 2009; Piepers et al., 2013) and 
other groups, as reflected in a meta-analysis, see a protective effect of CNS against major 
pathogens in challenge studies (Reyher et al., 2012). Conversely, Berry and Hillerton (2002) 
found that untreated quarters with CNS infections had a 4.2-4.7 times greater risk of new 
infections with Streptococcus uberis or coliforms at calving compared with uninfected, untreated 
quarters when assessing 499 quarters. Characterization of the effects of individual CNS species 
requires further investigation. As no important differences in LS, milk production, risk of 
removal, or clinical mastitis cases caused by CNS were found between groups in the current 
study, we do not believe that influences of these pathogens on bacteriological cure nor new 
infection risk is concerning on this particular dairy.   
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New IMI during the dry period is also variable and has been documented to range from 
6.4% to 25% at the quarter level (Godden et al., 2003; Pantoja et al., 2009; Arruda et al., 2013). 
Intramammary infections present at calving have important economic consequences that result 
from declines in milk quantity and quality and increases in cases of clinical mastitis (Bradley and 
Green, 2000, Archer et al., 2014). Accordingly, dairies attempt to minimize these consequences 
with the use of dry cow products. While antimicrobial products might result in reductions in new 
IMI, the ranges provided were described for herds on which BDCT was performed; total 
elimination of IMIs is difficult to achieve. Variation in the prevalence of IMI at calving between 
herds demonstrates that infection status is influenced by many factors including cow (e.g. parity, 
SCC), management (e.g. frequency of cleaning bedding), and farm characteristics [e.g. facilities, 
pathogens present on the farm (Green et al., 2007; Green et al., 2008)]. Alterations of these 
factors, when appropriate, could reduce IMIs. With use of SDCT, we found the proportions 
(LSM) of untreated low-risk quarters acquiring new IMI over the dry period to be 11.2%. This 
compares to the treated low-risk quarters at 8.9%. These values were similar to the weighted 
mean incidences calculated by Robert et al. (2006b) of 9.9% and 6.5% for untreated and treated 
quarters, respectively, when considering new IMIs in 13 studies that compared SDCT with 
BDCT. When a model was generated for risk of new IMI in the current study, we were unable to 
find a statistical difference between the treatment groups. No statistical differences were found 
for new IMIs when culture diagnostics were used for targeting treatment at the cow or quarter 
level in a recent trial and a pilot study (Cameron et al., 2014; Patel et al., 2017). Our odds ratio of 
0.77 was similar to the pooled relative risks of 0.58 and 0.55 described in 2 meta-analyses that 
compared BDCT to SDCT (Robert et al., 2006b; Halasa et al., 2009a). The meta-analysis 
performed by Halasa et al. (2009a), noted that while significant differences in relative risk were 
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seen for protection against new quarter IMI, no statistical differences were calculated when the 
selection unit was the cow. When the Robert et a. (2006b) meta-analysis considered comparisons 
between a non-treated group and a BDCT group, differences in new IMI between groups were 
significant in 15 of 25 studies; however, pooled differences were statistically significant for 
streptococcal and Staphylococcus aureus IMIs and not for IMIs caused by CNS or coliforms. 
Significant findings in the majority of the studies could be due to the fact that contributions of 
streptococcal species and Staph. aureus represented more than 35% of IMIs in 50% of the 
studies included. One trial included in the meta-analysis, Berry and Hillerton (2002), found that 
while the overall new IMI risk was significantly higher in the untreated versus treated cows, the 
most frequently cultured organism contributing to new IMIs in low SCC herds was S. uberis; no 
significant differences were found in the prevalence of CNS post-calving between treated and 
untreated groups.  In contrast, on our trial dairy, less than 2 percent of infections were caused by 
Strep. spp. with a majority of new infections (57.5%) described as CNS. A small percentage of 
infections were diagnosed as Corynebacterium spp. These 2 groups of minor pathogens are 
known to infect quarters at the end of the dry period, and in the current trial, we speculate that 
we do not observe larger differences in IMI postpartum between the treatment groups as the 
preventive action of the dry cow antimicrobial is no longer effective (Oliver and Jayarao, 1997; 
Bradley et al., 2003).  
Internal teat sealant was not used in the current trial; use of an external teat sealant, 
rather, was a part of the existing protocol. Several studies show a benefit to the use of internal 
teat sealant, amounting in fewer infections and lower SCC in the subsequent lactation, whether 
used alone or in combination with antimicrobials (Godden et al., 2003; Rabiee and Lean, 2013). 
When introduced into healthy quarters, the application of an inert, internal teat sealant without 
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antibacterial properties is not risk-free; a case report indicates that improper administration could 
lead to outbreaks of mastitis pathogens (Milnes and Platter, 2003).  While the efficacy of a one-
time application of external teat sealant over the course of the dry period has been questioned, 
there are studies that show that some are effective at preventing new IMIs during the dry period 
when applied regularly or according to label (Hayton, 2003; Timms, 2004; McDougall et al., 
2008). Although no differences were detected between groups for the new IMI outcome in the 
current trial, numerical reductions in new IMIs in the TS group could have occurred with use of 
an internal teat sealant versus an external teat sealant. Further research needs to be performed to 
determine how our algorithm performs with use of an internal teat sealant. 
  Cow-level outcomes such as the amount and quality of milk produced as well as clinical 
mastitis and culling risks, are more economical outcomes, as they are more visible to the 
producer than bacteriological cure and new IMI risk. When linear regression models were used 
to analyze first-test date milk production or longitudinal production over the first 30 DIM, no 
important differences were found between treatment groups. This agrees with findings from 2 
studies that followed selectively treated cows for greater than 180 DIM (Rajala-Schultz et al., 
2011; Cameron et al., 2015). Additionally, the referenced studies found no statistical differences 
in SCC or log transformation of SCC between the treatment groups, similar to the LS 
comparisons in current trial. These results differ from findings by Rajala-Shultz et al. (2011) and 
Scherpenzeel et al. (2014) who found that either next-lactational SCC or SCC at calving and 14 
DIM, respectively, was significantly lower than that of untreated cows. Dissimilarities between 
findings could be due to the presence of higher levels of major pathogens on the included dairies, 
the lack of teat sealant use, or the inclusion of herds with BTSCC >250,000 cells/mL.  
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In the current trial, no important differences were found between treatment groups when 
assessing the risk of clinical mastitis during the trial period. Cameron et al. (2014) used culture 
as a screening tool in addition to individual SCC and found no statistical differences in clinical 
mastitis cases in the first 120 DIM between the selective and blanket treatment groups. In the 
current trial, the number of cows enrolled with a single mastitis event was not evenly distributed 
between the groups; more cows that had experienced a case of mastitis were allocated to the TS 
group. Despite enrollment distributions, a higher number of next-lactation mastitis cases were 
described in the ABXTS group. The number of clinical cases within 30 DIM described for 
enrolled animals corresponded with the monthly incidence rate at this dairy. The fact that only 
low-risk cows were represented in this figure might explain why this number was not as high as 
expected for fresh animals. Accordingly, the first studies on decreased use of dry cow therapy in 
herds with low BTSCC were not selective, treatment was omitted for all cows; cows were not 
separated based on risk or infection status. This often resulted in an increased incidence rate of 
clinical mastitis. For example, when no screening process was used in a low BTSCC herd 
(140,000 cells/mL; n = 50 cows) to treat 2 and leave 2 quarters untreated within the same cow, 
there was a 10-fold increased risk of clinical mastitis in the untreated quarters (Schukken et al., 
1993). Similarly but more recently, Scherpenzeel et al. (2014) used a split udder design on 1,657 
cows with individual low SCCs (<150,000 cells/mL for primiparous and <250,000 cells/mL for 
multiparous) and found that the incidence of clinical mastitis was 1.7 times higher in quarters 
dried without antimicrobials. Finally, our findings also differed from Berry and Hillerton (2002) 
in which untreated quarters at dry-off had significantly more cases of clinical mastitis over the 
dry period. In those quarters with IMIs at freshening, the incidence of a subsequent case of 
clinical mastitis was significantly greater for untreated cows.  While all herds included in the 
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Berry and Hillerton trial (2002) had a BTSCC of 150,000 cells/mL, only cows with no IMI, 
CNS, or Corynebacterium spp. one week before dry-off could be randomized into treatment 
groups. Therefore, cows at risk due to historically higher SCC or multiple mastitis events were 
among the cows included in the non-treated group. Inclusion of more variables in our algorithm 
allowed us to capture cows with these characteristics. Berry and Hillerton also noted 
discrepancies in detection rates between farms and between pathogen types, and noted that one 
farm contributed to a large portion (>70%) of the clinical cases. Employees responsible for 
mastitis detection in the current trial were blinded to treatment and therefore could not be biased 
when detecting cases of clinical mastitis.  
The few cases of clinical mastitis experienced over the trial period (n = 14) could explain 
why mastitis was not important in a model that evaluated culling. Culling was not statistically 
different between treatment groups. A limited number of SDCT trials evaluate or describe 
survival or culling risks between treatment groups. Østerås and Sandvik (1996) found a 
numerically shorter lifespan (30 d shorter) for cows in placebo-treated and untreated groups 
versus those cows receiving antibiotics in infected quarters when using Cox modeling over an 
entire lactation. However, Cox and logistic regression analysis did not produce a significant 
association with the dry cow therapy regimen in that study. 
   To our knowledge, this is the first clinical trial that used a computer-automated system 
that relied on DHIA test-day data and recorded mastitis events to determine dry cow antibiotic 
treatment. Using bacteriological culture is the current gold standard to diagnose an IMI. 
Accordingly, the accuracy measurements of the algorithm to identify IMI in this study are based 
on comparisons to this diagnostic tool. Nearly all (>90%) of the low-risk quarters were 
uninfected at dry-off, indicating that the method of using sequential test-day SCC (as an average 
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of the last 3) in addition to the use of last-test-day SCC and mastitis events was good at 
identifying cows that had mostly uninfected quarters on the trial dairy. At the apparent 
prevalence of IMI at the current dairy, the positive and negative predictive values of the 
algorithm were approximately 70%. These values indicate, based on initial quarter-level culture 
results, the probability that a cow identified as low-risk, was experiencing an IMI, and was not 
treated with antibiotics was 30% (1-NPV); the probability that a cow identified as high-risk, was 
not experiencing an IMI, and was treated was 30% (1-PPV). High prevalence of minor pathogens 
might explain suboptimal predictive values. When only cows with major pathogens were 
characterized as infected, the NPV and PPV became 92% and 38%, again suggesting that a large 
proportion cows designated by the algorithm as high-risk were not infected, but treated. More 
importantly, cows allocated by the algorithm to the low-risk group infrequently cultured with 
major pathogens. One must recognize that the algorithm was used not only to capture and treat 
cows with current infections (culture positive) but also those cows at risk for acquiring infections 
throughout the dry period, a characteristic that would be difficult to predict or include in these 
calculations. The PPV was higher than the 42.5 and found in a SDCT trial that used a SCC 
threshold of 200,000 cells/mL for 3 consecutive months before dry-off and no cases of mastitis 
to determine which cows to treat (Torres et al., 2008). Reasons for dissimilarities in predictive 
values could be due to the addition of criteria in the current algorithm or differences in IMI 
prevalence on the test dairies.  For an increase in apparent prevalence of 5%, the PPV and NPV 
of the algorithm would be 74.5% and 66.2%; for a decrease of 5%, PPV and NPV would be 
65.8% and 75.1%. The predictive values of our algorithm are impacted by study design. 
Treatment assignment was on the cow level while bacteriological sampling was on the quarter 
level. A discrepant quarter-level result within one cow could largely affect the predictive value 
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calculation. As an example, if a cow was defined as low-risk by the algorithm but had one 
bacteriologically positive quarter and 3 negative quarters, the overall NPV of the algorithm 
would decrease. Regardless, we elected to apply treatment at the cow level as other groups have 
shown an interdependence of quarters towards new infection during the dry period, particularly 
in herds with higher risk of infection (Browning et al., 1994; Robert et al., 2006a). Additionally, 
72% of large US dairies use DHIA for milk recording data, and while the most accurate 
relationship exists between quarter-level SCC and IMI, producers only have access to cow 
composite information (USDA, 2016a; Schukken et al., 2003).    
We used a threshold of 200,000 cells/mL as a component of our algorithm. Other groups 
have shown that this is the optimal level to decrease error related to detection of IMIs, with the 
highest sensitivities and specificities amounting to at best 0.75 and 0.90 (Dohoo and Leslie, 
1991; Schepers et al., 1997). However, the sensitivity and specificity of using only last-test SCC 
as an indicator of IMI at a threshold of 200,000 cells/mL is approximately 0.4 and 0.8 (Pantoja et 
al., 2009). This likely is due to the slight increases in SCC experienced by a late-lactation cow as 
she approaches dry-off and is a reason why decisions should not be based exclusively on a late 
lactation SCC (Schepers et al., 1997; Bradley and Green, 2004). On the contrary, Green et al. 
(2007) found that at least one SCC ≥200,000 cells/mL within the last 90 d before drying off was 
associated with an increased rate of clinical mastitis in the periparturient period. The most 
efficient use of thresholds in a SDCT protocol was identifying cows using 3 months’ SCC 
records with a threshold of 200,000 cells/mL for cows without clinical mastitis during the 
lactation and a threshold of 100,000 cells/mL during the rest of the lactation for cows with 
clinical mastitis during the first 90 DIM (Torres et al., 2008). These findings support the need to 
interpret SCC as well as other health data, e.g. mastitis events, when making treatment decisions.  
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Treatment decisions are also influenced by economics. A benefit of the algorithm used in 
this trial is the adaptability of the parameters used to define a low-risk cow. The SCC thresholds 
can be manipulated to increase sensitivity and decrease risk. Because no important differences 
were seen in milk production, LS, clinical mastitis cases, or culling, savings in labor and 
antimicrobial costs would result with use of SCC thresholds lower than those tested. Few SDCT 
studies provide economic analysis and the directionality of the impact is dependent upon 
accuracy, labor, and costs of the test method, cost of the antibiotic, and the prevalence of IMI at 
dry-off in the herd. Use of quarter-level culture results to drive selective treatment on a farm with 
a dry-off IMI prevalence of 34.8% resulted in a savings of $2.77 per cow using fixed costs for 
materials, labor, and IMM antibiotics (Patel et al., 2017). When a threshold composite SCC was 
employed in a SDCT protocol to model economic returns, only 2 out of 8 scenarios resulted in 
gains: use of a 50,000 cells/mL cutoff for both heifers and cows or use of a 150,000 cells/mL for 
heifers and a 50,000 cells/mL cutoff for cows (Scherpenzeel et al., 2016). The alternate 6 
strategies resulted in economic losses over benefits due to differences observed in the incidence 
rates of clinical mastitis and subclinical mastitis between the treated and untreated animals. 
Another economic model was built to calculate farm-specific costs of mastitis related to the dry 
period using trial data and expert interviews. In it, SDCT was economically the best option as 
compared with BDCT or no antimicrobial use (Huijps and Hogeveen, 2007). However, the 
optimal decision was dependent upon the herd-specific rate of infection and other farm traits 
such as the attitude of the farmer toward risk. One should note that if regulations are placed on 
antimicrobial dry tube use for US dairies, economics might play less of a role on the selection of 
a SDCT protocol.   
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One weakness of the current trial is the inclusion of a single dairy rather than a 
probabilistic sample of all eligible dairies. Using a power of 80% and a Type I error risk of 0.05, 
a sensitivity analysis for each regression model indicated that we were able to detect odds ratios 
of 0.3 or lower and 1.3 or greater for bacteriological cure and new infection risks, respectively, 
odds ratios of 0.3 or lower for both clinical mastitis and culling risks, a difference in LS of 0.4 or 
greater, and a difference in longitudinal milk production of 1kg when comparing TS versus 
ABXTS. This herd represented dairy farms in the region that might wish to employ a SDCT 
program with respect to production, BTSCC, facilities, and herd size. As indicated from the large 
ranges of prevalence of quarter-level infection status at dry-off and postpartum, there is much 
variability between dairies. This variability could result in detectable differences in the outcomes 
investigated, but smaller, significant differences might not always be important. This is 
corroborated in the study by Rajala-Schultz et al. (2011) in which a SCC difference as small as 
20,000 cells/mL was found to be significant when 4 dairies were included in a trial. Likewise, 
results could be largely influenced by one herd and the effects of SDCT can be opposite across 
herds (beneficial in some and detrimental in others). This dictates the need for farm-specific 
decisions when developing dry cow protocols. Overall, the willingness of producers to adopt a 
selective treatment strategy at dry-off relies on an accurate, easily accessible, and cost-effective 
method to identify cows, reserving antimicrobial treatment for cows that will benefit most.   
 
CONCLUSIONS 
 Use of selective dry cow therapy protocols, such as the algorithm identified in this trial, 
protects aspects of public health by reducing the risk of bulk tank antimicrobial residues and 
minimizing the potential for antimicrobial resistance. Similar protocols at appropriate dairies can 
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reduce dry cow antimicrobial use by approximately 60% without negative consequences on new 
infection risk or cow-level production and health outcomes. More research is needed to 
determine the characteristics of farms that lead to successful implementation of SDCT 
algorithms, however, utilizing only on-farm data would obviate the need for microbiologic or 
cow-side methods that require labor, time, and money. 
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Mastitis is a prominent disease in the dairy industry, causing 2 billion dollars in yearly 
losses, attributed to consequential decreases in milk production, milk discard, treatment and 
labor costs, and decreases in reproductive efficiency. To combat these losses and to address and 
prevent clinical disease, traditionally, all clinical cases and all quarters prior to dry-off are treated 
with antimicrobials. Alternatively, “prudent use” involves administration of products only to 
animals that would benefit from their use. Reasons for prudent use include preserving the 
sustainability of veterinary and human formulations, decreased risk of antimicrobial resistance, 
decreased risk of residues in agricultural products, and potential economic returns. In many 
situations, antimicrobials are useful and their ability to resolve disease for appropriate cases 
should not be challenged; as such, approaches for implementation of protocols should rely on 
research findings. For mastitis, this includes the findings that a large proportion of clinical cases 
produce negative culture results and that a majority of quarters at dry-off are also culture-
negative. Additionally, high spontaneous resolution of gram-negative cases has been reported, 
while the refractory or resistant nature of others to antimicrobials should also be considered. On 
the contrary, non-contagious, gram-positive pathogens are susceptible to antibiotics. To 
accomplish prudent use of antimicrobials for the treatment and prevention of mastitis, this 
research explored and successfully implemented strategies that acknowledge such findings. 
 
Summary of the Results 
The first objective was to evaluate if noninferiority could be established for a semi-
synthetic penicillin, hetacillin, versus the 3rd generation cephalosporin, ceftiofur. Noninferiority, 
defined as hetacillin being comparative in outcomes within a margin of 15% relative to ceftiofur, 
was conclusive for bacteriological cure, pathogen cure, survival to day 30 and survival to day 60. 
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When logistic and linear models were used to explore outcomes, no statistical differences were 
found in bacteriological cure risk, pathogen cure risk, clinical cure risk, postevent milk 
production, and linear scores (LS). Cows treated with hetacillin were more likely to have a 
clinical cure than ceftiofur by day 4. No differences were observed between groups when Cox 
proportional hazards were performed for exit from the herd or in the risk for a subsequent 
mastitis event. Hospital days differed favorably for hetacillin, allowing milk from hetacillin-
treated cows to contribute to the bulk tank 1.8 d sooner. These findings support the use of a 
narrow-spectrum antibiotic for clinical mastitis (CM) treatment as an alternative to a 3rd 
generation cephalosporin, which is a critically important drug class to human medicine according 
to the world health organization. 
The second major objective was to assess a delayed pathogen-driven treatment protocol 
based on results received from a diagnostic laboratory within 1 d of the mastitis event. Results 
showed no statistical differences in days to clinical cure, postevent milk production, next test-day 
LS, and odds of survival 30 and 60 d post-enrollment between cases in the blanket therapy group 
and cases in the pathogen-based treatment group. However, pathogen-based cows experienced 3 
fewer days in the hospital than blanket therapy cows. This protocol resulted in a reduction in 
antimicrobial use of 68.5% on the trial dairy.  
Once successful implementation of a pathogen-based protocol with daily sample retrieval 
and prompt reporting of results was established, the ability to apply this strategy on moderate-
sized dairies without access to a professional laboratory was investigated. Results indicate that 
when samples were picked up and results reported 5 d per week, or when farm employees were 
trained to perform on farm culture (OFC), compliance to the protocol and satisfaction with the 
experience was high. Reductions in antimicrobial usage ranged from 6.8% to 92.5% dependent 
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on farm protocol and pathogen profile of the herd. Application of the protocols did not contribute 
to large undesirable changes in bulk tank somatic cell count, milk production, or monthly 
mastitis incidence. Decreased antibiotic use resulted in savings between $2,200 and $4,600 per 
dairy ($3.00-$6.00 per cow), per year.  
Selected milk samples from the pathogen-based trial were then used to explore the 
metagenomic profiles of CM cases to determine if these cases represent a “missed opportunity” 
for treatment. The data generated from metagenomic analysis suggested that there is not an 
inherent “mastitic microbiome” in culture-negative or E.coli-positive cases that indicates that a 
cow will experience negative outcomes, such as larger decreases in milk production or increases 
in linear scores. 
The last major objective was to evaluate a culture-independent, data-driven, selective 
dry-cow therapy (SDCT) program. Results showed that when low-risk cows identified by the 
algorithm were not treated with antimicrobials at dry-off, they did not differ in new infection 
risk, milk production, LS, culling, or CM risk from low-risk cows that were treated. 
Bacteriological cure differed between the groups with 19/20 non-cured quarters experiencing 
CNS infections. The employed algorithm decreased dry-cow antibiotic use by approximately 
60%. 
 
Overall Conclusions and Future Directions 
Based on the results generated during this Ph.D., implementation of a pathogen-based 
treatment protocol can be successful if results are supplied by a university diagnostic laboratory, 
veterinary laboratory, or OFC. However, access to a laboratory or training and guidance for OFC 
may not be feasible. The biggest needs to facilitate the implementation of the protocols presented 
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are diagnostic tools that provide prompt and accurate results.  Many research groups and animal 
health companies are investigating cow-side or on-farm diagnostics such as PCR for rapid 
determination of etiology and application of selective treatment protocols. The creation of 
selective culture agar that facilitates accurate and quick diagnosis by untrained personnel is 
continuously being explored for on-farm use. Also, as we become a technology and computer-
driven society, using these means as a way of teaching, communication, and diagnosis can 
enable and assist dairies in their use of pathogen-driven programs.  For example, using OFC and 
a standardized photo-capture system to submit queries to diagnostic labs for generation of results 
would promote confidence in their own interpretation of bacterial growth.   
In regards to research needs, in the field of metagenomics there are few longitudinal 
studies of mastitic quarters with permutations of treatments and pathogen types. Such research 
would elucidate pathogen-specific changes in the microbial profile of the mammary gland as 
well as the impacts of antimicrobial use or prudent use protocols on the microbiome. 
Additionally, as profiles can vary by farm and by animal, a large survey of the milk microbiome 
of animals across the country and in different management systems would be beneficial. 
Defining the specifics of “appropriate” dairies for selective treatment programs is still 
underway.  No research project accounts for the variability across dairies in respects to size, 
management, genetics, or pathogen profiles to permit the generalizability of the findings to all 
facilities.  If provided the resources, it would be useful to assess how successful these protocols 
are in different management systems, in the US and around the world.   
Importantly, knowledge attained from the research presented in this dissertation has been 
shared with practitioners, farmers, and industry professionals at conferences, meetings, and in 
magazines with hopes that protocols will be applied at appropriate dairies. However, 
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understanding dairy farmers’ behavior, motivations, and barriers can influence how veterinarians 
translate research into practice, and can guide professionals to effective ways of implementing 
new protocols. To this end, collaborative work with Dr. Lorin Warnick’s laboratory and with Dr. 
David Just, a behavioral economist at Cornell University, will employ the theory of planned 
behavior and structural equation modeling using survey answers from NY dairy owners to 
determine what exactly drives antibiotic use decisions. Results from this research may direct 
practitioners in approaches that create behavioral changes on dairies that currently employ 
blanket therapy. 
Future directions for our laboratory for SDCT include collaborative work with Dr. Sandra 
Godden at the University of Minnesota and Dr. Alfonso Lago at Dairy Experts (Tulare, CA). A 
project will explore and compare options for SDCT in regions across the US using different 
protocols (algorithm-based and culture-based) and will investigate the ability of 2 rapid 
diagnostic tests for identifying quarters with an IMI at dry-off. Additionally we will describe the 
effect of antibiotic treatment of uninfected cows at dry off on the milk microbiome after calving, 
and on udder health and cow performance in early lactation. Sequencing will also be performed 
on colostrum samples from the SDCT trial included in this dissertation. More specifically, Dr. 
Carla Foditch from Dr. Lorin Warnick’s laboratory will perform shotgun sequencing on 
colostrum samples to determine if antimicrobial residues and/or resistant organisms are 
differentially present in colostrum from animals that were treated versus those that were not. 
Additionally, cow-side residue tests are currently being optimized and validated for colostrum 
samples and again, samples in the SDCT trial will be investigated for the presence of residues.  
In closing, implementation of protocols that promote prudent use of antimicrobials will 
not contribute to the reduction of mastitis on dairy farms; prevention of mastitis should be the 
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goal. Overall strategies should rely on the three points of the epidemiological triangle: the agent, 
the host, and the environment. To this end, dairies should optimize dry cow management and 
cow comfort, improve immune status via vaccination and provision of quality nutrition, and 
decrease infection pressure by maintaining cow and facility cleanliness. Additionally, post-
milking teat disinfection, culling of chronic cases, and milking machine maintenance should also 
be considered. Knowledge of these many aspects of mastitis control and management can be 
acquired via review of additional publications. 
